

Molecular Characterization of Important Regions of the Lumpy Skin Disease Virus Genome

by

Celia Stipinovich

Submitted in fulfilment of part of the requirements
for the degree of Master of Science
in the Faculty of Natural and Agricultural Sciences
Department of Microbiology and Plant Pathology
University of Pretoria

Prof. L. H. Nel
Dr. G. J. Viljoen

January 2001

Preface

I wish to acknowledge the following, without whom these few pages would not exist:

Friends and colleagues at OVI Applied Biotechnology for accommodating me in their facilities, as well as the great staff of OVI Molecular Biology's Sequencing Lab (including Morné Coetzee)

UP Main Campus friends and staff from the Departments of Microbiology, Genetics and Biochemistry for their valued advice, in particular Jonathan Keytel for his invaluable advice and assistance with matters *in silico*

The National Research Foundation and University of Pretoria, for funding

The supervisors, Dr. Gerrit J. Viljoen (OVI) and Prof. Louis H. Nel (UP) for their dependable support and *critique*

and Frank T. Vreede, project leader, for his expert guidance.

*Through Him
With Him
In Him*

CONTENTS

Preface.....	ii
Summary.....	vi
List of Tables.....	viii
List of Figures.....	ix
Abbreviations.....	x

CHAPTER I - REVIEW OF THE LITERATURE

1.1 Introduction	
1.1.1 Poxviruses in history.....	2
1.1.2 The origins, epidemiology and distribution of capripoxviruses.....	4
1.1.3 The clinical disease.....	6
1.2 Classification	
1.2.1 Capripoxviruses and their host specificities.....	9
1.2.2 Transmission and spread.....	10
1.3 The molecular biology of poxviruses	
1.3.1 Morphology.....	12
1.3.2 Genome structure.....	13
1.3.3 Poxvirus replication	15
1.3.4 Virus-Host interactions.....	25
1.4 Vaccines	
1.4.1 Lumpy Skin Disease Vaccines.....	37
1.4.2 Pox-vectored vaccines.....	38
1.5 Aims of this study.....	41

CHAPTER II - THE RESTRICTION ENDONUCLEASE MAPPING, SUB-CLONING AND SEQUENCING OF LSDV *PstI* CLONES -E, -M, -K, -F and -G

2.1 Introduction.....	44
2.2 Materials and Methods	
2.2.1 Restriction endonuclease mapping of the <i>PstI</i> clones.....	47
2.2.2 Cloning.....	48
2.2.3 Sequencing.....	51
2.3 Results and Discussion	
2.3.1 The restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -M clone.....	60
2.3.2 The restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -K clone.....	61
2.3.3 The restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -E clone	65
2.3.4 The restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -F clone	67
2.3.5 The restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -G clone	68
2.3.6 The mapping and cloning of a fragment in <i>PstI</i> -G clone spanning an <i>AseI</i> junction.....	70
2.3.7 Sequencing.....	72
2.4 Conclusions.....	74

CHAPTER III: DNA SEQUENCE ASSEMBLY AND ANALYSIS

3.1 Introduction.....	76
3.2 Materials and Methods	
3.2.1 Hardware.....	78
3.2.2 DNA sequence editing.....	78
3.2.3 DNA sequence analysis - GCG.....	78
3.2.4 SMART (V 3.1) analysis of ORFs.....	80
3.2.5 The identification of promoters.....	81

3.3 Results and Discussion	
3.3.1 Nucleotide sequences of LSDV <i>PstI</i> fragments.....	82
3.3.2 SMART analysis.....	86
3.3.3 LSDV ORFs.....	88
3.3.4 Nucleotide composition (GCG).....	96
3.3.5 Comparison of poxvirus genome organisations.....	97
3.3.6 Relationship of LSDV to other poxviruses.....	97
3.3.7 Discussion of the regulatory elements.....	100
3.4 Conclusions.....	105

CHAPTER IV- CONCLUDING REMARKS	
.....	107

CHAPTER V- APPENDICES AND REFERENCES	
5.1 Appendix I.....	112
5.2 Appendix II.....	113
5.3 Appendix III.....	115
5.4 References.....	120
5.5 Papers and congress contributions.....	151

Summary

Molecular Characterization of Important Regions of
the Lumpy Skin Disease Virus Genome

by

Celia Stipinovich

Supervisor: Prof. L. H. Nel
Department of Microbiology and Plant Pathology
University of Pretoria

Co-supervisor: Dr. G. J. Viljoen
Applied Biotechnology Division
Onderstepoort Veterinary Institute

In this study, almost 29 000 bp of the capripoxvirus lumpy skin disease virus genomic DNA were sequenced, analysed and compared with the sequences of other poxviruses. *PstI* clones -E, -M and -K represent 12 530 bp of the left hand terminal region, whereas *PstI* clones -F and -G represent 16 356 bp, from the central region of the genome. The terminal regions of poxvirus genomes are of particular interest and importance, as they contain the genes required for host range specificity and virulence, while the central regions encode the essential genes for viral replication and survival within the host. It was first necessary to sub-clone *PstI* clones into smaller fragments, after precise restriction mapping and the development of cloning strategies for each of the *PstI* clones. Forty-six non-overlapping subclones were consequently generated. The recombinant bacterial clones were sequenced in the forward and reverse directions with M13 vector primers, and edited by using Apple Macintosh Sequence Navigator™ sequence analysis software. To assemble the non-overlapping LSDV subclones, the edited DNA sequences

were first translated to amino acid sequences in six reading frames, after which open reading frames (ORFs) of at least 50 amino acids were identified visually, and blasted against the SwissProt protein database. Homologous poxvirus proteins were then used as templates to assemble the LSDV DNA fragments into continuous sequences. Oligonucleotides were designed from the DNA sequences to sequence the regions spanning the gaps between clones. Further analysis included the identification of specific protein motifs (SMART), and the identification of the regulatory promoter sequences. Thirty four LSDV ORFs are encoded in the sequenced regions, representing a diverse group of potential proteins involved in functions such as viral transcription and mRNA synthesis, nucleotide metabolism, protein modification, structural functions, cellular functions and most importantly, host-related functions. Additionally, one LSDV ORF without homology to any other poxvirus protein has been identified, suggesting that this protein is possibly involved in the limitation of LSDV to bovine cell infection.

LIST OF TABLES

Table 1 -	Classification of the <i>Poxvirinae</i>	8
Table 2 -	Commercial primers for the sequencing of bacterial vector plasmids....	52
Table 3 -	Primers designed for primer-walking sequencing to sequence gaps.....	53
Table 4 -	Summary of RE sites in LSDV <i>PstI</i> clones -E, -M, -K, -F and -G.....	59
Table 5 -	Identified LSDV ORFs and blastp matches of known specific genes with known or unknown function.....	82
Table 6-	E5L - Identification of ankyrin repeats.....	86
Table 7 -	E6L - Identification of Immunoglobulin-like domains.....	86
Table 8 -	F4R - Identification of tyrosine phosphatase motifs.....	87
Table 9 -	Identification of transmembrane regions.....	87
Table 10 -	Identification of signal peptide sequences.....	88
Table 11 -	Nucleotide composition.....	96

LIST OF FIGURES

Figure 1 -	Clinical signs of cow with LSDV.....	7
Figure 2 -	Micrograph of cowpox virus (Dr. F. Fenner).....	12
Figure 3 -	Micrograph of cowpox virus - thin section (Dr. F. Fenner).....	13
Figure 4 -	Late promoter consensus sequence (Davison and Moss, 1989).....	24
Figure 5 -	A linear representation of the LSDV <i>PstI</i> map.....	45
Figure 6 -	Restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -M clone	60
Figure 7 -	Restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -K clone	61
Figure 8 -	<i>DraI</i> RE maps of pGEM/pMOS recombinants in insert orientations A and B.....	63
Figure 9 -	<i>DraI</i> digests of recombinant 1 200 bp clones, illustrating recombinant K1200 and recombinant pMOS/pGEM in orientations A and B.....	64
Figure 10 -	Restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -E clone	65
Figure 11 -	Restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -F clone	67
Figure 12 -	Restriction endonuclease mapping and sub-cloning of the <i>PstI</i> -G clone	68
Figure 13 -	Restriction endonuclease map of clone BC6	70
Figure 14 -	Linear comparison between the left-hand terminal regions of SPV, LSDV and VV genomes.....	97
Figure 15 -	Alignment of LSDV early promoters with the VV consensus.....	100
Figure 16 -	Alignment of LSDV late promoters with the VV consensus sequence...	102
Figure 17 -	Alignment of LSDV intermediate promoters with two characterised VV intermediate promoters, I3 and I8 (Hirschman <i>et al.</i> , 1990) and the LSDV consensus sequence.....	104

ABBREVIATIONS

A	-	adenine
Å	-	angstrom
A ₂₆₀	-	absorbency at 260 nanometer
aa	-	amino acid
AD	-	Anno domini
AMP	-	ampicillin
ANK	-	ankyrin repeat motif
ATPase	-	adenosine triphosphatase
bp	-	base pair
°C	-	degrees Celcius
C	-	cytosine
CaCl ₂	-	calcium chloride
CAM	-	chorioallantoic membrane
CAP	-	capripox virus
CHO	-	chinese hamster ovary
CIP	-	calf intestinal phosphatase
CPV	-	cowpox virus
dNTP	-	2'-deoxyribonucleoside-5'-triphosphate
ddNTP	-	dideoxynucleotide triphosphate
dH ₂ O	-	distilled, sterilised water
DMSO	-	dimethyl sulfoxide
dNTP	-	deoxynucleotide triphosphate
DNA	-	deoxyribonucleic acid
ds	-	double stranded
DSPc	-	dual specificity phosphatase, catalytic domain
DTT	-	dithiothreitol

<i>E. coli</i>	-	<i>Escherichia coli</i>
EDTA	-	ethylene diamine tera-acetate
EGF	-	epidermal growth factor
EPG	-	electropherogram
EPV	-	entomopoxvirus
EtBr	-	ethidium bromide
EtOH	-	ethanol
Fig.	-	figure
FPV	-	fowlpox virus
FTP	-	file transfer protocol
G	-	guanine
GP	-	goatpox virus
h	-	hour
IG	-	immunoglobulin
IL	-	interleukin
IFN	-	interferon
ITR	-	inverted terminal repeat
kbp	-	kilobase pairs
KCl	-	potassium chloride
kD	-	kilodalton
LB	-	Luria-Bertani
LD ₅₀	-	lethal dose 50
LSD	-	lumpy skin disease
LSDV	-	lumpy skin disease virus

M	-	molar
MCP	-	monocyte chemotactic protein
MCS	-	multiple cloning site
MCV	-	molluscum contagiosum virus
mM	-	millimolar
MnCl ₂	-	manganese chloride
mRNA	-	messenger ribonucleic acid
MsEPV	-	melanopus sanguinipes entomopox virus
MYX	-	myxoma virus
µg	-	microgram
µl	-	microlitre
mg	-	milligram
MHC	-	major histocompatibility complex
min	-	minute
ml	-	millilitre
NaOAc	-	sodium acetate
NaOH	-	sodium hydroxide
ng	-	nanogram
nt	-	nucleotide
OD	-	optical density
OIE	-	Office International des Epizooties
ORF	-	open reading frame
OV	-	orf virus
OVI	-	Onderstepoort Veterinary Institute
p	-	plasmid
Pipes	-	Piperazine-N, N'- bis[2-ethane-sulfonic acid]
Ppi	-	inorganic pyrophosphate

PTPc	-	Protein tyrosine phosphatase, catalytic domain
RE	-	restriction endonuclease
RNA	-	ribonucleic acid
RNAse A	-	ribonuclease A
RPOL	-	ribonucleic acid polymerase
rpm	-	revolutions per minute
RVFV	-	rift valley fever virus
S	-	seconds
SFV	-	sheep fibroma virus
SP	-	sheeppox virus
SPV	-	swinepox virus
str	-	strain
T	-	thymine
TBE	-	tris borate EDTA
TEMED	-	tetramethylethylenediamine
TK	-	thymidine kinase
TNF	-	tumor necrosis factor
U	-	unit
UNIX	-	uniplexed information and computing system
UV	-	ultraviolet
VAR	-	variola virus
VETF	-	viral early transcription factor
VGf	-	virus growth factor
VV	-	vaccinia virus



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

CHAPTER I

Review of the Literature

1.1 INTRODUCTION

1.1.1 Poxviruses in history. The Poxviridae is a large family of double-stranded DNA viruses that infect vertebrates (the Chordopoxvirinae) and insects (the Entomopoxvirinae). These viruses are characterised by complex capsid architecture, their ability to replicate in the cytoplasm of infected cells, and their efficiency in de-arming or delaying many different host antiviral responses.

Although vaccinia virus is the type member of the family (Fenner, 1979), probably the most famous member is the agent of the historical smallpox scourge of mankind; i.e. variola virus, which is now eradicated. Smallpox first appeared in China and the Far East at least 2000 years ago, and the Pharaoh Ramses V is believed to have died of the smallpox in 1157 B. C. (Fenner *et al.*, 1988; Hopkins, 1983). The disease was established in Europe in 710 A. D., and was introduced to America by Hernando Cortez in 1520, causing the deaths of at least 3.5 million Aztecs in the next two years. Meanwhile, in the great cities of 18th century Europe, smallpox had reached plague proportions, killing hundreds of thousands of people. At least five reigning European monarchs succumbed to the virus during the 18th century (Hopkins, 1983).

The practice of variolation originated around the 10th century- Asia, Africa and China, whereby pus from a smallpox pustule was deliberately inoculated into the skin, in the hope that a mild, protective and non-transmissible disease would result (Baxby, 1991). Properly done, it did produce a protective lifelong immunity against the naturally spreading disease, but had a mortality of about one in 200. In spite of the risks, variolation was successfully introduced into England by Lady Mary Wortley-Montagu and into America Cotton Mather and Zabdiel Boylston in 1721 (Miller, 1957; Winslow, 1974), providing some control over the spread of the disease. The most important advance in the control of smallpox, however, was the introduction of vaccination (*vacca* = cow) by Edward Jenner. On the 14th of May, 1796, Edward Jenner used cowpox inoculate from a milkmaid, Sarah Nemes, to “vaccinate” eight year old James Phipps, who Jenner later challenged with variola virus, and showed that the boy was protected.

Vaccination had the advantage over variolation that it had no mortality and left a trivial lesion at the vaccination site (Jenner, 1798).

For at least 100 years thereafter, the “vaccine” strains were propagated from arm to arm, with vaccination almost universally adopted worldwide around 1800. Although the virus was eradicated from Europe and North America, it remained endemic in South America, Africa and Asia. In 1967 smallpox was still endemic in 33 countries, and it was the Intensified Smallpox Eradication Program initiative of the World Health Organization, which aimed to achieve global eradication of smallpox within ten years, that finally achieved eradication of smallpox’s variola virus. The last case of endemic smallpox occurred in Merka, Somalia, in October 1977. In 1980, the WHO declared smallpox eradicated, and in March 1983, the WHO reported that 155 of its 160 member states and associated members had officially discontinued vaccination (Nakano, 1986).

Fenner regularly used the abovementioned eradication of smallpoxvirus as an example of biological control in his Florey lectures of 1979, in the context that a virus can be used to confer protective immunity against a related but pathogenic one. A classic example of biological control however, is provided by another of the poxvirus family members: myxoma virus causes a mild, benign infection in its evolutionary host, the North American brush rabbit (*Sylvilagus californicus*) or the South American tapeti (*Sylvilagus brasiliensis*), but it causes a rapid systemic and lethal infection, known as myxomatosis, in European rabbits (*Oryctolagus cuniculus*). Mortality rates reach up to virtually 100% (Fenner, 1983). Myxomatosis was deliberately introduced into Australia in 1950 and into Europe in 1952 to control *O. cuniculus*. It was at first spectacularly successful in controlling the rabbit pest (Fenner, 1983), but later proved to be ineffective, due to the combination of increased host resistance in the surviving rabbit populations and genetic attenuation of field virus strains (Fenner and Ratcliffe, 1965; Kerr and Best, 1998). Despite its ultimate failure to control the rabbit population, myxomatosis is an extensively-characterised veterinary disease that provides a well-defined *in vivo* model for the study of virus-encoded virulence factors, including those involved in the evasion of the host immune response (Cameron *et al.*, 1999).

1.1.2 The origins, epidemiology, and distributions of capripoxviruses

“Knopvelsiekte”, referring to the characteristic lumps in the hide of infected cattle, is an alternative name for lumpy skin disease (LSD) in southern Africa, and was first described in 1931 under the name of “pseudo-urticaria” by MacDonald in Northern Rhodesia. According to him, the disease had been completely unknown to the experienced cattlemen of the area when the disease made its appearance in Lusaka and Mazabuka in 1929 (MacDonald, 1931; Morris, 1931). Von Backstrom (1945) described the same disease as “Ngamiland cattle disease” in 1945, when it broke out in Bechuanaland, and in 1944 it was reported in the Marico district of Northern Transvaal, by Mare (Thomas and Maré, 1945).

In March of 1945, material collected from the Marico outbreak was taken to Onderstepoort Veterinary Institute, where Thomas, Robinson and Alexander used it in transmission experiments. They injected emulsions of skin nodules into a group of cattle housed in the isolation stables. Five animals reacted from the fourth to the thirty-eighth day after injection. By some unknown manner, the infection spread from the isolation stables, to two other stables located some 80 and 200 yards away, respectively. These stables were being maintained as *Anaplasma centrale* reservoirs. In a period of 77 days after the first case was observed at Onderstepoort, 43 of the 83 animals in the *A. centrale* stables manifested clinical symptoms of LSD, and an unknown number developed inapparent signs. Some of these inapparently-infected cattle (which later proved to be infected) were bled to several farmers, and two of the oxen bled on the 16th of March showed clinical symptoms on the very next day, but it was too late to recall the blood, as most of it had already been used. Twelve days later, a number of cattle inoculated with the infected blood developed the clinical symptoms of lumpy skin disease. This was the first positive proof that the disease could be transmitted by blood inoculation (Henning, 1949).

While the epizootic was at its peak at Onderstepoort, lumpy skin disease broke out on three neighbouring farms separated from the institute by the Apies River. All cattle in the area, including those from the Institute’s stables, watered at this river, although the 600

cattle kept on Kaalplaas, a region of the institute located about two miles from the infected stables, did not appear to be affected by the disease outbreak. At the end of May 1945, a number of outbreaks also occurred in the nearby then-village of Pretoria North, but it was not clear if these outbreaks were associated with the Onderstepoort epizootic, or if the disease had been contracted from animals that were brought from the Western Transvaal.

For the rest of 1945 and throughout 1946 the disease spread throughout South Africa, reaching the Cape peninsula in June 1946. During this time, it also entered Swaziland, Natal and Mozambique (MacOwan, 1959). Despite its rapid spread, the disease often jumped for several miles, leaving large areas unaffected. Diesel recorded in 1949 that approximately 8 000 000 animals had been infected with the disease. By 1956, lumpy skin disease had been reported from the Belgian Congo, Northern and Southern Rhodesia, South West Africa, and Madagascar (I. B. E. D., 1956). Lumpy skin disease was confirmed in Kenya for the first time in December 1957 in the Nakuru farming district (MacOwan, 1959). From then on it was recorded in Sudan in 1971, Chad in 1973 and Niger in 1973, suggesting an initial northward and then westward extension of the disease (MacOwan, 1959; FAO reports, 1973; Ali and Obeid, 1977). In 1974, an epizootic was recorded in Nigeria's Federal Capital Territory (Nawathe *et al.*, 1978). The first reports of LSD outside of Africa were from Kuwait in 1986 to 1988 (Anonymous, 1988), and the disease was subsequently diagnosed in the cattle of the village of Tel El Kabir, Egypt, in October 1988 (House *et al.*, 1990).

In contrast, the other capripoxvirus family members are endemic in sheep and goats in Central and North Africa, the Middle East, Pakistan, India, Nepal and parts of the Chinese Peoples Republic (FAO, 1985), where they are considered to be of major economic importance in sheep and goat husbandry (Kitching, 1983). Sheep- and goatpox has been endemic to the Yemen Arab Republic and the Sultanate of Oman since the early eighties (Kitching *et al.*, 1986). Sheeppox has also been recorded in recent years in Italy, and goatpox has been reported in the western USA and Sweden (Odend'hal, 1983).

1.1.3 The clinical disease. Clinically, lumpy skin disease can be acute, sub-acute or inapparent in the bovine host. The disease is characterised by fever and the sudden appearance of firm circumscribed skin nodules, 1-5 cm in diameter and larger, which affect the full thickness of the skin. The lesions usually undergo necrosis. Similar lesions may be present in the skeletal muscles and the mucosae of the digestive and respiratory tracts. Lameness resulting from inflammation and necrosis of tendons, and from severe oedema of the brisket and legs are also characteristic of the disease (Weiss, 1968). Superficial lymph nodes draining infected areas of the skin may become enlarged to up to ten times their normal size (Weiss, 1968). While morbidity may vary from 5 to 100 %, mortality rarely exceeds 5% (Woods, 1988). Direct losses due to lumpy skin disease are not the main reason that LSD is considered a disease of major economic importance in Africa. Main economic losses result from indirect causes, for example, secondary infection, sterility, stenosis of the trachea, cachexia, decreased milk yield (up to 50% yield loss) and damage to the hide (Henning, 1949). LSDV is classified as an OIE List A disease (OIE Manual, 1996). A disease closely resembling lumpy skin disease clinically is caused by a completely unrelated virus of the herpes virus group. This so-called “Allerton” virus, also known as pseudo-lumpy skin disease, was described by Weiss in 1963. The virus has since been identified as bovine herpes virus II (Nawathe *et al.*, 1978).



Figure 1: Clinical signs of cow with LSDV (Photograph with courtesy of Dr. P. Hunter, OVI)

The virus causing lumpy skin disease was first isolated in tissue culture by Alexander *et al.* (1957). It was subsequently recovered on numerous occasions from the skin lesions of infected cattle in South Africa as well as Kenya. There is no doubt that this virus, described by Alexander *et al.* (1957) as the Group III virus (prototype Neethling), is the cause of lumpy skin disease (Alexander and Weiss, 1959; Prydie and Coackley, 1959).

1.2 CLASSIFICATION

Smallpox was specifically a human disease, and molluscum contagiosum virus, of the genus molluscipoxvirus, still afflicts only humans. Some poxvirus family members, like the cowpox, monkeypox and vaccinia viruses, have a wide range of potential hosts, while others like variola, camelpox and the lumpy skin disease viruses are restricted to a narrow host range. Capripoxviruses affect only ungulates, usually causing clinical disease in only one species (Weiss, 1968). The factors that determine this host range specificity or lack thereof at the genomic level are of major interest in this study.

Table 1: Classification of the *Poxvirinae*

Subfamily	Genus	Members	Natural Host
Chordopoxvirinae	Avipoxvirus	Fowlpox virus Canary pox Junco pox Pigeon pox Quail pox Sparrow pox Starling pox Turkey pox	Birds
	Capripoxvirus	Sheeppox virus Goatpox virus lumpy skin disease virus	Ungulates Ungulates Cattle
		Cotia virus- unclassified (Ueda <i>et al.</i> , 1995)	Unknown
	Leporipoxvirus	Myxoma virus Shope fibroma virus Hare fibroma virus Squirrel fibroma virus	Leporids and Squirrels
	Molluscipoxvirus	Molluscum contagiosum	Humans

Orthopoxvirus	Vaccinia virus Variola virus- variola major - Alastrim variola minor Buffalopox Camelpox Cowpox Monkeypox Rabbitpox Raccoonpox Taterapox volepox ectromelia virus (mousepox)	Very broad	
Parapoxvirus	Orf virus Pseudocowpox Chamois contagious ecthyma	Ungulates	
Suipoxvirus	Swinepoxvirus	Pigs	
Yatapoxvirus	Yaba monkey tumor virus Tanapox	Primates	
Entomopoxvirinae	Entomopoxvirus A	<i>Melolontha melolontha</i> EPV	Coleopterans
	Entomopoxvirus B	<i>Ansacta moorei</i> EPV	Lepidopterans
	Entomopoxvirus C	<i>Chironomus luridus</i> EPV	Dipterans
		<i>Melanoplus sanguinipes</i> EPV	Orthopterans

(Cameron *et al.*, 1999; Afonso *et al.*, 2000; Moss, 1990). Prototypal members and natural restricted hosts are boldfaced.

1.2.1 Capripoxviruses and their host specificities. Sheep- and goatpox viruses both cause highly contagious diseases, but differ with respect to incubation periods and virulence in their respective hosts. Sheeppox is often fatal in sheep, whereas goatpox is usually less severe. Some authors have distinguished between the host specificities of the Kenyan sheep- and goatpox strains, and those of the Middle East and India (OIE, 1989; Merck Vet. Man., 1986; Odend'hal, 1983; Kitching, 1983). Thus, Kenyan strains have been described which infect both sheep and goats, whereas a virus such as the Sersenk strain of goatpox virus from Iraq is strictly pathogenic for goats (Kitching, 1983). Lumpy skin disease virus is closely related to the sheep- and goatpox viruses (Alexander *et al.*, 1957; Prydie and Coakley, 1959). LSDV isolates from different countries cannot be distinguished serologically from each other, and LSDV cannot be differentiated from the sheep and goat pox viruses by serum neutralization and fluorescent antibody tests (Davies

and Otema, 1981). Despite the close serological relatedness, there is only one type of virus responsible for true lumpy skin disease (Weiss, 1968).

All of the capripoxviruses studied so far have been shown to share a very high (> 95.8%) nucleotide sequence homology (Gershon and Black, 1988). Kitching *et al* (1989) demonstrated that it is possible to study and compare individual virus isolates by the use of simple restriction endonuclease digest patterns. The endonuclease *HindIII* has proved to be the most useful to distinguish between capripoxvirus isolates, as digestion produces approximately 40 fragments with a wide range of sizes (Kitching *et al.*, 1989). This approach was used by Kitching and colleagues (1989) to subdivide the capripoxviruses into four types: Type I isolates were derived from sheep only and type II isolates were derived exclusively from goats. Type III isolates were derived from sheep, goats and cattle but were restricted to Africa, whereas type IV isolates were derived from sheep or goats in the Middle East or Africa (Gershon *et al.*, 1989). It has also been suggested that a type IV isolate may have arisen by genetic recombination between a type II and type III isolate (Gershon *et al.*, 1989), which has implications for the use of recombinant pox virus vaccines, where recombination with a naturally occurring pox virus may occur.

1.2.2 Transmission and spread. Many African and some Middle-Eastern countries support large populations of free-living indigenous wild animals in addition to domestic animals, and their possible role in maintenance and spread of LSD has been investigated: LSD may possibly be transmitted by biting insects (Weiss, 1963; Haig, 1957). In field outbreaks, the resurgence of the disease has been consistently associated with the onset of rains and the emergence of large numbers of the suspected vectors, *Stomoxys calcitrans* and *Culex mirificus* (Woods, 1988). For viral transmission to occur, very close contact between animals may therefore not be necessary. Only cattle have been reported to be affected during outbreaks of LSD, but Davies (1980) reported antibodies in a high proportion in buffalo in East Africa following an epizootic in cattle. Despite this, he failed to detect antibodies in sera from seven other species of wild ruminant examined (Davies, 1982). However, Hedger and Hamblin's (1983) study of free-living wildlife demonstrated antibodies in impala (*Aepyceros melampus*), giraffe (*Giraffa camelopardalis*), kudu (*Tragelaphus strepsiceros*), waterbuck (*Kobus ellipsiprymnus*)

reed buck (*Redunca arundinum*) and springbok (*Antidorcas marsupialis*). In giraffe and reedbuck, virus neutralising titres were of similar levels to those in convalescing cattle, and were assumed to be indicative of past infection. Some ten years prior to the aforementioned surveys, Young *et al.* (1970) investigated the pathogenicity of LSDV for wild species, artificially infected giraffe, impala, African buffalo (*Syncerus caffer*) calves and black wildebeest (*Connochaetes gnou*) with LSDV. Both giraffe and impala died with macroscopic and microscopic lesions characteristic of LSD in cattle, and a significant rise in antibodies was recorded in the impala before death. Neither wildebeest nor buffalo responded clinically or serologically to inoculation of virus.

Since virus isolation from these wild animals has not yet been successful, it has been difficult to place significance on serological titres in random surveys, when only low neutralising antibody titres are recorded. It is known that sera from some animals may contain non-specific inhibitors (Patty, 1970). Due to the close serological relationship between LSD and Kenya sheep- and goatpox viruses, it is possible that some low serum neutralisation titres in wild animals may be due to cross-reactions with other as yet unidentified viruses. Failure of virus isolation and negative or low titres in the above serosurveys would therefore suggest that wildlife might not play a significant part in the maintenance and spread of LSDV (Hedger and Hamblin, 1983).

1.3 THE MOLECULAR BIOLOGY OF POXVIRUSES

1.3.1 Morphology. Munz and Owen (1966) examined negatively stained preparations of purified LSDV under the electron microscope, and observed virus particles that were morphologically similar to the M-forms of VV described by Westwood *et al.* (1964) or the type I VV particles described by Nagington and Horne (1962) and Müller and Peters (1963). Poxvirus virions are oval or brick-shaped bodies about 200 to 400 nm long with axial ratios of 1.2 to 1.7. The external surface contains ridges that may be arranged in parallel rows or, in the case of parapoxviruses, as a single continuous helix. LSDV virions are approximately 295 x 270 nm and are either seen as the the “M” or mulberry form because of a covering of cord-like elements (Kitching and Smale, 1986), or as the “C” or capsule form, also observed by Muntz and Owen (1966), which is surrounded by a membrane. LSDV virus particles measure approximately 3500 Å in length, and 3000 Å in width, with an axis ratio in the region of 1.2 (Munz and Owen, 1966).




Figure 2: Micrograph of cowpox virus (Dr. Frank Fenner, Australian National University, 1997). Specimen stained with 3% phosphotungstic acid (PTA). The bar represents 100 nm

In cross-section, a pox virion displays a lipoprotein bi-layer, called the outer membrane, surrounding the core. Extracellular forms of poxviruses, released by budding, have been

shown to contain an additional lipoprotein envelope scavenged from the host Golgi apparatus (Dales and Siminovitch, 1961; Medzon and Bauer, 1970; Nagington and Horne, 1962; Peters, 1956). In vertebrate poxviruses, including LSDV, the core appears biconcave with two structures of unknown function, called lateral bodies, nestled in the concavities. In contrast, the core of insect poxviruses may be kidney-shaped with a single lateral body, or brick-shaped, with surrounding material of intermediate density (Westwood *et al.*, 1964; Easterbrook, 1966). The core itself houses a twisted and folded nucleoprotein fiber (Solosky and Holowczak, 1981; Peters, 1956).




Figure 3: Micrograph of cowpoxvirus- thin section (Dr. Frank Fenner, Australian National University, 1997)

lb- lateral bodies, c-core

the bar represents 100 nm

1.3.2 Genome structure. Poxviruses have the largest known viral genomes (139-288 kbp) each consisting of a linear, double-stranded DNA molecule with covalently linked termini (Baroudy *et al.*, 1982). Cross-linking of poxvirus DNA was first considered because of the rapid renaturation of fowlpox and vaccinia virus DNA, and the inability to separate the two strands (Berns and Silverman, 1970; Jungwirth and Dawid, 1967;

Szybalski *et al.*, 1963). These terminal A+T-rich incompletely base-paired loops of about 100 nucleotides each, were later confirmed by direct sequencing (Baroudy *et al.*, 1982; DeLange *et al.*, 1984). The two ends of the genome inside of the hairpin loops are identical but inverted in sequence (Garon *et al.*, 1978; Wittek *et al.*, 1978). Such inverted terminal repetitions (ITRs) vary in length from 0.7 kbp in the Bangladesh strain of variola, to 12 kbp in the Copenhagen strain of vaccinia (Goebel *et al.*, 1990; Massung *et al.*, 1994). In place of ITRs, variola virus has asymmetrical small arrays in the terminal regions, which distinguishes variola DNA from DNA of many other orthopoxviruses (Fenner *et al.*, 1989; Esposito and Knight, 1985; Antoine *et al.*, 1998; Shchelkunov *et al.*, 1995). Shope fibroma virus terminal inverted repeats seem to be lacking in any repetitive DNA (Willer *et al.*, 1999). In some cases, terminal repeat regions contain expressed genes thought to contribute to phenotypic variability, host-range specificity and pathogenicity (Wittek *et al.*, 1980). The large, conserved central DNA region predominantly contains genes essential for virus structure and replication (Fenner *et al.*, 1989; Buller *et al.*, 1991; Moss *et al.*, 1990; Esposito and Knight, 1985; Esposito, 1991). Gene density for poxviruses is very high, and ORFs are usually separated by only a small number of bases. The fowlpox genome, currently the largest sequenced (288 kbp), contains 260 ORFs (Afonso *et al.*, 2000). The large number of genes is possible due to the apparent absence of introns, the relatively short promoter sequences, and relatively short ORFs. Although both strands of poxvirus DNA are transcribed, overlapping genes are not common. Early and late genes frequently occur in clusters, but can be dispersed across the length of the genome (Moss, 1990).

The genome of capripoxviruses has been partially characterised by hybridisation studies, and shows clear similarities to other poxviruses, notably vaccinia. For example, genome fragments of vaccinia virus and capripox virus cross-hybridise under low-stringency conditions, and a 100-115 kb piece of the genome is co-linear in organisation within the two viruses (Gershon *et al.*, 1989). No cross-hybridisation could be detected between VV DNA and the respective left- and right-hand terminal 8 and 25 kb of capripoxvirus DNA or between capripoxvirus DNA and the respective left- and right-hand terminal 38 and 35 kb of VV. An exception was the hybridisation of the 4.5 kb *HindIII* K-fragment from the

left end of vaccinia to a region near the right end of the capripoxvirus genome. This is a small region that could have translocated between the ends of one or other of the genomes during their divergence (Gershon *et al.*, 1989). From summation of the lengths of restriction endonuclease fragments separated by pulsed field gel electrophoresis, SALSDV genome size was determined to be 152 kbp (unpublished data, cited by Fick and Viljoen, 1994).

A high A+T- content of capripoxvirus genomes is indicated by the presence of relatively high frequency of A+T-rich restriction enzyme sites for example *DraI*, and relatively low frequency of G+C-rich sites for example *PstI* and *Sall*. The A+T- content for the capripox thymidine kinase (TK) gene, for example, has been determined as 72.4%, in contrast to 66.4%, 61.6%, and 68.6% for VV, SFV and FPV, respectively (Gershon and Black, 1989). The genomes of the parapoxviruses, which have the same host-range as the capripoxviruses, are of a similar size but have a A+T content of around 37% (Wittek *et al.*, 1979). The high A+T content of capripox DNA may reflect virally controlled aspects of DNA synthesis, such as the characteristics of the capripoxvirus DNA polymerase, or the levels of expression of virally encoded enzymes involved in the biosynthesis of A or T nucleotides, such as TK (Gershon and Black, 1989). In the latter respect, the genomes of poxviruses reported to possess a TK gene are A+T-rich, whereas the presence of a TK gene has not been reported on the G+C-rich genomes of the parapoxviruses (Gershon and Black, 1989). As a result of their widely different G+C contents, the OV and vaccinia (VAC) genomes do not cross-hybridise and homology between these two viruses is evident within the predicted amino acid sequences, but is generally not evident within the DNA sequences (Mercer *et al.*, 1995).

1.3.3 Poxvirus replication. The large dsDNA genomes of poxviruses enable them to have complex virions, and to produce a range of virus-specific enzymes, unlike more limited viruses, which are heavily dependent on cellular enzymes and processes. For example, the enzyme thymidine kinase, which supplies components of eukaryotic DNA synthesis, is only present in actively dividing eukaryotic cells. By producing viral versions of cellular enzymes, the virus ensures that they are available when and where the

virus needs them. The production of infectious virions is dependent on cellular RNA polymerase II (Hruby *et al.*, 1979; Silver *et al.*, 1979; Spencer *et al.*, 1980). Uniquely, for poxviruses and African swine fever virus, their DNA is replicated in the cytoplasm rather than the nucleus, although vaccinia DNA has been demonstrated in the nucleus of infected cells in some systems (La Colla and Weissbach, 1975; Gafford and Randall, 1976, Archard, 1983).

Poxvirus replication occurs in distinct phases. Instead of producing all of the viral proteins simultaneously, poxviruses produce different groups of proteins spread across the genome at particular and appropriate times. The timing is often dependent upon prior viral syntheses, and on specific viral control functions. Different promoters control the transcriptional timing for each group of proteins, which are activated by different but specific stimuli. Most of the current knowledge of poxvirus-gene expression and mRNA synthesis is derived from studies on vaccinia virus (Moss 1990, 1992). Gene expression was initially divided into two phases, namely an early and a late phase, but the discovery of an intermediate class of genes called for a revision of the model for vaccinia virus reproduction, and indicated a more elaborate control of gene expression during the virus infectious cycle (Vos and Stunnenberg, 1988). A cascade model has been proposed, in which early proteins are required for intermediate transcription and proteins encoded by intermediate genes are required for the activation of late transcription (Vos and Stunnenberg, 1988). Furthermore, DNA replication is involved in the regulation of gene expression, a mechanism commonly used among DNA viruses (Tooze, 1981).

a) Entry and uncoating, and transcription of early genes

Both single- and double-membrane forms of poxviruses are infectious. Enveloped virions enter the cell by fusion of the envelope with the cell membrane (Chang and Metz, 1976), although electron micrographs have also demonstrated virus particles fused to membranes within vacuoles caused by surface invagination, which is the entry route for single-membrane forms (Dales and Kajioka, 1964). The epidermal growth factor (EGF) receptor has been implicated as the portal of entry for vaccinia viruses (Eppstein *et al.*, 1965; Marsh and Eppstein, 1987). Soon after penetration, the outer membrane of the

virion is degraded by cellular enzymes, exposing the viral core. After the virus cores have been released into the cytoplasm, a second uncoating event, controlled by the viral genome occurs. A putative 23 kD uncoating protein with trypsin-like activity has been described by Pedley and Cooper (1987), and the uncoating of all cores in the cell is synchronized (Cairns, 1960; Jolik, 1964; Dales, 1965). The nucleoprotein complex passes out through pores in the core walls (Dales, 1965).

Early transcription starts immediately after the virus has entered the cell, and does not require *de novo* synthesis of viral factors or enzymes: all the necessary components, including by the viral polymerase responsible for transcription, are present in the infectious virus particle (Caplan and Holowczak, 1983; Kates and McAuslan, 1967; Munyon *et al.*, 1967). The poxvirus is therefore fully equipped to synthesize fully functional mRNA. Eukaryotic mRNAs typically have a methylated cap structure at their 5' ends. Capping and methylation of vaccinia virus mRNA is accomplished by a 127-kD multifunctional enzyme complex composed of 97-kD and 33-kD subunits (Boone *et al.*, 1977). Polyadenylation of the viral 3'-mRNA tails is catalyzed by the poly(A)polymerase of vaccinia virus, which contains a 55-kD and a 33-kD subunit. Polyadenylation is thought to be important for the stability of mRNA molecules (Moss *et al.*, 1975). Other components of this transcriptional system have been characterised and include DNA topoisomerases, which modify the topological state of DNA via the breakage and rejoining of DNA strands. Poxviruses are the only known eukaryotic viruses that encode their own topoisomerases. The DNA topoisomerase is able to relax both positively and negatively supercoiled DNA in the absence of an energy cofactor, and has the properties of a cellular type I enzyme, except that it is resistant to camptothecin (Bauer *et al.*, 1977; Fogelson and Bauer, 1984; Shaffer and Traktman, 1987; Shuman *et al.*, 1988). The failure of attempts to construct a mutant vaccinia virus with deletions within the topoisomerase gene suggest that it plays an essential role in the replication cycle of poxviruses (Shuman *et al.*, 1989).

Other components of the proposed transcriptional system include a deoxyribonuclease enzyme with ligase activity, which can catalyze nicking-joining reactions (Lakritz *et al.*,

1985; Pogo and O'Shea, 1977; Merchlinsky *et al.*, 1988; Reddy and Bauer, 1989), a DNA-dependent ATPase thought to play a role in gene expression (De Lange, 1989), and a serine/threonine protein kinase (Kleiman and Moss, 1975; Kleiman and Moss, 1975). Factors required for initiation (Broyles *et al.*, 1988; Broyles and Moss, 1988) and termination (Shuman *et al.*, 1987; Shuman and Moss, 1988) have also been described.

The ability of extracts of vaccinia virus cores to transcribe early genes *in vitro* (Golini and Kates, 1985; Rohrman and Moss, 1985) suggested the presence of a specific transcription factor, which exists in a labile complex with RNA polymerase and the mRNA-capping enzyme (Broyles and Moss, 1987) and which are (late proteins) packaged into newly assembled virus particles (Vos and Stunnenberg, 1988). Highly purified RNA polymerase preparations were unable to initiate RNA synthesis, which prompted a complementation assay for transcription factors. A specific vaccinia virus early transcription factor (VETF) was detected and isolated from core extracts (Broyles *et al.*, 1988). Purified VETF is a heterodimer of two polypeptides of 82 kD and 77 kD, and displays DNA-dependent ATPase activity. The VETF binds to early promoters, the transcriptional start site for early genes, in a manner comparable to the TATA-box factor of eukaryotic RNA polymerase II promoters (Breathnach and Chambon, 1981; Broyles *et al.*, 1988).

Early transcripts, which are less abundant than late transcripts, are of a defined length (Venkatesan *et al.*, 1981). This is due to the fact that early mRNA transcription is terminated by a specific early transcriptional stop signal, TTTTNT (Rohrman *et al.*, 1986; Yuen and Moss, 1987). Transcription stops 20 to 50 bp downstream of the TTTTNT termination sequence of many VV early genes (Yuen and Moss, 1987). Sometimes, the terminator is far downstream of the end of the coding region, at other times, inside a late gene; furthermore, it is not uncommon for a single terminator to occur following two or more early genes, suggesting the formation of a 3'-co-terminal nested set of mRNAs. Examples of internal terminator sequences, thought to be non-functional because of secondary RNA structure, have been noted in a few VV genes (Lee-Chen *et al.*, 1988; Luo and Shuman, 1991). Several approaches have been taken to define the

In contrast with the critical region, which tends to be A-rich, the spacer region in natural promoters tends to be T-rich (Davison and Moss, 1989). The sequence of the spacer region has only a limited effect on promoter strength, since no mutation in this region was found to prevent transcription (Davison and Moss, 1989). Davison and Moss (1989) also proposed a simple model for transcriptional initiation, in which the critical region binds a transcription factor, thus allowing entry of the RNA polymerase complex. The latter might associate with the factor before or after the factor has bound to DNA. Initiation then takes place at a certain distance from the binding site, dictated by the stereochemistry of the complex formed between transcription factor, RNA polymerase and template DNA. The region in which initiation can occur efficiently has a size of 7 bp *in vivo*, but can be considerably larger *in vitro*. The reasons for this difference are unknown, but may depend on the higher order of molecular structure present in the virion than is present in the *in vitro* system. In the study of Davison and Moss (1989), with only one exception, initiation was confined to purines. In fact, initiation did not occur in the initiation region if purines were absent, even if the critical region was present. The sequence at the initiation site has an effect on promoter strength owing to several features: the presence of A and G residues, their locations with respect to the critical region, and their context. Most natural promoters have more than one purine in the initiation region, and the rules governing the relative use of each initiation site appear complex. Beyond the level of promoter sequence, the possibility remains open that the level of expression of a particular early gene may be influenced by its location with respect to adjacent genes (Davison and Moss, 1989). One LSDV early promoter PA8R, from the *BamHI* P-fragment of the Neethling strain has been characterised. PA8R closely resembles critical regions of known poxvirus early promoters (Fick and Viljoen, 1999).

b) DNA replication

Vaccinia DNA replication starts about two hours after infection, quickly reaches a maximum and ceases a few hours before infectious progeny virions are produced. Viral DNA is nicked immediately after uncoating (Pogo, 1977), possibly by the site-specific nuclease described by Lakritz *et al.* (1985), or even the DNA topoisomerase (Sharma *et al.*, 1994). The vaccinia virus DNA polymerase is expressed early in infection, and has a

molecular weight of about 110 kD and an associated 3'-exonuclease activity (Chalberg and Englund, 1979). DNA replication begins near the ends of the molecule, and involves a strand displacement mechanism, with the formation of small DNA fragments covalently linked to RNA primers (Esteban *et al.*, 1977). Only one strand is replicated from either end (Pogo *et al.*, 1981). There is evidence for concatameric forms of replicated DNA (Archard, 1979; Moyer and Graves, 1981; Holowczak, 1983; Baroudy *et al.*, 1983). Cross-linking of the progeny molecules occurs late in the infectious cycle (Esteban and Holowczak, 1977; Pogo and O'Shea, 1978).

A close examination of the terminal loops at the ends of the VV genome led to the suggestion of an alternative self-priming method of DNA replication, involving the formation of nicks which generate 3' ends (Baroudy *et al.*, 1982; Moyer and Graves, 1981). These 3' ends then allow priming for DNA replication, which is similar to the model proposed for the replication of single-stranded parvovirus DNA (Tattersall and Ward, 1976) and eukaryotic telomeres (Bateman, 1975). This model can account for the regeneration of incompletely base-paired loops and flip-flop sequence rearrangements (Moss, 1990).

Variola and vaccinia viruses encode at least two other enzymes involved in nucleotide metabolism, which enable the high levels of DNA synthesis: thymidine kinase (TK) and ribonucleotide reductase. The vaccinia virus TK was the first poxvirus gene to be mapped by marker rescue (Weir *et al.*, 1982) and expressed by cell-free translation of mRNA (Hruby and Ball, 1982; Weir *et al.*, 1982). Although the TK gene is not required for virus growth in tissue culture cells, it presumably provides a selective advantage in non-replicating cells that have low levels of thymidylic acid, for in animals, TK- mutants are significantly attenuated (Buller *et al.*, 1985). The "Kenya sheep and goat pox" vaccine strain genome fragment containing the TK gene was sequenced by Gershon and Black in 1989. Another virus-encoded enzyme involved in poxvirus replication, ribonucleotide reductase, is induced soon after vaccinia virus infection. This enzyme converts ribonucleotides to DNA precursors, (Slabaugh *et al.*, 1984).

An unusual feature of the Shope fibroma virus (SFV) genome, is the partial absence of most of the genes involved in nucleotide biosynthesis (Willer *et al.*, 1999). Variola and vaccinia viruses encode several such genes, as mentioned above, while molluscum contagiosum encode none at all. SFV thymidylate and guanylate kinases are absent, while thymidine kinase is still encoded (Willer *et al.*, 1999). SFV also encodes only the smaller R2 subunit of the ribonucleotide reductase, presumably rendering it dependent upon host cell functions for the synthesis of DNA biosynthetic precursors. A similar situation is observed in human cytomegalovirus except that this virus encodes only the larger R1 subunit (Bankier *et al.*, 1991). Why SFV should retain only one half of an $\alpha 2\beta 2$ protein is unclear. It has been observed that heterodimers composed of a vaccinia R1 subunit and mouse R2 subunit are catalytically active (Hendricks and Mathews, 1998), and it has been suggested that SFV has evolved to exploit the opposite arrangement consisting of the SFV R2 and host R1 subunits (Willer *et al.*, 1999).

c) **Transcription of intermediate genes**

Intermediate genes are transcribed immediately after DNA replication (which is essential for the de-repression of intermediate genes), and requires positive *trans*-acting transcription factors, which are present in an active state in the infected cells prior to the onset of DNA synthesis. It was suggested by Vos and Stunnenberg (1988) that these transcription factors are encoded by early viral genes. Alternatively, host proteins or viral structural proteins might be involved in the activation of intermediate transcription, as is the case for the structural protein Vmw65 in HSV transcription (O'Hare and Goding, 1988; Preston *et al.*, 1988).

An intermediate promoter for vaccinia virus was characterised by mutational analysis (Hirschmann *et al.*, 1990), and shown to consist of an upstream element from -20 to -9, and a downstream element from +1 to +9, relative to the $TA_{(3-6)}T$ transcriptional initiation site. These elements are sufficient to direct intermediate transcription both *in vivo* and *in vitro*. The size and position of the upstream element relative to the transcriptional site is comparable to the upstream regions of similar elements in late promoters of VV (Davison and Moss, 1989). The upstream element appears to be essential for intermediate promoter

activity, and the distance between this AAANAA element and the RNA start site is not conserved (Hirschmann *et al.*, 1990), but is generally between 12 and 15 nucleotides long. The mutation of a C residue to an A at position -19 in the vaccinia I3 promoter converts the intermediate promoter into a late promoter, which suggests that the C residue at position -19 in the natural promoter might be detrimental to late promoter activity (Hirschmann *et al.*, 1990). DNA replication is not sufficient for the activation of late transcription either, and it appears that trans-acting transcription factors, encoded by intermediate genes are essential (Wright and Moss, 1987; Vos and Stunnenberg, 1988).

d) Viral transcription of late genes

The switch from early to late transcription in lumpy skin disease virus occurs at approximately nine hours post infection (Fick and Viljoen, 1994). Late messenger sequences are only transcribed after DNA synthesis commences (Oda and Joklik, 1967; Kaverin *et al.*, 1975; Boone and Moss, 1978). The encoded RNA sequence starts within three consecutive A-residues present in a conserved TAAAT element in the non-coding DNA strand. (Rosel *et al.*, 1986; Berthelot *et al.*, 1986; Weir and Moss, 1987; Lee-Chen and Niles, 1988). This poly(A) head is probably generated by slippage (stuttering) of the polymerase complex during transcription initiation (DeMagistris and Stunnenberg, 1988; Schwer and Stunnenberg, 1988). On average, late mRNAs are much longer than those coding for the early proteins, often many-fold longer than the length required to encode their translation product (Cooper *et al.*, 1981; Mahr and Roberts, 1984). This may relate to unusual processing events (Berthelot *et al.*, 1987). Four studies have been done on separate late promoters, in order to precisely define the region necessary for late gene regulation. Each investigation involved linking a late promoter to the coding region for chloramphenicol acetyltransferase, mutating upstream sequences, and assaying promoter activity in a transient expression system, or in recombinant viruses (Cochran *et al.* 1985; Berthelot *et al.* 1986; Weir and Moss, 1987). An extensive study of the sequence elements involved in late gene regulation *in vivo*, was later done by detailed mutagenic analysis (Davison and Moss 1989). From the results of these investigations, late promoters were defined by the transcription initiation site TAAAT sequence. This motif often forms part of the initiating methionine codon, by being followed by a G. In strong late promoters,

the TAAAT is preceded by a short spacer of 4-10 nucleotides, and then a T-rich tract of 5-15 nucleotides. The data of Davison and Moss (1989) further indicate that the least detrimental mutations of the TAAAT sequence are CAAAT, TAAAG and TAAAA. A natural example of a functional promoter with the latter of these mutations is demonstrated in the vaccinia A2L gene. Promoters that deviate from the consensus (of Davison and Moss) have been described, and may represent other regulatory classes (Lee-Chen and Niles, 1988; Vos and Stunnenberg, 1988).

```

-40                                     +1  +4      +9
GGATTTAATAAAAAATATTTTAAAAAAATTTTCAAATA TAAAT GGATA
ATC A   C   T   TA      T T T   A T           G
TA      A

```

Figure 4: Late promoter consensus sequence, derived from the alignment of characterized vaccinia virus late promoter sequences (Davison and Moss, 1989).

A late promoter, PA7L from the *BamHI*-P fragment of the Neethling strain has been characterized. It contains the conserved TAAAT motif, although this is separated from the ATG codon (at position +8) of the ORF P1L, to form a TAAATAAAATG motif (Fick and Viljoen, 1999).

e) Viral assembly and release

The initial stages of virion formation occur in circumscribed, granular electron-dense areas of the cytoplasm apart from cell membranes. In the subsequent stages of development, the immature viral envelopes appear spherical, with a dense nucleoprotein mass embedded in a granular matrix. Electron microscopy studies suggest that the nucleoprotein enters the immature envelopes just before they are completely sealed (Morgan, 1976). Mature virus particles move out of the assembly areas, and are transported to the cell periphery where they may become enveloped by additional membranes (Morgan, 1976). High-voltage electron microscopy of whole infected cells revealed a membrane-like sheath surrounding mature virions, which align themselves with cytoplasmic fibres (Stokes, 1976). Immunofluorescence studies indicated that the

fibres are actin-containing microfilaments of the cell cytoskeleton (Hiller *et al.*, 1981). The double-layered membrane surrounding the mature virus particles is derived from the Golgi apparatus (Hiller and Weber, 1985). The enveloped viral particles fuse with the plasma membrane, resulting in the externalization of the virion, still enclosed by one layer of Golgi membrane (Payne and Kristensson, 1979).

1.3.4 Virus-Host interactions

1.3.4.1 Poxviruses and the evasion of the immune response. A virus able to evade the host immune response, has the advantage to propagate itself over one which is rapidly neutralised and destroyed in the eukaryotic arsenal of antiviral strategies. An important feature of the early inflammatory response to an initial virus challenge, is the influx and activation of leukocytes. Leukocytes help to initiate the earliest phases of antiviral immune activation (Nathanson and McFadden, 1997; Zinkernagel, 1996). Neutrophils, monocytes/macrophages, and Natural Killer (NK) cells in particular (all leukocytes) participate in the first wave of cellular infiltration, but require directional signals in order to migrate to the injured tissues bearing infected cells (Ben-Baruch *et al.*, 1995; Springer, 1994). Poxviruses have been known to actively interfere with the host's immune response by mimicking various host proteins involved in cell signaling and immune regulation (Smith, 1993). This includes interfering with complement function, interference with MHC-I presentation, interference with cytokine production/function, interference with interferon-induced protein kinase, interference with apoptosis and interference with inflammation. (Harper, 1998).

a) Virus-encoded Interferon gamma and receptor homologs

Interferon- γ (IFN- γ) is a cytokine (of which chemokines make up a class), which functions within the immune system as a potent anti-viral and immunoregulatory stimulant (Epstein, 1984; Vilcek *et al.*, 1985; Farrar and Schreiber, 1993). The importance of IFN- γ in response to poxvirus infection has been demonstrated many times. In a murine experimental model, infection with vaccinia virus, which is usually effectively cleared by the immune system, becomes lethal when monoclonal antibodies to IFN- γ are added (Ruby and Ramshaw, 1991). In immuno-deficient mice, where vaccinia

virus infection is lethal, clearance is achieved when a recombinant virus expressing IFN- γ is injected (Kohonen-Corish *et al.*, 1990; Ramshaw *et al.*, 1992). Interferon- γ has also been proven to be critical in the recovery of mice from ectromelia virus infection (mousepox) (Karupiah *et al.*, 1993). In order to infect successfully, poxviruses have evolved several strategies to counteract the pleiotropic effects of IFN- γ . For example, the RNA-dependent protein kinase pathway is responsible for inducing the anti-viral effects of interferons in the host. The E3L gene of vaccinia virus encodes an inhibitor of the double stranded RNA-dependent protein kinase (Chang *et al.*, 1992), while vaccinia protein K3L blocks the same pathway at the stage of phosphorylation of the alpha subunit of eukaryotic initiation factor II (Davies *et al.*, 1992). The aforementioned are intracellular processes, but poxviruses are also capable of inhibiting IFN- γ extracellularly, before the cellular receptors are engaged (Mossman *et al.*, 1995). Cells infected by myxoma virus were shown to secrete a 37-kDa virus-encoded protein, which has homology to the ligand-binding domain of the known mammalian interferon- γ receptor, and effectively functions as a soluble interferon- γ receptor homolog (Upton *et al.*, 1992). Putative interferon- γ binding proteins have since been identified in the genomes of Shope fibroma virus, vaccinia virus, variola virus, ectromelia virus and swinepoxvirus (Upton *et al.*, 1992; Goebel *et al.*, 1990; Shchelkunov *et al.*, 1993; Massung *et al.*, 1993, 1994; Mossman *et al.*, 1995).

b) Virus-encoded chemokines and chemokine receptors homologs

Chemokines are a family of structurally related cytokines, which selectively induce chemotaxis and activation of phagocytic cells and lymphocytes. They are also able to rapidly trigger integrin-mediated leukocyte migration (Roitt, 1997). The production and secretion of chemokines can be induced at inflammatory sites, for example, virus-infected cells or tissues. A chemokine receptor homolog produced by the virus on the surface and/or on the inside of the infected cells could therefore result in the inhibition of the release of chemokines and, thus, inhibition of the chemokine-induced inflammatory response against the virus infection. Graham *et al.* (1997) reported a novel class of secreted poxvirus proteins, collectively termed T1/35kDa. These proteins interact with a broad spectrum of chemokines *in vitro*, and retard the extent of leukocyte influx into

virus infected lesions *in vivo*. The mechanisms of these interactions remain to be demonstrated. Based on their primary structure, particularly the conservation of a four-cysteine motif, the chemokine receptor family is divided into two classes: C-C and C-X-C, according to whether the first two cysteinyl residues in the motif are adjacent or separated by an intervening residue (Schall, T. J. 1991). Chemokines signal through a family of serpentine receptors, which span the cell surface seven times, are coupled to G proteins, and are generally class restricted, binding either to CC or CXC chemokines. It has been shown though, that multiple chemokines from within a family can bind and signal through common receptors (Kelvin *et al.*, 1993; Murphy, 1996). Based on amino acid identity, Cao *et al* (1995) demonstrated that the Q2/3L ORF of a capripoxvirus is closely related to the C-C or C-X-C chemokine receptor family. Further structural and topological analysis of the deduced amino acid sequence of ORF Q3/2L revealed that it has key structural characteristics of the G-protein-coupled receptor superfamily; e.g., seven hydrophobic regions (predicted to span the cell membrane) and cysteinyl residues in the first and second extracellular loops, that are implicated in forming a disulphide bond. The sequence identity is highest in the transmembrane-spanning domains. The possibility of there being homologs of this Q2/3L ORF in other capripoxviruses represented by Iraq goat pox, Nigeria sheep pox, and lumpy skin disease, was evaluated by Southern blot analysis of *HindIII* restriction endonuclease digests. ORF Q2/3L homologs were detected only in the equivalent fragments in all of the capripoxviruses examined, except for Iraq goatpox DNA. The equivalent locus in Iraq goatpox DNA is present in a larger fragment (Gershon *et al.*, 1988). Only a single copy of the Q2/3L ORF, located in the left terminal region, is present in the capripoxvirus genome. In contrast, swinepoxvirus contains two almost identical ORFs (C3L and K2R) located within the ITR at each terminus (Massung *et al*, 1993). The equivalent gene was not present in vaccinia virus (Johnson *et al*, 1993).

c) Tumor Necrosis Factor (TNF) inhibitors

Tumor necrosis factors (TNF) $-\alpha$ and $-\beta$ are two related cytokines named for their cytotoxic effects on certain tumor cells, but also have immunoregulatory functions. Macrophages that have engulfed an impostor are activated by agents such as IFN- γ and

TNF- β , amongst others. Consequently, the macrophages become microbicidal. IFN- γ sets the cell up for destruction by inducing the formation of TNF receptors (Roitt, 1997). A poxviral TNF was identified by Upton *et al.* (1991). Secreted poxviral TNFs would presumably bind to receptors on the infected host cell, preventing the signalling for cell destruction.

d) Viral inhibition of the complement cascade

The complement system is a multicomponent triggered enzyme cascade, which is used to attract phagocytic cells to invading microbes and engulf them (Roitt, 1997). Some twenty proteins are involved in the complex. Along with blood clotting, fibrinolysis and kinin-formation, the complement proteins produce a rapid, highly amplified response to a trigger stimulus. This occurs by a cascade phenomenon, where the product of one reaction is the enzymic catalyst of the next (Roitt, 1997). Briefly, the most abundant component of the complement system, C3, is split by a convertase enzyme formed from its own cleavage product C3b and factor B. The C3b product associates with the microbial surface, which stabilises it against breakdown caused by factors H and I. As it aggregates, C3b becomes covalently linked to the microorganism. The next component, C5, is activated, yielding a small peptide viz. C5a. The residual C5b binds to the surface and assembles the terminal components C6-9 into a membrane attack complex, which is freely permeable to solutes, and can lead to osmotic lysis of the pathogen. C5a is also a potent chemotactic agent for lymphocytes and greatly increases capillary permeability. C3a and C5a act on mast cells, causing the release of further mediators such as histamine, leukotriene B₄ and tumor necrosis factor, with effects on capillary permeability and adhesiveness, and neutrophil chemotaxis; they also activate neutrophils (the major circulating phagocytic polymorphonuclear granulocyte). Following the activation of complement with the ensuing attraction and stimulation of neutrophils, the activated phagocytes bind to the C3b-coated microbes by their surface C3b receptors and ingest them (Reid, 1995; Law and Reid, 1988). The 35-kD major secreted protein of vaccinia virus was recently identified and its sequence revealed that it closely resembled a family of eukaryotic proteins that have 60 amino acid repeats (Kotwal and Moss, 1988). Computer searches indicated that it most closely resembled a complement control protein

that binds to complement C4b. *In vitro* data indicate that the purified protein does inhibit the classic complement pathway (Moss, 1990). Two genes identified in the rabbitpox virus genome have homology with the β chain of complement component C4a, and their roles in viral virulence have been demonstrated (Bloom *et al.*, 1991).

e) Interleukins

Interleukin-I (IL-I) is also a chemokine, and reacts on endothelial cells, fibroblasts and epithelial cells to secrete (another) chemokine, MCP-I, a potent monocyte chemotactic protein that attracts mononuclear phagocytes. It has been reported that a cowpox gene, *crmA*, encodes an inhibitor of the interleukin-1 β converting enzyme, which can inhibit these inflammatory processes (Ray *et al.*, 1992). Interleukin I- β receptors have also been identified in other poxviruses (Alcami *et al.*, 1992; Spriggs *et al.*, 1992).

All of the above-mentioned poxvirus encoded proteins seem to lack the membrane anchor and cytoplasmic domain found in their cellular counterparts. Furthermore, they are secreted from the infected cells, and are incapable of cellular signal transduction. They appear to modify pathogenesis by binding and neutralising the respective cytokine before it can react with its cellular receptor (Moss, 1990).

f) Serpin-like proteins

Serpin homologs have been identified in numerous poxviruses including vaccinia, ectromelia, cowpox, swinepox and myxoma viruses (Massung *et al.*, 1993). In cowpoxvirus, the serpin homolog inhibits the cellular IL-1 β converting enzyme (Ray *et al.*, 1992), and interferes with the lipoxigenase pathway of arachidonic acid metabolism (Palumbo *et al.*, 1993). Presumably, the immune response is influenced by the alteration of the synthesis of various arachidonic acid metabolites, including leukotrienes such as the chemoattractant LTB₄, and prostaglandins (Palumbo *et al.*, 1993).

1.3.4.2 Poxvirus genes contributing to host-range specificity and pathogenicity.

Many different types of poxvirus-encoded proteins and their functions have been presented so far. In addition to the genes commonly shared by the many species of

poxvirus, including those involved in DNA replication, nucleotide metabolism, and immuno-regulatory proteins, individual poxviruses also encode proteins that don't seem to have homologs in the other poxviruses. These proteins have been suggested by various authors to be factors which determine pathogenesis and the host range specificity, allowing the respective virus to survive and replicate in a particular animal host.

It has previously been suggested that the essential core of vertebrate poxviruses be defined by the region from vaccinia ORF F9L at the left to near ORF A29L at the right. This represents 102 kbp. The same conclusion for the position at the left end of a postulated central core was reached in an analysis of swinepox virus (Massung *et al.*, 1993). In addition, deletion mutants of vaccinia virus have revealed that all of the open reading frames at the left end of the genome and up to and including ORF F4L are not required for growth in cell culture (Perkus *et al.*, 1991). The deletion mutants also showed that at the right end, ORFs B13R to B29R are nonessential, and a number of open reading frames between ORFs A42R and A56R have been shown to be nonessential for growth in cell culture. These ORFs may therefore play crucial and specific roles during natural infection, to ensure virus survival in the host (Buller *et al.*, 1991; Smith, 1993; Johnson *et al.*, 1993).

The host-interactive proteins include homologs of epidermal growth factor, probably for increasing virus-susceptible cell numbers around infectious centers; a zinc-finger protein, and protein kinases, which have the potential to influence viral gene expression and macromolecular synthesis. Also included are proteins (for example, haemagglutinin protein and serine protease inhibitor analogues) that potentially influence viral spread by altering infected cell membranes, and cellular erythrocyte ankyrin-related proteins that may specify tissue tropism.

a) Ankyrin-like proteins

In 1987, Breedon and Nasmyth reported a ~33 residue repeating motif in the sequence of two yeast cell-cycle regulators, Swi6p and Ccd10p, and in the Notch and LIN-12 developmental regulators from *Drosophila melanogaster* and *Caenorhabditis elegans*

(Breedon and Nasmyth, 1987). Subsequently, the discovery of 24 copies of this sequence in the cytoskeletal protein ankyrin (Lux *et al.*, 1990) led to the naming of this motif as the ankyrin (ANK) repeat. ANK-repeat proteins carry out a wide variety of biological activities and have been detected in organisms ranging from viruses to humans. The motif has now been recognized in >400 proteins (Bork, 1993), including cyclin-dependent kinase (CDK) inhibitors, transcriptional regulators, cytoskeletal organizers, developmental regulators and toxins (Michaely and Bennet, 1992; Axton *et al.*, 1994). These molecules are present in the nucleus, cytoplasm and the extracellular environment. The number of repeats within any one protein is highly variable: the *Drosophila* plutonium protein contains only two repeats (Axton *et al.*, 1994), but 20 or more are not uncommon. Some ANK-repeat proteins consist solely of ANK repeats; others are multi-domain molecules in which ANK repeats are combined with other unrelated structural modules.

Shchelkunov and colleagues' analysis of VAR and VV proteins (1993) demonstrated that both viruses code for a large set of ankyrin-like proteins, and two of these, the MIL and KIL genes of VV were previously found to determine the virus host cell range in cell cultures (Goebel *et al.*, 1990). VV does not propagate on the CHO cell line, although this line is permissive for another orthopoxvirus, CPV. It was shown (Spehner *et al.*, 1988) that the CPV gene coding for the 77 kDa protein, in which three ANK-repeats were identified, is responsible for this property of the virus and, when integrated into the VAC genome, allows the latter virus to propagate in CHO cells. Drillien *et al.* (1978) were furthermore able to demonstrate that, for VV, the infection of non-permissive CHO cells resulted in a rapid inhibition of the protein synthesis both of the host cell and the virus. The mutant of VV with a deleted KIL gene is also incapable of multiplication in cultures of human MRC-5, KB or Hep-2 cells. This process is accompanied by a rapid inhibition of protein synthesis both of the virus and the infected cell (Drillien *et al.*, 1981). The individual repeats or their groups in ankyrin-like proteins are supposed to form binding sites for various integral membrane proteins of the cell cytoskeleton. The first three-dimensional structure of an ANK-repeat molecule, that of 53BP2 bound to the p53 cell-cycle tumor suppressor (Gorina and Pavletich, 1996), was determined almost ten years

after the discovery of the motif. This and subsequent structures have shown that the ANK-repeat motif can be defined as a β -hairpin-helix-loop-helix ($\beta_2\alpha_2$) structure. Clearly, specific types of residues are prevalent at any one position within the consensus. However, ANK repeats can sustain a considerable variety of amino acid substitutions (Michaely and Bennett, 1992; Bork, 1993). In many ANK-repeat molecules, sequence insertions occur most often within that region that connects helix 2 to the first β -strand of the adjacent repeat. The differences in amino acid sequences of each repeat could account for their different specificities (Lux *et al.*, 1990).

The ANK-repeat consensus: (Sedgwick and Smerdon, 1999)

1 10 20 30
D _ _ G _ TPLHA _ _ _ G _ _ _ VV _ LLL _ _ GADVNA _

Binding to target molecules commonly involves contacts with the tips of the β -hairpins and the surface of the helical bundle facing into the ankyrin groove. In general, these residues are not conserved in the ANK consensus. As such, they are not structurally constrained and are ideally located to perform binding roles. The molecular stacking of the repeat motifs allows incorporation of additional non-conserved elements that might contribute both to the structural stability of the domain, and to the binding to the target molecule (Sedgwick and Smerdon, 1999). In VAR, ORF G3R is the most typical ankyrin-like protein among those detected in poxviruses. It contains five ankyrin repeats. (Shchelkunov *et al.*, 1993). A unique characteristic of CPV is that not only does it have the widest host range among the orthopoxviruses, but also the widest set of genes coding for the proteins with multiple ankyrin repeats (Shchelkunov *et al.*, 1997).

b) Kelch-like proteins

The kelch family of proteins is defined by a 50 amino acid repeat that has been shown to interact with actin (Xue and Cooley, 1993). This motif was first identified as a tandemly-arranged repeating sequence in the C-terminal domains of a number of poxvirus ORFS (Goebel *et al.*, 1990; Koonin *et al.*, 1992). However, it was a prior description of the

same motif in the kelch protein of *Drosophila*, as a distinct structural motif, that led to the term “kelch repeat” (Xue and Cooley, 1993). Proteins containing kelch repeats have been identified in a diverse set of organisms, including the A55R and C2L ORFs of vaccinia virus (Goebel *et al.*, 1990; Koonin *et al.*, 1992), the predicted *Ipp* protein and Ectoderm-neural cortex of mice (Chang-Yeh *et al.*, 1993; Hernandez *et al.*, 1997), spe-26 of *Caenorhabditis elegans* (Varkey *et al.*, 1995), α - and β -scruin of *Limulus* (Way *et al.*, 1995), the bovine and human calicins (von Bulow *et al.*, 1995), human NRP/B (Kim *et al.*, 1998), and human NS1-binding protein (Wolff *et al.*, 1991). Direct evidence of actin association has been demonstrated for *Limulus* α -scruin (Sanders *et al.*, 1996), in which the actin binding activity of the protein has been localized specifically to the kelch repeat domains of the molecule. Additional evidence of actin association in members of the kelch family includes co-precipitation and co-localization of mouse ENC-1 in a transfected medulloblastoma cell line (Hernandez *et al.*, 1997), co-localization of actin filaments with *Drosophila* kelch in ovarian ring canals (Xue and Cooley, 1993), co-sedimentation of human IPP fusion proteins (Kim *et al.*, 1999), and the disruption of actin filament localization in the spermatocytes of *C. elegans* spe-26 mutants (Varkey *et al.*, 1995). In addition to the kelch repeat motif, most kelch proteins also possess a ~120 amino acid motif, usually found at the extreme N-terminus of the protein, and referred to as the POZ domain (Bardwell and Treisman, 1994). The POZ domain has been reported to mediate homo- and hetero-dimerization *in vitro* and the formation of multimeric complexes *in vivo* (Bardwell *et al.*, 1994; Robinson and Cooley, 1997).

Metabolism of animal viruses, depending on their peculiarities, suggests the use of structures of cytoplasmic or nuclear protein cell skeleton, as well as cell membranes. In particular, virus-specific cytopathic effect can be caused by a specific reconstruction of the elements of cell skeleton and certain membranes. The aim of this reconstruction is to create the conditions for viral propagation (Luftig, 1982). The cytoskeleton proteins are coded by a large set of genes, which are characterised by tissue-specific expression. This accounts for the difference in the protein contents of the “framework” of various cell types, which affects the function of these cells (Steinert and Roop, 1988). Various cell types may also differ in their membrane contents. The above differences can also affect

such parameters of virus propagation inside the organism such as tissue tropism (Shchelkunov *et al.*, 1993). The detection of genes that determine the tissue tropism of viruses is important for the fundamental understanding of virus-cell interaction, and also for the creation of more safe live vaccines.

c) Virus Growth Factor (VGF)

The vaccinia virus growth factor (VGF) is encoded in the left terminal region, and is thought to be involved in pathogenesis. VGF binds to the epidermal growth factor receptor (EGFR), induces phosphorylation of EGFR, and the proliferation of certain cell types (King *et al.*, 1986; Stroobant *et al.*, 1985; Twardzik *et al.*, 1985). Deletion of this gene from VV results in the attenuation of the virus (Buller and Palumbo, 1991). It has been suggested that in SPV, the absence of this gene, together with the complement-binding C4b binding protein of vaccinia, and a secreted vaccinia protein NIL homolog may be responsible for the highly attenuated SPV phenotype, and the characteristically mild natural infections in swine (Massung *et al.*, 1993).

d) Other proteins and novel poxvirus-encoded proteins

Exclusive or novel genes are difficult to define, because novelty will depend on the size of the poxvirus sequence database and upon the cut-off point of for alignment scores. Furthermore, alignment scores are dependent upon protein size, and it is easy to miss homologous genes if they happen to be very small. Nevertheless, all authors of poxviral genome sequence publications report genes that do not seem to have homologs in any other of the poxvirus species. The most novel variola protein, according to Massung *et al.*, is ORF B22R, which shows poor homology to current database proteins. The protein (Mr = 214K) has six possible transmembrane domains, suggesting that it may locate to virion or infected-cell membranes, and thereby impact infection. Another exclusive VAR gene is ORF D6R, which contains a complete zinc-finger motif not found in a truncated 21.7 kD VV homolog (Kotwal *et al.*, 1988). Variola ORF D11L specifies a homolog of the vaccinia ORF C7L product known to influence viral infectivity for certain cell lines (Perkus *et al.*, 1990), but ORF D11L includes an Arg-Gly-Asp cell-adhesion motif (Rhoulati and Perschbacher, 1986) which could profoundly influence tissue tropism.

Finally, variola ORF J5.5R (of which 45 residues have partial homology to vaccinia ORF A55R), is an analogue of vascular endothelial growth factor having a homolog in the genus *Parapoxvirus* (personal communication to Massung *et al.*, by A. J. Robinson), suggesting that vascular endothelial growth factor is a virulence determinant stemming from a common poxvirus ancestor. Several genes of vaccinia and variola viruses are absent in Shope fibroma virus, suggesting that SFV may not use the same infection route(s) as do other Chordopoxviruses. SFV appears to lack homologs of the A-type inclusion proteins (Willer *et al.*, 1999). These genes have been shown to be mutable in a variety of Orthopoxviruses, but most viruses produce at least a truncated form of the protein that may promote infection of phagocytic cells by intracellular mature virions (Ulaeto *et al.*, 1996). The complete absence of any Shope fibroma virus gene homolog is unusual and predicts that Leporipoxvirus infections might produce relatively small amounts of intracellular mature virions (Willer *et al.*, 1999). A very interesting example of another unusual protein encoded by a poxvirus, is the *Leporipoxvirus* S127L gene product: this gene encodes a 52.5-kDa product that is homologous to proteins belonging to the family of type II cyclobutane pyrimidine dimer (CPD) photolyases (Willer *et al.*, 1999). Photolyases catalyze a light-dependent reaction that returns CPD adducts back to their component pyrimidines, thus reversing the damage caused by ultraviolet light. Although a similar gene is encoded by molluscum contagiosum virus (Afonso *et al.*, 1999), this is the first DNA repair gene of its kind found to be encoded by a Chordopoxvirus, in fact, any mammalian virus (Willer *et al.*, 1999). The presence of this gene is particularly unusual in that whilst marsupials such as the common opossum (*Monodelphis domestica*) are known to encode photolyases (Yasui *et al.*, 1994), no placental mammal has yet shown to have retained the gene. Because it is generally believed that poxvirus originally acquired most genes from their hosts, this discovery has raised interesting questions concerning the evolutionary history of a New World virus now thought to only infect rabbits (Willer *et al.*, 1999). Preliminary experiments show that the gene can complement an *E. coli* *phr* (photolyase deficient) mutation *in vivo* (D. Willer, M. Moon and D. Evans, unpublished data) and imply that Leporipoxviruses can repair the damage caused by ultraviolet light exposure either before and/or during viral infection (Willer *et al.*, 1999). Other genes encoded exclusively by Leporipoxviruses

include a 34-kD α 2,3-sialyltransferase nearly identical to the myxoma enzyme recently characterised by Jackson and colleagues (Jackson *et al.*, 1999). Shope fibroma virus sialyltransferase presumably catalyses an identical reaction and likewise promotes viral virulence. Another SFV gene product, S141R also has a previously identified myxoma gene homolog (MA56)(Jackson *et al.*, 1999), encodes a 24-kDA protein that is predicted to contain two transmembrane helices and resembles the immunoglobulin-like domains of a large family of eukaryotic cell-surface proteins (Willer *et al.*, 1999).

Database searches with several SPV ORFs revealed no significant homology to any previously identified poxvirus polypeptides. Of these, the C1L and C3L ORFs are the most interesting. The C1L ORF, located nearest the terminus and encoding a polypeptide of 340 amino acids, shows limited homology to the members of the immunoglobulin superfamily, and also contains the tripeptide RGD, a cell attachment sequence found in a variety of cellular glycoproteins (Rouslahti and Pierschbacher, 1986, Massung *et al.*, 1993). The C3L ORF exhibits 25% identity at the amino acid level with the G-protein coupled receptor family, and is predicted to have six transmembrane domains (Massung *et al.*, 1993). No significant homologs were reported for SPV ORFs C7L and C9L, either (Massung *et al.*, 1993).

As an increasing amount of poxviral genome sequences become available, it is possible, even likely, that homologs of these exclusive genes will be identified. Massung and colleagues (1993a) suggested, against the argument that host range specificity and virulence is determined by function-specific genes, that rather small differences, as presented above, between homologous poxvirus proteins augment the collective contributions of all proteins in determining the systemic or localised nature of infection by these different viruses.

1.4 VACCINES

1.4.1 Lumpy Skin Disease Vaccines Two live attenuated strains of capripoxvirus have been used as vaccines specifically for the control of LSD (Capstick and Coakley, 1961; Carn, 1993): a strain of Kenya sheep pox and goat pox virus passaged 18 times in lamb testes or fetal calf muscle cells, and the South African vaccine strain (Neethling), which originated from the adaptation of a strain of LSDV to propagation in embryonated eggs. The strain of virus selected for these propagation studies was the Neethling type of Group III virus described by Alexander *et al.* in 1957. This virus had been stored in freeze-dried form after four passages in calf kidney, and six passages in lamb kidney tissue cultures. After reconstitution, the virus was seeded on to lamb kidney tissue cultures. On the 5th day, when cytopathogenesis was almost completed, the culture was stab-inoculated into fertile eggs and incubated. Eggs containing dead embryos on succeeding days had their embryos together with the chorioallantoic membrane (CAM) harvested, emulsified, and re-injected into the next series of eggs. At each stage, each inoculum prepared for egg passage was passed to lamb kidney or –testis monolayers to determine the cytopathic effect on tissue culture (the attenuated virus produces no cytopathic effect upon monolayer tissue cultures), and the material was titrated to determine the LD₅₀ end-point (where the attenuated virus is not lethal to the chick embryo). The strain was passaged for 45 generations. (van Rooyen *et al.*, 1959). At the 20th passage level, the virus failed to cause a generalized skin eruption or other signs of illness in cattle, and only produced a local swelling at the site of inoculation in about 50% of animals injected. The local reactions disappeared within four to six weeks without any evidence of necrosis. Virus could not be re-isolated from the blood or the local lesions of inoculated cattle, and there was no evidence of reversion of virulence of the attenuated virus by re-passage in lamb kidney tissue cultures (Weiss, 1960). The modern LSDV Neethling vaccine is prepared in much the same way (*Office International des Epizooties Manual*, 1996).

All strains of capripoxvirus examined so far, whether of bovine, ovine or caprine origin, share a major neutralising site, so that animals recovered from infection with one strain are resistant to infection with any other strain. Consequently, it is possible to protect cattle against LSD using strains of capripoxvirus derived from sheep or goats (Coakley

and Capstick, 1961). Protection following vaccination is probably life-long, although as immunity wanes, local capripoxvirus replication will occur at the site of inoculation, but the virus will not become generalised. Both strains of capripoxvirus used routinely as vaccines can produce a large local reaction at the site of inoculation in cattle breeds, which some stock owners find unacceptable. This has discouraged the use of vaccine even though the consequences of an outbreak of LSD are invariably more severe (OIE Manual, 1996).

1.4.2 Pox-vectored vaccines. After the eradication of the smallpox virus, and consequently the lack of reasons to vaccinate against it, vaccinia virus was considered for use in the immunoprophylaxis of other diseases. Live recombinant poxviruses-vectored vaccines have significant advantages over more conventional vaccines, yielding long-lasting protective immunity to more than one disease simultaneously and in this regard, offer huge potential (Weir *et al.*, 1982; Nakano *et al.*, 1982; Mackett *et al.*, 1982, Panicani and Paoletti, 1982).

Vaccinia virus has a capacity for at least 25 000 bp of additional DNA (Smith and Moss, 1983), but the large size of the poxvirus genome makes it necessary to rely on homologous recombination for the insertion of foreign DNA. This procedure depends on infrequent recombination events occurring in infected cells between the poxvirus DNA flanking the foreign gene, and homologous DNA within the poxvirus genome. For efficient expression of foreign genes, vaccinia virus promoters had to be used in the construction of the recombinants. A series of plasmid vectors for vaccinia were constructed, based on the scheme outlined by Mackett *et al.* (1982). Such plasmids contain a DNA segment (with a vaccinia virus transcriptional promoter region and one or more restriction endonuclease sites for insertion of a foreign gene) that is flanked by DNA from a non-essential region of the vaccinia genome. The choice of promoter determines the time and level of expression, whereas the flanking DNA determines the site of insertion. Insertion into the thymidine kinase (TK) gene provided a simple method of selecting recombinant virus that had a TK⁻ phenotype. The cells were consequently infected with vaccinia virus and transfected with the recombinant plasmid. The virus

progeny were then incubated with a monolayer of TK⁻ cells, and 5-bromodeoxyuridine is added to the agar overlay to prevent plaque formation of TK⁺ parental virus. Other screening methods that don't rely on special cell lines have also been developed (Chakrabarti *et al.*, 1985). Alternatively, DNA hybridisation (Panicali *et al.*, 1982) or specific antibody binding (Smith *et al.*, 1983; Paoletti *et al.*, 1984) may be used for primary identification of recombinant plaques. Over the past fifteen or so years, several of these live recombinant vaccinia vaccines have been produced, and their ability to protectively immunise experimental animals against a variety of viruses has been demonstrated. Some good examples of these recombinant vaccinia vaccines are the hepatitis B surface antigen (Smith *et al.*, 1983; Moss *et al.*, 1984), influenza hemagglutinin gene (Smith *et al.*, 1983, Panicali *et al.*, 1983), herpes simplex type I glycoprotein D (Cremer *et al.*, 1985), hepatitis B surface antigen + herpes simplex D glycoprotein (Paoletti *et al.*, 1984), vesicular stomatitis virus genes (Mackett *et al.*, 1985) and a rabies virus recombinant (Wiktor *et al.*, 1984). Occasional adverse clinical reactions in response to wild type vaccinia virus (Lane and Millar, 1971), and its broad host range, however, limits the use of vaccinia virus as a general vaccine vector (Arita and Fenner, 1985). Species-specific poxviruses such as fowlpox virus (Taylor and Paoletti, 1988) and canarypox virus (Taylor *et al.*, 1988), offer certain advantages: they do not spread to non-target species since outside their host-range, and infection leads to incomplete replication. This, nevertheless, appears to be sufficient for the expression of foreign genes and the induction of a protective immune response (Taylor and Paoletti, 1988). A fowlpox recombinant expressing the fusion (F) protein of Newcastle disease virus (NDV) has been generated at OVI, and is currently under evaluation in small animal trials as a vaccine against Newcastle disease (Z. Wang, unpublished data).

Modified live capripox vaccines have achieved promising levels of immunity, and these viruses therefore also have excellent potential as alternative antigen vectors to vaccinia virus for veterinary applications. Such a recombinant capripoxvirus was constructed by Romero *et al.* (1993), and contains a full-length cDNA of the fusion protein gene of rinderpest virus. The gene was inserted in the thymidine kinase gene of the capripox genome under the control of the vaccinia virus major late promoter p11, together with the

E. coli gpt gene in the opposite orientation under the control of the vaccinia early/late promoter p7.5. A vaccine prepared from the recombinant virus protected cattle against clinical rinderpest after a lethal challenge with a virulent virus isolate. In addition, the vaccine protected the cattle against lumpy skin disease.

Because it is restricted to its bovine host, LSDV is another excellent candidate as a viral vaccine vector. OVI is currently investigating the development of its LSDV vaccine strain as a recombinant vector veterinary vaccine. A Rift Valley fever virus (RVFV)/LSDV recombinant, previously generated by the insertion of the RVFV glycoprotein genes, G1 and G2, into an intergenic region in the LSDV genome, has been evaluated in sheep. Sheep receiving the RVFV/LSDV vaccine all sero-converted. All sheep survived a virulent viral challenge, but the RVFV/LSDV-vaccinated animals showed an overall lower temperature profile, shorter period of viraemia and a quicker and elevated neutralising antibody response compared with control groups. This preliminary data suggests that the RVFV/LSDV recombinant vaccine is as good, if not better than the Smithburn vaccine currently in use against RVF (unpublished data).

The terminal regions of the LSDV genome containing the genes for host range specificity and virulence are non-essential for growth in tissue culture, and therefore viral replication and survival. They make ideal sites then, for the insertion of foreign genes. The sequencing of the LSDV genome would enable the identification of these genes, as well as their regulatory elements, as the success of a recombinant viral vaccine is very much dependent on the levels of immunity that is induced in the host, and a strongly-expressed protein under the control of a well-characterised, strong LSDV promoter would be ideal.

1.5 Aims of this study

LSDV is a capripoxvirus causing an economically serious disease of cattle in Africa and the Middle East, resulting in its classification as an OIE List A disease. Despite the availability of vaccines, periodic outbreaks still occur. The South African vaccine strain (also called the Neethling strain) of LSDV is the subject of this study. In order to gain a better understanding of the virus-host interaction, specifically the genetic factors which determine the virulence of the virus (or avirulence in the case of a vaccine strain) and the bovine-specific nature of LSDV infection, the determination of the nucleic acid sequence of the viral genome to identify the responsible genes is necessary. Virtually no nucleotide sequence data is published for LSDV. Once the genome sequence is determined, we would be better equipped to understand the virus-host interaction, and ultimately be able to develop safer and more effective vaccines. Regions of the genome that are non-essential for the replication cycle of the virus are of particular importance, as LSDV shows enormous potential as a recombinant vaccine vector.

The first aim of this study was to clone central and terminal regions of the LSDV genome, specifically those regions expected to encode the genes involved in host range specificity and virulence. From the known sizes and locations of the *PstI* clones in the LSDV genome, the *PstI* -E, -M and -K clones from the left terminal regions of the LSDV SA vaccine strain genome were selected, representing approximately 12 700 bp of the left hand terminal sequence, a variable region in which the pathogenicity and host-range specificity genes of poxviruses are known to occur. Additionally, *PstI* clones -F and -G, representing about 16 800 bp of the central regions of the genome (containing essential genes required for viral replication and survival) were selected for cloning, sequencing and analysis.

The second aim after determining the nucleotide sequences of the clones, was to assemble the fragments into a continuous LSDV DNA sequence. Large-scale laboratories sequencing other poxvirus genomes use a "shotgun" cloning and automated sequencing approach. As a result of limited infrastructure this was not possible here, and so the mapping and cloning approach would be a more systematic one. To distinguish between

similar-sized clones bearing different LSDV fragments, a restriction endonuclease pattern profiling method was used. Computer analysis was used to assemble non-overlapping sub-clone sequences into the correct orders and orientations. This involved using the sequences of homologous poxvirus proteins from the public databases as templates, to assemble the sub-clone amino acid sequences into full-length ORFs. Oligonucleotides designed from LSDV sequences would be used to primer-walk gaps in DNA sequence in certain regions.

The third aim of this investigation was to use computer analysis to translate assembled LSDV nucleotide sequence into amino acid sequences. Open reading frames were identified, and through homology searches of public databases, possible functions were assigned to the putative LSDV proteins. Several proteins with possible roles in host-range specificity and virulence were identified in the sequenced regions.

CHAPTER II

The Restriction Endonuclease Mapping, Sub-cloning and Sequencing of LSDV *PstI* Clones -E, -M, -K, -F and -G

2.1 INTRODUCTION

Poxviruses have the largest known viral genomes (139-288 kbp). Several complete genomic DNA sequences have been deposited in GenBank to date, including a single viral member of the Entomopoxvirinae family, *Melanoplus sanguinipes* entomopoxvirus (MsEPV) (Afonso *et al.*, 1999), as well as those of several *Chordopoxvirinae* family. The latter include the *Orthopoxviruses* vaccinia (VV) (Goebel *et al.*, 1990; Antoine *et al.*, 1998) and variola (VAR) (Massung *et al.*, 1994; Shchelkunov *et al.*, 1995), *Molluscipoxvirus* molluscum contagiosum virus (MCV) (Senkevich *et al.*, 1997) *Avipoxvirus* Fowlpox virus (FPV) (Afonso *et al.*, 2000), and the *Leporipoxviruses* Shope (Rabbit) Fibroma Virus (SFV) (Willer *et al.*, 1999) and myxoma virus (MYX) (Cameron *et al.*, 1999), with new complete genomic DNA sequences well underway to completion. In this study, important regions of the previously-unsequenced genome of the capripox virus, lumpy skin disease virus (LSDV), were selected for DNA sequencing and analysis. It was first necessary to sub-clone large fragments into smaller ones that could be sequenced in the forward and reverse direction, and therefore the locations of infrequent six-base restriction endonuclease sites in the LSDV clones had to be mapped, so that cloning strategies could be devised.

The restriction endonuclease *HindIII* has successfully been used in the molecular characterisation of different capripoxviruses (Kitching *et al.*, 1989) and in addition to the *HindIII* restriction endonuclease maps thereby generated for SA-LSDV, *AvaI*, *Sall* and *PstI* maps have also been compiled (unpublished data presented in the MSc dissertation of Perlman, 1993, UCT). *AvaI* cleaves the 152 kbp genome into seven fragments, varying from 47.35 kbp to 2.1 kbp, whereas *Sall* cleaves the genome into six fragments, ranging in size from 33.15 kbp to 2.8 kbp. The enzyme *PstI* cuts more frequently than the aforementioned, generating 13 fragments ranging in sizes of 42.0 kbp to 2.4 kbp, and was therefore considered to be the most suitable enzyme for cloning the LSDV genome.




Figure 5: A linear representation of the LSDV *PstI* map (Unpublished data in the MSc dissertation of Perlman, UCT 1993). DNA fragment sizes are given in kilobase pairs, with the regions of importance in highlight. The *PstI*-E clone is 12.0 kb in total; the 7 kb *EcoRI/Pst* fragment is indicated above.

To date, all the *PstI* fragments except the three largest, namely -A, -B and -C, have been cloned into bacterial vector pGEM3Z (F. T. Vreede and D. B. Wallace, OVI). In the cloning of *PstI*-E, the original 12.1 kbp fragment was cleaved at an internal *EcoRI* site, resulting in the cloning of a 7 kbp sub-fragment. It was confirmed to be of the *PstI* E-fragment by hybridization to a Southern blot of a LSDV *PstI* genomic digestion (F. T. Vreede). Furthermore, it was later shown that this *PstI*-E sub-fragment is adjacent to the *PstI*-M fragment i.e., furthest from the left terminus. The remaining 5 kbp *PstI*-E fragment has not yet been cloned. Our laboratory is also involved in cloning *BamHI* fragments overlapping the uncloned *PstI* fragments, and in the cloning of the terminal hairpin loops.

The cloning and sequencing of the terminal hairpin loops of poxvirus genomes has been unsuccessful in most cases. The sequences for the terminal hairpin loops of VV are available (Goebel *et al.*, 1990), which was achieved by the chemical degradation sequencing method of Maxam and Gilbert (1980). In a different approach for the myxoma virus terminal regions, blunt-ended adaptors were ligated to 25 and 29 bp oligonucleotides. The oligonucleotides were designed to be complementary to the upper and lower DNA strands. In a PCR reaction, the terminal sequences adjacent to the hairpin loops were amplified after which the products were sequenced. The actual loop sequence was not determined however (Cameron *et al.*, 1999).

This chapter describes the mapping the LSDV *PstI* clones with restriction endonucleases and the sub-cloning of LSDV DNA fragments into bacterial sequencing vectors. The application of manual and automated sequencing, to determine the linear order of the deoxyribonucleotides from selected regions of the LSDV genome, is also described. It was expected that the LSDV genome would have a high frequency of A+T- nucleotides, as suggested by the high frequency of A+T- rich restriction endonuclease sites in the capripoxvirus genomes (Gershon and Black, 1989). Once the nucleotide sequences were assembled and translated to amino acids (Chapter III), it was expected that several genes involved in pathogenicity and in the restriction of the virus to bovine cell infection would be identified in the selected regions.

2.2 MATERIALS AND METHODS

2.2.1. Restriction endonuclease mapping of the *PstI* clones. Glycerol stocks of a selection of *E. coli* LSDV *PstI*-fragment clones were inoculated into LB medium with ampicillin and grown overnight, with shaking at 37°C. The randomly selected clones from each *PstI* fragment were: M₇₂, M₉₄, M₁₀₂, E₄, E₅, E₆, K₁, F₃, F₁₁, F₁₄, G₂₆, G₂₇, G₂₈ (see Fig. 5 for genomic positions of *PstI*-E, -M, -K, -F and -G). Clones were named according to order of isolation by F. T. Vreede (personal communication). The plasmids were isolated from the pelleted bacterial cells by the modified alkaline lysis, or “miniprep” method (Birnboim and Doly, 1979; Ish-Horowicz and Burke, 1981; Sambrook *et al.*, 1989). Restriction enzyme digests for mapping purposes were performed in 10µl reaction volumes: 10X restriction buffer supplied by the enzyme’s supplier, 0.5 U of enzyme, ~ 500ng of plasmid DNA, and distilled water to make up the volume. The reaction was incubated for an hour in a 37°C waterbath, after which RNase A at a concentration of 10mg/ml was added, and incubated for a further 5 to 10 minutes. 5µl of loading dye (bromophenol blue/ 40 % sucrose) was added, and loaded onto an ethidium bromide-stained (EtBr) 1% agarose gel, with undigested plasmid and a phage-λ DNA *PstI* marker, and electrophoresed at 90-100 volts until the fragments had migrated sufficiently. Restriction enzyme double digests were assembled in 10µl volumes, where enzymes were selected on their optimal requirement for similar buffer components. In cases where the enzymes required totally different buffer conditions, a buffer titration was performed, and the reaction was incubated for an additional half-hour. After electrophoresis, the EtBr-stained DNA bands could be visualised by trans-illumination with long wavelength ultraviolet light (UVP M-20). Images were captured by Lumi-Imager™ (Boehringer Mannheim). Band fragment sizes were estimated according to the *PstI*- Bacteriophage λ DNA ladder.

2.2.2. Cloning

a) Preparation of LSDV insert DNA

~500ng of plasmid DNA was digested in reaction volumes of 25µl or more, with the supplied 10X buffer and 0.5 U of restriction enzyme. The reaction was incubated for 90 minutes in a 37°C water bath, after which 10 µl of RNase A at a concentration of 10mg/ml was added, and incubated for a further 10 minutes. 20µl of loading buffer was added, and 20µl volumes of the reaction loaded into separate wells of an EtBr-stained 1% agarose gel. A λ-*PstI* DNA marker, and uncut plasmid were also loaded alongside. Electrophoresis at 90-100 V for 45 minutes was performed, or until the fragments had separated fully. Bands of the correct sizes were excised from the agarose gel with a clean, sharp scalpel. DNA was purified from the agarose using one of several commercial DNA purification kits, according to the manufacturers' specifications. These kits included the Talent Cleanmix DNA purification kit™, Gene Clean™, NucleoTrap™ (Machery-Nagel) and QiaQuick Spin™ (Qiagen). DNA fragment concentrations were determined spectrophotometrically (Pharmacia GeneQuant spectrophotometer).

b) Preparation of Vector DNA

One of two vectors were used for cloning of all insert DNA viz. pGEM3ZF+/- (Promega), or pMOSBlue (Amersham). Both are pUC-based and therefore contain commonly-used six-base restriction endonuclease sites in their multiple cloning sites (MCS). pMOS also has a site for *NdeI* in its MCS, which was used to clone fragments generated with *AseI*, since digestion with *AseI* and *NdeI* yields compatible ends.

pGEM or pMOS-plasmid-containing *E.coli* cells were inoculated into LB medium supplemented with ampicillin, and grown with shaking overnight in a 37°C incubator. Vector plasmids were isolated from pelleted bacterial cells by the "miniprep" method, and resuspended in dH₂O. Vector plasmid DNA was linearised with the appropriate restriction enzyme/s in 25µl reaction volumes: ~500ng of plasmid DNA, 10X buffer supplied with the restriction enzyme, or a buffer compatible to both in the case of directional cloning strategies, 0.5U DNA of restriction enzyme/s and dH₂O to make up

the volume. The reaction was incubated at 37°C for 60 minutes and loaded onto an EtBr-stained 1% agarose gel, alongside undigested plasmid DNA and the λ -*PstI* marker. This was electrophoresed at 90-100 V for 45 minutes, the linear plasmid bands (3199 bp and 2800 bp for pGEM3Z and pMOSBlue, respectively) were excised from the agarose with a clean sharp scalpel, and purified with one of the aforementioned kits according to the manufacturer's specifications. The linear vector DNA was resuspended in dH₂O, and the concentration determined by spectrophotometry (Pharmacia GeneQuant spectrophotometer).

In cases where the cloning would be directional (i.e. the ends of the linearised vector are generated with different restriction enzymes) the vector was used directly for the ligation reaction. In cases where only one enzyme was used to linearise the vector, the ends were dephosphorylated to prevent self-ligation. 0.5 U of Calf-Intestinal Phosphatase (CIP) (Roche) was added to the total volume of purified linear DNA, together with the CIP-10X buffer, and dH₂O, usually to a volume of 40µl. The dephosphorylation reaction was incubated in a 37°C water bath for 20 min. The reaction volume was raised to 200µl by the addition dH₂O, and a 3X volume (600µl) of Phenol/Chloroform/Isoamyl alcohol was added, to purify the vector DNA. After vortexing, centrifugation (13000 g's) and removal of the aqueous DNA-containing phase, DNA was ethanol-precipitated and washed before being resuspended in dH₂O. Concentration of the DNA was estimated spectrophotometrically (Pharmacia GeneQuant spectrophotometer). Vector DNA was stored at -20°C.

c) Ligation Reactions

Ligation reactions were assembled in 10µl reaction volumes: insert and vector DNA was combined in a molecular ratio of 3:1, respectively, with 0.5 U of T4 DNA ligase enzyme (Roche), the supplied 10X buffer, and dH₂O. Ligation reactions were incubated in a water bath of 15°C, overnight, or at 17°C for at least 4 hours. Ligation reactions were stored at -20°C if not used immediately.

d) Competent cells and transformations

Two methods of preparing competent *E. coli* DH5 α cells were used: the first was the standard Calcium Chloride method, (Cohen *et al.*, 1972; Sambrook *et al.*, 1989) the second was the High Efficiency Transformation method as described by Inoue *et al.* (1990). The second method was found to yield cells that have superior competency levels to those prepared by the calcium chloride method, and had the added advantage of remaining highly competent after storage in liquid nitrogen at -70°C for longer than 12 months. This method required inoculated DH5 α cells to be grown at 18°C, with shaking, to an OD of 0.6 at A600, which took approximately 53 hours. Pelleted cells were then resuspended in TB-buffer, consisting of 10mM Pipes, 55mM MnCl₂, 15mM CaCl₂ and 250mM KCl. Cells are stored with added DMSO at a final concentration of 7%, in liquid nitrogen.

Cells taken from the liquid nitrogen were allowed to defrost at room temperature, and then placed on ice. 200 μ l of cells were aliquotted into plastic tubes, and 2 μ l of the respective ligation reaction added. The cells were incubated in watery ice for 30 minutes, and then heat-shocked at 40°C for 30 seconds. The tubes were returned to the ice for 5 minutes, before 800 μ l of LB medium (without ampicillin) was added, and the tubes incubated, with shaking, at 37°C, for one hour. 200 μ l of cells were plated onto LB plates containing ampicillin, and grown overnight at 37°C.

e) Screening for recombinant DNA clones

Individual colonies were picked from agar plates and inoculated into 2ml of LB medium with ampicillin. Cells were grown for a minimum of six hours at 37°C, with shaking. 150 μ l of the cultures were screened for plasmids with inserts according to the “fast prep” method described by Beuken *et al.* (1998). After electrophoresis, 10 μ l each of the cell lysates were loaded onto EtBr-stained 1% agarose gel, potential recombinant plasmids were identified on grounds of their increased size and hence their slower migration in the gel. Cells from potential recombinant cultures were pelleted and the plasmids extracted by the “miniprep” method. To confirm a recombinant, restriction enzyme sites flanking

the insertion sites (and/or known to not have a site in the insert itself) in the plasmid were cut with the appropriate enzyme (usually *EcoRI* [Promega] and *HindIII* [Promega]). These restriction enzyme digests were performed in 10 μ l reaction volumes. Again this included the 10X restriction buffer supplied by Promega, 0.5 U of the respective enzyme, ~ 500ng of plasmid DNA, and dH₂O to make up the volume. The reaction was incubated for an hour in a 37°C water bath, after which RNase A at a concentration of 10mg/ml was added, and incubated for a further 5 to 10 minutes. 5 μ l of loading buffer was added, and loaded onto an EtBr-stained 1% agarose gel, with undigested plasmid, an undigested wild-type (pGEM or pMOS) plasmid and a phage- λ DNA *PstI* marker, and electrophoresed at 90-100 volts or until the fragments had migrated sufficiently. Triplicate glycerol stocks were prepared of confirmed recombinant plasmids by adding 200 μ l of 100% sterile glycerol to 800 μ l of recombinant cultures, and stored at -20°C.

2.2.3 Sequencing

2.2.3.1 Preparation of DNA template for sequencing. Fresh overnight cultures of the clones to be purified for sequencing were pelleted by centrifugation (13000 x g). Boehringer Mannheim's High Pure Plasmid Isolation Kit™ was used to isolate the recombinant plasmids from the respective clones. In principle, the *E. coli* cells were lysed by the alkaline method. Nucleic acids bound specifically to the surface of glass fibres of the *High Pure* filter tube in the presence of a chaotropic salt. Since the binding process was specific for nucleic acids, the bound plasmid DNA was purified from salts, proteins and other cellular impurities by a washing step, and could then be eluted in a low salt buffer or water. DNA for sequencing purposes was eluted from the spin columns with 100 μ l of dH₂O. DNA template quantitation is critical for successful sequencing reactions. DNA concentrations were determined by a Pharmacia GeneQuant spectrophotometer: 2 μ l of purified plasmid was diluted in 98 μ l of dH₂O. This gave a dilution factor of 1 in 50, which was then equated to a DNA concentration in ng/ μ l.

2.2.3.2 Primers and primer walking. pGEM3Z (Promega) and pMOSBlue (Amersham) are both pUC-based bacterial vectors, and therefore contain binding sites for the M13 forward and reverse primers. The SP6 reverse primer and T7 forward primer were used in some cases, and prime sequences close to the MCS in both vectors. The M13 primers anneal further upstream and downstream of the multiple cloning sites than the T7-promotor or SP6 primer sites, and were therefore used in the majority of the sequencing reactions, as the actual recombination site is important to confirm the correct clone, its orientation in the vector, and for the accurate reading of DNA sequence close to the priming site.

Table 2 : Commercial primers for the sequencing of bacterial vector plasmids

Primer	DNA Sequence
M13+ (GibcoBRL)	5' -TGT AAA ACG ACG GCC AGT- 3'
M13- (GibcoBRL)	5' -CAG GAA ACA GCT ATG AC- 3'
T7- (Promega)	5' -TAA TAC GAC TCA CTA TAG GG- 3'
SP6+ (Promega)	5' -TAT TTA GTT GAC ACT ATA G- 3'

Primer sequence, method of primer synthesis, and approach to primer purification can have a significant effect of the quality of the sequencing data obtained in dye terminator cycle sequencing reactions. The recommendations made for primer design (ABI PRISM™ Protocol) were followed:

- 1) primers with long runs of a single base were avoided
- 2) primers were at least 18 bases long to ensure good hybridisation
- 3) primer melting temperatures were kept above 45°C.
- 4) a primer content of at least 50% G+C was retained, with a few exceptions, and it was sometimes necessary to extend the primer sequence beyond 18 bases to keep the melting temperature above the recommended lower limit of 45°C

Primers containing palindromic sequences, that would lead to self-ligation, were avoided

Table 3: Primers designed for primer-walking sequencing to sequence gaps

Name	Priming site	DNA sequence	MW	% G+C	T _m (50mM NaCl)
K440	K1200	5'-CCA AAA ACT AGC GAC AGC-3'	6,734.0	50.0%	52.08°C
K875	E2700/ 1450	5'-GCA CAG TTA GTA GCG CC-3'	6,392.0	58.8%	53.48°C
K12/K5P	K500; L	5'-GCA CAT AAG TAG TTT ACA CTG C-3'	8,237.0	40.9%	52.95°C
G68/602P	G6800/ 602	5'-CCG GAA TTG GAG ATG TTT C-3'	7,198.0	47.4%	51.78°C
G68/550P	G6800/ 550	5'-GCA CAT CTT CCC CAT CCT G-3'	7,014.0	57.9%	56.27°C
F66A	F6600	5'-CAT CCC ATA TGG TTG CC-3'	6,327.0	52.9%	50.54°C
F66B	F6600	5'-GGC ACC TAA CCT ACC ATC-3'	6,664.0	55.6%	52.45°C
F29A	F2900	5'-CCA CTG AAA AGA GTG GAG C-3'	7,201	52.6%	53.95°C
F29B	F2900	5'-GGA ACA GGG TAC TAC CG-3'	6,435.0	58.8%	51.43°C
F29C	F2900	5'-CGG GTT CTC TAC CCA AAG C-3'	7,094.0	57.9%	56.05°C
E2150A	F2900	5'-GAT GGA AAA AGT AAC GAC-3'	6,844.0	38.9%	46.27%

Primers were manufactured by Integrated DNA Technologies, Inc., and diluted in dH₂O to a final concentration of 1.5 pmol/μl.

2.2.3.3 The automated DNA sequencing reaction. The ABI PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer) was used according to the manufacturer's specifications. The protocol was modified by scaling the reaction mix down to a quarter-reaction.

a) The cycle sequencing reaction

A typical reaction was therefore assembled in 50µl tubes, on ice, as follows:

4-6µl	plasmid DNA template (~600ng)
1µl	primer (1.5pmol/µl)
2µl	kit (quarter-reaction volume)
1.6µl	5x buffer (PE Applied Biosystems, kindly supplied by Joelle vd Walt, UP)
	dH ₂ O

13µl	total volume

Cycle sequencing was performed on a GeneAmp PCR System 2000 thermal cycler™ (Perkin Elmer) under the recommended parameters:

Denaturation: 96°C for 30 seconds/ Annealing: 50°C for 15 seconds/ Elongation: 60°C for 4 minutes (25 cycles).

b) Purification of extension products

The 13µl reaction volume was transferred to a 500µl Eppendorf tube containing 25µl of 96% Ethanol, and 1µl of 3M NaOAC, at room temperature (resuspending very gently with a pipette- no vigorous mixing or vortexing). This was left to precipitate in the dark for 10 minutes. The samples were then centrifuged at 13 000 rpm for 30 minutes, and all the liquid was carefully removed with a pipette, taking care to avoid the area of the (invisible) pellet. 250µl of 70% EtOH was then added (no mixing or vortexing) and centrifuged again on a benchtop centrifuge at 13 000 rpm, for 15 minutes.

All EtOH was carefully aspirated with a pipette, and then vacuum-dried for 10-15 minutes. The tubes containing the dried, pelleted DNA was stored at -4°C until the gel was run, and transported on ice.

c) Gels

Sequencing reactions were analysed on an ABI377 sequencer at either the division of Molecular Biology at OVI, or the Faculty of Natural and Agricultural Sciences, UP. Long Ranger™ gel solution matrix, a ready-to-mix gel solution is used by both laboratories, which is cast and allowed to polymerize. This gel solution was able to give a 25 to 30% increase in read length and an increase in base calling accuracy on automated sequencers when compared with standard polyacrylamide gels. Prior to loading, the dried pellet was resuspended in $4\mu\text{l}$ of 1:5 blue dextran/ EDTA: deionized formamide, denatured at 95°C and put onto ice. $0.5\text{-}1\mu\text{l}$ was loaded, depending on the size of the gel.

2.2.3.4 The Manual DNA sequencing reaction

a) Denaturing of double-stranded plasmid template

The following reaction was assembled:

$8\mu\text{l}$ plasmid template DNA- of miniprep quality ($\sim 500\text{ng}$)

$2\mu\text{l}$ dH_2O

$1\mu\text{l}$ 2M NaOH/2mM EDTA

After incubation at 37°C in a water bath for 30 minutes, the reaction was stopped by the addition of 0.1 volumes of 3M NaOAc (pH4.5-5.5). The denatured DNA was precipitated by adding 2.5 volumes 100% EtOH, and then incubated at -70°C for 15 minutes. After being centrifuged at 12 000 rpm, room temperature, for 10 minutes, the pellet was air-dried and resuspended in $7\mu\text{l}$ dH_2O

b) Annealing of template and primer

The reaction for the annealing of the primer to the template was assembled as follows:

- 7 μ l denatured DNA template
- 2 μ l SequenaseTM 5x reaction buffer
- 1 μ l primer (M13+) at 1.5pmol/ μ l

The total volume of 10 μ l was incubated on a 65°C heating block for 10 minutes, followed by incubation in a 37°C water bath for 10 minutes, and then left at room temperature for 10 minutes. The reaction was spun briefly to collect the contents of the tube, and then placed on ice until required.

Four tubes with each respective termination mix (ddATP, ddCTP, ddGTP and ddTTP) were prepared, clearly marked and left at room temperature until use.

c) Radiolabelling of DNA

The reaction for the labelling of the DNA was assembled as follows:

- 1 μ l 0.1M DTT
- 2 μ l diluted labelling mix
- 0.5 μ l [α -³⁵S] dATP
- 0.25 μ l Polymerase,
and dH₂O to a total volume of 5.5 μ l

the above was added to the 10 μ l of template DNA mix, and incubated for four minutes at room temperature.

d) Termination of the reaction

For the termination reaction, 3.5 μ l of the radiolabelled DNA was added to each of the respective termination tubes, and incubated for five minutes at 37°C. 4 μ l of termination stop reagent from the kit was added to each tube to terminate the reactions, and tubes were stored at -20°C overnight, until use. Prior to loading, the samples were boiled for five minutes, and the tubes put onto ice.

e) Gel assembly and electrophoresis

A six percent sequencing gel was prepared as follows: 42g of urea, 15ml of 40% acrylamide, and 10ml of 10X TBE was dissolved in 25ml of dH₂O. The volume was adjusted to 100ml with dH₂O. 100ml of TEMED and 200ml of freshly prepared 10% APS was added. The gel was injected between thoroughly cleaned and assembled glass plates, and allowed to polymerise overnight.

BIO RAD Sequi-Gen® GT Sequencing Cell apparatus was assembled as per the instruction manual and the buffer tank filled with 0.5X TBE. Stop solution was loaded in some of the wells, and the pre-run at 2000V was started and left for one hour and 40 minutes. 3 μ l of each sample was then loaded into the wells in the order A-C-T-G, and electrophoresed at 2000V for two hours before a further 3 μ l volume was loaded and allowed to run for a further two hours. The gel was removed, dried in a Savant slab gel drier (SGD5040) for one hour, and placed in an autoradiography cassette. In a darkroom, film was placed into the cassette, and left overnight for exposure. To develop the autoradiography film, it was taken from the cassette and dipped into the developer for five minutes, before being washed with dH₂O. After it was dipped in fixer for five minutes it was rewashed in dH₂O and hung out to dry. DNA sequence was read from the bottom of the gel upwards, from left to right, in the order A-C-T-G.

2.3 RESULTS AND DISCUSSION

Five LSDV *PstI* fragments between 2400 and 8500 bp in size had to be sub-cloned into fragments small enough to be sequenced. Besides restriction maps for *HindIII*, *PstI*, *AvaI* and *SalI* (Perlman, MSc dissertation, UCT 1993- unpublished data), the locations of RE sites in the LSDV genome were unknown. In order to determine which restriction enzymes cut LSDV DNA at regular intervals, for the generation of fragments with desired sizes, restriction digests with a variety of commonly used enzymes had to be performed on each *PstI*-fragment plasmid. The restriction patterns that were generated were used to compile RE maps for each *PstI* fragment. Four-base cutter enzymes were not used, as they cut more frequently and therefore generate too many smaller fragments to be of use for sub-cloning. The results of the screening of the *PstI* clones for restriction sites follows in Table 4.

Table 4: Summary of restriction endonuclease (RE) sites in LSDV *PstI* clones -E, -M, -K, -F and -G (gels not shown). RE sites occurring in the MCS of pGEM3Z and/ or pMOSBlue are boldfaced. No value indicates that the particular clone was not screened with that RE.

PstI clone:

RE	Manufacturer	M	K	E	F	G
<i>AccI</i>	Boehringer Mann.	0	0	0	3	3/4
<i>AseI</i>	Amersham	3	>3	>6	>6	>6
<i>BamHI</i>	Amersham	0	0	1	0	0
<i>BclI</i>	NEB	1				
<i>BglII</i>	Roche	1	0			0
<i>Clal</i>	Sigma		2			
<i>DpnI</i>	Amersham	>6				
<i>DraI</i>	Amersham	3	4			
<i>EcoRI</i>	Promega	0	0	0	3	0
<i>EcoRV</i>	Amersham	1				
<i>EcoT22I</i>	Amersham	0	0			
<i>HindIII</i>	Promega	1	1	3	3	1
<i>Hinfi</i>	Amersham		>1			
<i>KpnI</i>	Amersham	0	0	0	0	0
<i>MluI</i>	Amersham	0	0			0
<i>NcoI</i>	NEB	0	0			0
<i>NdeI</i>	Amersham	0	0			
<i>NheI</i>	Amersham		0			0
<i>NotI</i>	Amersham	0				0
<i>NsiI</i>	Boehringer Mann.	1	0			0
<i>PvuI</i>	Boehringer Mann.	2	0			0
<i>PvuII</i>	Amersham	1	0			0
<i>RsrII</i>	Boehringer Mann.	0	0			
<i>SacI</i>	Roche	0	0	0	0	0
<i>SalI</i>	Amersham	0	0	0	1	1
<i>SfiI</i>	Boehringer Mann.	0				0
<i>SmaI</i>	Amersham	0	0	0	0	0
<i>SpeI</i>	Boehringer Mann.	0	0			
<i>SphI</i>	Amersham	0	0	0	1	
<i>StyI</i>	Boehringer Mann.	0	0			
<i>TaqI</i>	Boehringer Mann.	>6				
<i>XbaI</i>	Amersham	0	0	0	2	0
<i>XhoI</i>	Amersham	0				
<i>XmnI</i>	NEB		1			

2.3.1 The restriction endonuclease mapping and sub-cloning of the *PstI*-M clone

The *PstI* M clone (~ 2 400 bp) was mapped first, due to its small size. Double digests of the parental *PstI*-M plasmid with *AseI/EcoRI*, *AseI/HindIII* and *AseI/PstI* confirmed that the two internal fragments of approximately 480 and 350 bp were flanked by two terminal fragments of approximately 700 bp in size (1a, Fig. 6 on opposite page). The fragment adjacent to the *EcoRI* site in pGEM3Z was named M700, followed by M480, M350 and the opposite terminal fragment, M650.

Neither the pGEM3Z nor the pMOSBlue cloning vectors contain an *AseI* site in their multiple cloning sites, but pGEM3Z contains three internal *AseI* sites (1a, Fig. 6). Digestion with *AseI* produces a TA- overhang which is compatible with the AT-overhang produced by cleavage with *NdeI* in the pMOSBlue multiple cloning site. The two internal fragments, M480 and M350 (1a, Fig. 6), have *AseI* termini and were separately cloned into a pMOSBlue vector with de-phosphorylated *NdeI* ends. Thereby, recombinant plasmid (p) M350 (1d, Fig. 6) and pM480 (1c, Fig. 6) were obtained. In order to clone fragments M650 and M700 directionally, the *PstI*-M clone was double digested with *PstI* and *AseI*. Fragments M650 and M700 are very similar in size, and co-migrated as a single band. Therefore, it was necessary to re-isolate each 700 bp band by two different RE reactions: an *AseI/HindIII* digest to isolate fragment M650, and an *AseI/EcoRI* digest to isolate fragment M700. These were then cloned directionally into *NdeI/HindIII* (1e, Fig. 6) and *NdeI/EcoRI* (1b, Fig. 6) vectors, respectively. These recombinants were confirmed by excising the fragments from the plasmids, and electrophoresing them alongside parental *PstI*-M plasmid digested once again with *AseI/PstI*. Religated *AseI/NdeI* sites have a CATAT sequence that is recognised by neither enzyme, and it was necessary to utilise sites flanking these to excise the inserts. The *PstI*-M fragments are of an appropriate size for automated DNA sequencing (<1 200 bp), and it was not necessary to sub-clone any of them into smaller fragments.




Figure 6: Restriction endonuclease mapping and sub-cloning of the *PstI-M* clone (not drawn to scale)

2.3.2 The restriction endonuclease mapping and sub-cloning of the *PstI*-K clone

The *PstI*-K clone insert is roughly 3300 bp in size. Double digests with *PstI/AseI*, *PstI/HindIII*, and *HindIII/AseI* confirmed the location of a terminal fragment of about 480 bp separated by a *HindIII* site from a fragment of about 650 bp (2a, Fig. 7 on opposite page). An *AseI* digest-generated fragment of approximately 500 bp was found to be adjacent to the 650 bp fragment. On the opposite side of the MCS, a 1200 bp fragment, named K1200, was found to be flanked by *AseI* sites. One of these was situated very close to the pGEM MCS (the distance between the *PstI* site and the *AseI* site was later determined to be eight basepairs by DNA sequencing). Fragment K1200 contains no other internal restriction sites for commonly used enzymes (Table 4). The three smaller fragments were named K480, K650 and K500, from the MCS *HindIII* side.

The cloning of fragments K480, K650 and K500 into vectors proceeded as follows: a digest of the *PstI*-K clone with *HindIII* isolated fragment K480 which was cloned into a vector with *HindIII* termini (2e, Fig. 7); a double digest of the *PstI*-K plasmid *AseI/HindIII* isolated fragment K650 which was cloned directionally into an *NdeI/HindIII* vector (2d, Fig. 7); and an *AseI* digestion isolated the K500 fragment which was cloned into a dephosphorylated *NdeI*-linearised vector (2c, Fig. 7). Recombinant plasmids were sequenced and analysed. Once the LSDV sequences were assembled in a linear order, it became evident that a small fragment was missing from the *AseI* junction of pK650 and pK500 (2a, Fig. 7). The fragment was not visible on agarose gel, and yet there was a gap in the peptide sequence of the predicted ORF. A *ClaI* site located within 15 nt of the *AseI* site of pK500 was identified by sequence analysis (Chapter III), and the distance between this site and the *HindIII* site of the vector was estimated to be approximately 700 bp in size. The K1200 fragment had not been cloned or sequenced at that time, and therefore the possibility other *ClaI* sites occurring within the *PstI*-K plasmid could not be excluded. A double digest with *ClaI/HindIII* produced a fragment which migrated at the appropriate size. The fragment was purified and cloned into pGEM3Z vector linearised with *HindIII* and *AccI*. Digestion with *AccI* produces sticky ends compatible with *ClaI*. Recombinant clones were sequenced and the missing fragment sequence, flanked by *AseI* sites, was discovered to be 71 bp in length (Appendix II).




Figure 7: Restriction endonuclease mapping and sub-cloning of the *PstI*-K clone (not drawn to scale)

The K1200 fragment cloning strategy was complicated by several factors: the pGEM3Z vector has three internal *AseI* sites: positions 224, 280 and 1512, which (if the MCS is also cleaved) yield 160-, 56-, 1200- and 1700 bp fragments (2a, Fig. 7). Firstly, fragment K1200 and the 1200 bp vector fragment co-migrate. It was not possible to separate the two electrophoretically, even on a 2 % agarose gel. To avoid this problem, the entire *PstI*-K insert could first be excised, before being digested in isolation with *AseI*. However, because pGEM3Z is 3200 bp in size and the *PstI*-K fragment is 3300 bp in size, they co-migrate. Again, separation by electrophoresis on a 2% agarose gel was unsuccessful, and this strategy was abandoned.

To discriminate between the K1200 fragment and the vector 1200 bp fragment, the pGEM3Z sequence was examined for unique restriction sites. An enzyme was required that would not digest the LSDV DNA, but would cleave the pGEM3Z 1200 bp fragment, allowing the K1200 fragment to be recovered intact. According to a MAPLOT (GCG) of six-base cutters, the following enzymes with sites in the pGEM3Z 1200 bp fragment were listed: *AlwNI*, *ApaLI*, *Bce83I*, *BsaWI*, *BsiEI*, *BsiHKAI*, *BspI286I*, *BssSI*, *EciI*, *HaeI*, *HaeII*, *HgiEII*, *MmeI*, *MspAII*, *SfcI* and *Tth1111I*, but since these enzymes are uncommon and expensive, a new strategy was sought. Instead of trying to eliminate the pGEM3Z 1200 bp fragment in order to isolate the K1200 fragment directly, I attempted to fragment the entire pGEM3Z vector in order to recover the entire *PstI*-K fragment (the fragments co-migrate due to similar size). If this was possible, then *AseI* digestions could be done on the purified, isolated *PstI*-K fragment. Restriction endonucleases which only cut in the pGEM3Z vector were sought. Of the commonly available enzymes, *XmnI* cuts pGEM3Z at position 1937, and *NdeI* cuts at position 2509. A double RE digestion was carried out, using *PstI* and *XmnI*, or *NdeI*. While the LSDV fragment would remain undigested at 3300 bp, the pGEM3Z vector would be cleaved into two smaller fragments, allowing the LSDV fragment to be purified from the agarose gel. A restriction endonuclease digest unfortunately proved that there was an *XmnI* site in the *PstI*-K insert, and the approach was abandoned. *PstI/NdeI* digests, followed by purification and *AseI* digests were attempted, but too much DNA was lost in the successive purification steps.

If the co-migrating 1200 bp fragments were "shotgun" cloned, there was possibly a way to distinguish between a pGEM3Z/pMOSBlue recombinant, and a pMOSBlue/LSDV recombinant. The co-migrating 1200 bp fragments with *AseI* termini were excised from the agarose, purified, and cloned into a dephosphorylated *NdeI*-linearised pMOS vector. Thirteen of twenty-four colonies picked were confirmed as recombinants by digestion with *EcoRI/HindIII*. The remaining colonies contained vector that had re-ligated. At this stage, it became evident that *DraI* is an enzyme that frequently cuts the LSDV genome. As a consequence it was decided to digest these recombinants with *DraI* in order to distinguish a possible LSDV-specific clone from a vector-specific clone. Before this was attempted, the *DraI* sites in the *PstI*-K fragment (particularly in the K1200 fragment), had to be mapped. In the subsequent *AseI/DraI* double restriction digests of the *PstI*-K plasmid, the K1200 fragment remained intact, and therefore lacked *DraI* sites. Secondly, the *DraI* map of the vector-specific 1200bp recombinant had to be determined. This was accomplished by RE mapping, and the maps of both orientations are given in Figure 8. The pGEM3Z 1200 bp fragment had one *DraI* site, which was used to distinguish between vector-specific and LSDV-specific recombinants.




Figure 8: *DraI* RE maps of pGEM/pMOS recombinants in insert orientations A and B. Fragment sizes are given in base pairs.

Bands expected with *DraI* digests (Fig. 8):

A: 2 100 bp + 1 300 bp + 600 bp (4 000 bp)

B: 1 900 bp + 1 500 bp + 600 bp (4 000 bp)

In orientation B, a vector-recombinant, when cleaved with *DraI*, would yield 1500-, 1900- and 600 bp fragments. In the opposite orientation (A), the fragments after *DraI* digestion would be 1300- 2100- and 600 bp in size. Alternatively, *DraI* digestion of an LSDV-specific recombinant would produce the common 600 bp band (from the pMOS vector) and the remainder of the recombinant plasmid (3400 bp) which includes the LSDV 1200 bp fragment, undigested by *DraI*. The thirteen recombinant plasmids were therefore digested with *DraI*, and the results are presented in the agarose gel of Figure 9, which follows:

LANE	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
CLONE	1	1	2	4	5	6	8	12	14	15	16	22	23	24			




Figure 9: *DraI* digests of recombinant 1 200 bp clones, illustrating pK1200 (clones 1, 4, 5, 6, 8 and 15), recombinant pMOS/pGEM in orientation A (clones 2, 12, 22 and 23) and pMOS/pGEM recombinants in orientation B (clones 14 and 24). Lane 1 is an *EcoRI/HindIII* digest of clone 1, to verify that the sizes of the insert is 1 200 bp; lane 16 is re-ligated pMOS; lanes 12 and 17 are lambda *PstI* DNA markers, with sizes indicated on the right.

All three species were therefore present, and pK1200 (2b, Fig. 7), represented by clones 1, 4, 5, 6, 8 and 15 had therefore been successfully constructed. This technique of *DraI* profiling was consequently used on the *PstI*-E, -F and -G clones, where several co-migrating fragments were of LSDV origin.

2.3.3 The restriction endonuclease mapping and sub-cloning of the *PstI* -E clone

The *PstI*-E clone which is approximately 7 000 bp in size is one of the larger plasmids. The fragment is flanked by an *EcoRI* site, and a *PstI* site, and this *PstI* fragment is the closest to the left hand terminus of the LSDV genome (see Fig. 5 for genomic positions). Many *AseI* sites were expected to occur in the LSDV DNA, and due to this, the plasmid was first sub-cloned into more manageable sizes. Three internal *HindIII* sites were mapped, dividing the *PstI*-E insert into the following fragments: a terminal 800 bp-fragment, 2700 bp fragment, 1300 bp fragment and a 2150 bp terminal fragment (3a, Fig. 10 on opposite page). They were named fragments E4000 (referring to the size of the re-ligated plasmid) E2700, E1300 and E2150, respectively. At this stage, the orders and orientations of E2700 and E1300 relative to each other were not known. This was only determined after sequencing and analysis (Chapter III). The 800 bp terminal fragment lies adjacent to the *EcoRI* site, therefore a single digest with *HindIII* excises fragments E2150, E1300 and E2700 and a 4000 bp fragment containing the original pGEM3Z vector (3200 bp) plus the 800 bp LSDV fragment. All of these were excised from the gel and purified, and the 4000 bp fragment was allowed to re-ligate, hence the naming of the 800 bp fragment (3e, Fig. 10). The E2150, E1300 and E2700 fragments were cloned into dephosphorylated *HindIII*-linearised vectors (3b, 3d and 3c, Fig. 10). Recombinants were confirmed by restriction endonuclease excision of the fragments. pE4000 did not need to be sub-cloned, but the remaining clones were still too large to obtain overlapping sequences from forward and reverse sequencing. Double restriction digests of pE1300 with *HindIII/AseI* located a 700 bp fragment flanked by *AseI* sites (3d, Fig. 10). This fragment is situated approximately 200- and 280 bp from either side of the MCS, respectively. The 700 bp fragment was excised with *AseI* and cloned into a dephosphorylated *NdeI*-linearised vector (3h, Fig. 10). The flanking regions of

approximately 200 and 280 bp in size were not cloned, and these sequences were determined by sequencing in the forward and reverse directions from the parental pE1300. This 700 bp-insert plasmid was named pE1300/700.

Two internal and co-migrating 700 bp fragments, generated by *AseI* were identified in pE2150 (3b, Fig. 10). The two terminal regions are approximately 200- and 250 bp respectively, and are also uncloned. Their sequences were determined from forward and reverse sequencing reactions of the parental E2150 plasmid. The two 700 bp fragments co-migrate, and were shotgun cloned. Recombinant 700 bp-insert clones were distinguished once again by *DraI* profiling: pE2150/702 (3f, Fig. 10) contains no internal *DraI* sites, and yields a 3500 bp band plus the 600 bp band, while pE2150/701 (3g, Fig. 10) has two internal *DraI* sites, producing five bands of 250 bp, 400 bp, 600 bp, 1000 bp, and 1450 bp, approximately (gel not shown). The recombinants were named pE2150/701 and pE2150/702 for convenience. Their orders and orientations relative to each other and the terminal flanking regions were not known at this stage.

pE2700 could be sub-cloned into four smaller fragments after digestion with *AseI* (3c, Fig. 10): E2700/800 (3i, Fig. 10) and E2700/1450 (3l, Fig. 10) were flanking fragments with *HindIII/AseI* termini. The two smaller fragments E2700/450 (3j, Fig. 10) and E2700/300 (3k, Fig. 10) were internal. Recombinants were confirmed by restriction endonuclease digestion.




Figure 10: Restriction endonuclease mapping and sub-cloning of the *PstI-E* clone (not drawn to scale)

2.3.4 The restriction endonuclease mapping and sub-cloning of *PstI*-F clone

The *PstI*-F fragment is the largest of the five selected, being 8500 bp in size. The initial *AseI* digest indicated that there were at least twelve internal *AseI* sites in the fragment, and many of these bands co-migrated. To disperse these sites, the *PstI*-F plasmid first had to be sub-cloned into smaller fragments using commonly-used enzymes, before the smaller *AseI*-generated sub-clones were constructed. *PstI*-F is the only fragment of the five that contains *XbaI* sites (Table 4), and mapping revealed two internal sites which divides *PstI*-F into a terminal 1700 bp fragment (pF1700), an internal 2900 bp fragment (pF2900) and a 3400 bp fragment (pF6600) (4a, Fig. 11 on opposite page). After an *XbaI* digest of the *PstI*-F plasmid, the 1700- and 2900 bp bands were purified and cloned into a dephosphorylated *XbaI*-linearised vector (4b and 4c, Fig. 11). The 6600 bp band, which still contained the original “parent” pGEM vector was purified and allowed to self-ligate in an overnight ligation reaction (4d, Fig. 11). All three *PstI*-F sub-clones were confirmed by restriction endonuclease digestion, and separately mapped with double digests of *AseI/XbaI*.

Digestion with *AseI* and *XbaI* cleaved pF1700 (4b, Fig. 11) into two fragments of ~1300 bp and 450 bp, which were cloned to produce pF1700/1300 (4e, Fig. 11), and pF1700/450 (4f, Fig. 11). pF1700/450 borders on pF2900.

Following double digests of pF2900 (4c, Fig. 11) with *XbaI/AseI*, five fragments could be mapped: terminal 950- and 650 bp fragments flanked internal bands of approximately 1000 bp, and two in the region of 300- to 350 bp. The fragments cloned into plasmids and were named pF2900/950 (4g, Fig. 11), pF2900/650 (4k, Fig. 11), pF2900/1000 (4j, Fig. 11), pF2900x (for the larger of the two smaller fragments) (4l, Fig. 11) and pF2900y (4h, Fig. 11). All five sub-clones were confirmed by restriction endonuclease digestion.

pF6600 (4d, Fig. 11) could be cleaved into six fragments of estimated sizes in descending order: 1000 bp, 800 bp, 470 bp, ~400 bp, ~380 bp and 300 bp. They were cloned into plasmids and named pF6600/1000 (4q, Fig. 11), pF6600/800 (4o, Fig. 11), pF6600/470 (4n, Fig. 11), pF6600/x (4m, Fig. 11), pF6600/y (4p, Fig. 11) and pF6600/300 (4l, Fig.




Figure 11: Restriction endonuclease mapping and sub-cloning of the *PstI*-F clone (not drawn to scale)

11), respectively. pF6600/300 contains the terminal fragment bordering on pF2900, and pF6600/1000 contains the opposite terminal fragment, although the orders and orientations relative to each other of the internal fragments were not known at this stage.

2.3.5 The restriction endonuclease mapping and sub-cloning of *PstI*-G clone

RE digestions of the *PstI*-G clone showed it to contain numerous internal *AseI* sites, the majority producing fragments of between 500- and 700 bp in size. The possibility therefore existed that if fragments migrating so close to each other were to be individually excised from an agarose gel, some cross-contamination would result. There is one *Sall* and one *HindIII* site each within the *PstI*-G fragment, where *HindIII* was mapped to cut within 500 bp of the terminus, and *Sall* cut closer to the center, producing a 1400 bp band, and a 6800 bp band (5a, Fig. 12 on opposite page). These fragments were still too large to sequence, but at least some of the *AseI* sites were distributed between them. Although *AccI* does appear to cut about four times in *PstI*-G clone (not shown), it produces degenerate ends and was not used. The *PstI*-G sub-clones were obtained by digesting the plasmid with *Sall*, isolating the 6800 bp band and cloning it into dephosphorylated *Sall*-linearised vector, and allowing the purified 4600 bp fragment (comprising 1400 bp of LSDV plus 3200 bp of pGEM3Z) to self-ligate. These two plasmids were named pG6800 (5c, Fig. 12) and pG4600 (5b, Fig. 12), respectively.

The construct pG4600 contains an internal *AseI*-ended fragment of 650 bp, which was cloned, and named pG4600/650 (5d, Fig. 12). The flanking regions were not cloned, but their sequences were determined by forward and reverse reactions from the parental pG4600 clone. *AseI* was again used in the sub-cloning of pG6800 (5c, Fig. 12). Single 800 bp, 700 bp, 550 bp and 300 bp fragments produced by digestion were isolated from agarose gel, purified and cloned. These clones were confirmed to contain inserts of the correct sizes, and named pG6800/800 (5h, Fig. 12), pG6800/700 (5i, Fig. 12), pG6800/550 (5g, Fig. 12) and pG6800/300 (5e, Fig. 12), respectively. At the approximate position of 500 bp, two co-migrating bands were excised and purified, and "shotgun"

cloned into a dephosphorylated *NdeI*-linearised vector. Once recombinants were identified, *DraI* digests were carried out, and, two different species were identified (bearing in mind that four possible profiles are possible if each insert is able to ligate in both orientations). pG6800/501 (5j, Fig. 12) has no *DraI* sites, while pG6800/502 (5i, Fig. 12) has one, close to its terminus. Similarly, pG6800/601 (5f, Fig. 12) and pG6800/602 (5k, Fig. 12) were cloned from the co-migrating 600 bp band of a pG6800 *AseI* digest. From the intensity of the band, and size estimations from various RE maps of the *PstI*-G clone, I expected to find three different fragments. A third, unique 600 bp *AseI* fragment was never obtained in this manner, although 119 recombinants were profiled. The absence of the third 600-bp fragment was revealed later on, once the assembly of the *PstI*-G fragment sequences (Chapter III) was underway.




Figure 12: Restriction endonuclease mapping and sub-cloning of the *PstI*-G clone (not drawn to scale)

2.3.6 The mapping and cloning of a fragment in the *PstI* -G clone spanning an *AseI* junction




Figure 13: Restriction endonuclease map of clone BC6. The target region is indicated as a red highlighted portion spanning a *ClaI* site.

The sequencing of the pG6800 constructs (5c, Fig. 12), and the analysis of the ORFs they encode, is described in the next chapter. The fragments were assembled into the correct orders and orientations, based on the identified ORFs. By comparison to various other poxviruses sequenced, the absence of the amino terminus of the DNA topoisomerase ORF, and a complete VAR H7 ORF homolog was evident. The missing piece occurred between constructs pG6800/550 and pG6800/601 (5c, Fig. 12, indicated by *). Instead of sequencing the missing fragment by primer-walking sequencing, it was decided to clone a DNA fragment that spanned the *AseI* junction between fragment G6800/601 and fragment G6800/550. GCG MAP analysis (Chapter III) of the partially assembled pG6800 (5c, Fig. 12) sequence identified an *NdeI* RE site located approximately 240 bp upstream of the *AseI* junction between pG6800/550 and the adjacent fragment. Further

RE mapping with both *NdeI* and *Clal* on pG6800 led to the restriction map of Fig. 13. The fragment spanning the *AseI* junction, including the missing fragment (which was suspected to be between 250 and 500 bp in size), was cloned: RE digestion of pG6800 with *NdeI* yielded four bands (Fig. 13). Co-migrating bands B+C were excised, purified and "shotgun" cloned into a pMOS vector. Clone B recombinants were identified by the additional *PstI* site (determined by RE digests) contributed by the pGEM vector sequence in the fragment. The correct recombinant, containing band C, was identified by the lack of this additional *PstI* site. The clone was named pBC6, and the insert found to be 490 bp in size by sequence analysis (Appendix II).

2.3.7 Sequencing

2.3.7.1 Automated DNA sequencing

Two representative electropherograms are presented in Appendix I

Example 1: G6800/800 REV (sequencing of a cloned fragment with vector sequence primers)

Example 2: F66A (primer walking sequencing)

Forward and reverse automated DNA sequences were edited in Sequence Navigator (Apple Macintosh), which is described in Chapter III: Assembly and Analysis.

2.3.7.2 Primer walking by automated DNA sequencing

EPG output files from the Apple Macintosh were visualized in Chromas (V.1.43, C. McCarthy), which runs in Windows off a PC platform. The DNA sequences were examined for the regions to be inserted, flanked by *AseI* sites. Being relatively short, the sequences were entered manually into the assembled *PstI* fragment sequences, using a text editor program (GCG). The sequences from primer walking sequencing are presented in Appendix II as short nucleotide sequences each flanked by two *AseI* sequences and the name of the adjacent fragment on either side.

The most noticeable feature of an LSDV electropherogram (EPG), is the high frequency of A and T nucleotides. M13 primers were used, which prime further upstream than the T7 and SP6 promotor primers, making it possible to read about 80 bp of the bacterial vector sequence upstream of the LSDV DNA sequence. As shown in the EPG of G6800/800 (Appendix I, Example 1), the peaks continue to be high and sharp for at least 400 base pairs thereafter, and the first N's, or uncalled bases, usually start appearing around 500 bp, although the sequence is still readable and editing possible. Primer walking sequences, using oligonucleotides designed specifically for LSDV sequences, start within 30 bp of the primer annealing site (Appendix I, Example 2- F66A).

It was observed that the read length of quality DNA sequence for quarter- and half-reactions are indistinguishable. Full reactions, with the manufacturer-recommended clean-up, is reported to yield in excess of 700 bp before the first uncalled base is seen,

and those for quarter reactions performed on LSDV were at least 600 bp in length. When designing primers for primer walking, the priming site was chosen to lie at least 50 bp upstream of the target junction site, to compensate for uncalled bases very close to the priming site. Usually, sequences within 30 bp of the priming site could be read. It was also observed that an additional 70% EtOH wash step improved the read length, and it was possible to read a few base pairs closer to the priming site. The recommended annealing temperature for cycle sequencing is 50°C, but the T_m s of the primers used varied from as low as 46.27°C for E2150A to 56.27°C for G68/550P. Despite the deviation from the recommended T_m , good sequences were obtained for all primers.

DNA sequences from primer walking and manual sequencing (Appendix II) were edited into the assembled *PstI* fragment sequences (refer to Table 3 for priming positions). Primer F66B was designed to amplify the region which spans the *AseI* gap between pF6600/800 and pF6600/y in the *PstI*-F clone (4d, Fig. 11), and an additional two *AseI* sites were identified. Two small fragments of 65 and 15 nt were incorporated into the *PstI*-F sequence.

At the junctions sequenced by primers F66A, K12/K5P, E2150A and F29A, no insertions were found. Primers F66A and K12/K5P were designed to read sequences spanning *AseI* junctions in intergenic regions. Primer E2150A was designed to span the intergenic *HindIII* site between E2150 and E2700 (3a, Fig. 10). Primer F29A was designed to sequence a small fragment presumed missing at an *AseI* junction within the RPOL gene. No insertion was found, and the LSDV homolog is therefore accepted to have a natural deletion in this region of the gene. Primer G6800/602 was designed to read the sequence of the missing fragment between G6800/602 and G6800/502 (5c, Fig. 12). Despite the size of the insert, the run was sufficiently long to identify the aforementioned flanking fragment sequences and both *AseI* sites. The new fragment was named G6800/603 (AppendixII).

2.4 Conclusions

In order to determine the DNA sequence of the five *PstI* clones selected for this study, each *PstI*-clone (-E, -M, -K, -F and -G) had to be sub-cloned into smaller plasmids, and sequenced in both directions. Due to limited genomic data, each *PstI*-clone first had to be mapped by double digests with commonly-used restriction enzymes. The RE maps thereby generated were used to develop cloning strategies in which clones smaller than 1000 bp could be constructed and sequenced. These clones did not overlap, and therefore there was a risk of missing very small fragments on the agarose gels from which fragments were excised for cloning. Cloning strategies were often complicated by co-migrating fragments, which led to the development of a *DraI* restriction pattern profiling system. This made it possible to distinguish between different recombinants of the same size, and this approach was used successfully in the cloning of the K1200 fragment, as well as several co-migrating fragments of the large *PstI*-F and -G clones. In total, 46 recombinant plasmids were constructed, containing almost 29000 bp of non-overlapping LSDV DNA. The large majority of these clones were constructed using the restriction endonuclease *AseI*, which recognises ATTAAT sequences in the A+T-rich LSDV genome, and produces ends compatible with *NdeI* in the MCS of bacterial cloning vector pMOSBlue. Once the DNA sequences were assembled and analysed (Chapter III), primers were designed from sequences of the cloned regions, to sequence regions excluded in the sub-clones (particularly at *AseI* junctions) by primer walking sequencing.

CHAPTER III

DNA Sequence Assembly and Analysis

3.1 INTRODUCTION

Large-scale sequencing projects, for example those of the already-sequenced poxvirus genomes, make use of automated sequencing machines directly connected to a computer. The amount of sequence that can be read from one sequencing reaction is limited, and therefore it is first necessary to cleave large sequences, using a frequent-cutter restriction endonuclease, such as *Tsp509I* (Afonso *et al.*, 1999, 2000), or by a physical method such as sonication (Cameron *et al.*, 1999). DNA fragments in the regions of between 1.5 and 3 kbp are then isolated and "shotgun"-cloned into bacterial vectors. Once these random, overlapping fragments are sequenced, it is possible to reconstruct the original sequence by searching for regions in common between the gel readings, using specialised software. Missing regions are sequenced by primer-walking, using oligonucleotides designed from partially assembled DNA sequences. Gap4, which is a commonly-used sequencing project management program in the Staden package, helps in the management of sequencing projects not only by assembling gel readings, but also by searching and removing vector sequences, repeat sequences and poor quality sequence regions which can cause problems when assembling the fragments (Staden *et al.*, 1998).

The cloning approach for the LSDV genome was more systematic than the abovementioned "shotgun" approach, which was not possible due to limited infrastructure. The major difference between this genome project and the abovementioned, is that none of the LSDV clones overlap, making a contig assembly program, such as Gap4, virtually useless. The linear order of the *PstI* clones relative to each other, were known from the restriction map compiled by Perlman (unpublished data presented in his MSc dissertation 1993, UCT), but the orientations of the *PstI* fragments were not (the directionally-cloned *PstI*-E-fragment being an exception). The subsequent sub-cloning strategies furthermore produced non-overlapping subclones, and the sequences had to be fitted together in the correct orientations and orders, in a manner that could not rely on overlapping regions. Additionally, very small fragments were overlooked on the agarose gels, and consequently were not cloned.

LSDV clones were sequenced as they were constructed. Analysis identified partial LSDV ORFs which were blasted against the public databases, and shown to be particular regions of homologous full-length poxvirus proteins. GenBank is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences (Benson *et al.*, 2000). There were approximately 11 101 000 000 bases in 10 106 000 sequence records as of December 2000, and the figures are expected to double in size approximately every 14 months. GenBank is part of the International Nucleotide Sequence Database Collaboration, which is comprised of the DNA DataBank of Japan (DDJB), the European Molecular Biology Laboratory (EMBL), and GenBank at NCBI. These organisations exchange data on a daily basis (<http://www.ncbi.nlm.nih.gov/Genbank>). Once a full-length poxvirus ORF was retrieved from GenBank, it was possible to fit the LSDV LSDV nucleotide sequences of the same protein together in the correct orders and orientations. It is known from the literature that the ORFs near the left-hand terminus of the poxvirus genome tend to read towards the left terminus, while those at the right-hand terminus read towards the right. This phenomenon gave clues as to which direction the LSDV ORFs should be orientated. By fitting the fragmented LSDV ORFs from the clones onto a full-length homologous protein from GenBank, it was furthermore possible to identify small missing DNA sequences spanning the *AseI* junctions, which were later determined by primer walking sequencing. Frameshifts in protein reading frames occur with the insertion or emission of a nucleotide, or where a nucleotide is incorrectly called by the sequencing software, and had to be corrected.

For the purposes of this study, a clone was regarded to present an ORF if the translated peptide initiated with a methionine codon, and was at least 50 aa in length. The LSDV ORF nomenclature includes the *PstI*-fragment containing initiating methionine codon, the linear position of the ORF in the *PstI*-fragment (from left to right), and the direction of the open reading frame (L or R). For example, ORF E3L initiates in the *PstI*-E fragment, and is the third ORF, reading towards the left. The degree of amino acid identity to the top hit was also taken into consideration, with amino acid identities exceeding 20-25% being considered probable evidence of homology, a common approach in other publications of poxvirus sequences.

3.2 MATERIALS AND METHODS

3.2.1 Hardware

Output from ABI377 sequencing managed on Power Macintosh 7600/132 with Mac OS version 7.5.5. Electropherograms (EPGs) were processed by ABI Prism Sequence Navigator Version 1.0.1 (Department of Microbiology, UP).

3.2.2. DNA sequence editing

Forward and reverse sequences were edited in the following manner:

- 1) Both forward and reverse sequences were imported into the layout, and EPGs opened.
- 2) base-calling was matched with EPG peaks
- 3) vector sequence of the multiple cloning site was cut off at the appropriate site: the recombinant *AseI/NdeI* sites have the sequence CATAAT in a forward sequence and a TATGGATT sequence in the reverse sequence
- 4) the reverse sequence was reverse-complemented, and both sequences selected
 - a) the comparative alignment option was used off the drop-down menu or
 - b) a “shadow” was created, and the reverse sequence slid along the forward sequence until the alignment was focused
- 5) the reverse sequence was copied onto the forward sequence at the appropriate junction, and the full-length edited sequence was exported to a file and diskette in Staden format.

3.2.3. DNA sequence analysis - GCG

(Wisconsin Package version 10.2, Genetics Computer Group (GCG), Madison, Wisc.), installed on Irix (UNIX).

Staden-format sequences were transferred from diskette, to the UNIX machine by File Transfer Protocol (FTP). GCG converts a specified file from Staden format, in which it was saved in Apple, to GCG format, prompted by the line-command **>fromstaden**.

Map (**>map**) displayed both strands of DNA sequence with restriction sites shown above the sequence, and all six possible amino acid translations shown below.

Open reading frames were visually identified (beginning with a methionine codon, and being at least 50 amino acids in length), and the specific nucleotide sequence, which had to be specified, was translated to amino acids (**>translate**). The output file was written as a *.pep* file. It was worthwhile to review the *.pep* file using the command **>more filename.pep**, to ensure that the correct reading frame was translated (one nucleotide position too many or too few would cause a frameshift) before the peptide sequence was blasted.

The Blastp algorithm (**>blastp**) was used to search the *.pep* amino acid sequence against the Swissprot protein database. The output file can be quite large, and has four parts: an administrative header (filename, copyright information, database size and references), followed by a list composed of hits with a) database accession number, b) brief description, c) score and d) the E- value.

The E-value gives some information on the probability of finding such a hit in the searched database. For example, and E-value of 8.4e-08 on the last line of the output implies that the probability of finding a match as good as this, by chance, in the current database is 8.4×10^{-08} . Put in another way, the BLASTP E-value is a probability value calculated for each sequence, and gives an estimate of the probability that the match happened by chance and is not significant (the lower the number, the better the match) (Lloyd *et al.*, 1999). This value should normally fall below 0.01 or exceed 0.1 (except in the case of very small proteins).

The third part to the blastp output file is a number of alignments of the query sequence with significant hits, and the fourth and final part gives more administrative and statistical information.

The accession numbers of top hits were used to **>fetch** the GenBank entry from the databases. The full-length, top-hit protein retrieved in this way was used for fitting LSDV protein fragments on to. Missing regions at fragment junctions could be identified in this way, and the GenBank protein was also used for fixing frameshifts. To fix frameshifts, conserved motifs from the top hit protein were used to track the true reading frame in three frames (depending on the orientation of the ORF in the LSDV genome). The linear sequence of genes from published poxvirus genomes also gave important clues as to the orders and orientations of the peptide sequences.

To assemble the fragments whose orders and orientations are now known from the peptide sequence, GCG files in which frameshifts had been edited (by referring back to the original electropherogram of the region) were opened in Sequence Navigator once again. Adjacent fragments were joined by cutting and pasting. Back in UNIX, additional sequences discovered by primer walking were edited in (**>nedit**), re-checked for frameshifts, and full-length ORFs blasted.

3.2.4 SMART (V3.1) analysis of ORFs (Schultz *et al.*, 1998; 2000)

Detecting non-enzymatic regulatory domains is essential to predict a novel protein's cellular role, binding partners and subcellular localisation. SMART (a Simple Modular Architecture Research Tool), accessible at <http://coot.embl-heidelberg.de/SMART>, is able to detect more than 400 domain families found in signalling, extra-cellular and chromatin-associated proteins. These domains are extensively annotated with respect to phyletic distributions, functional class, tertiary structures and functionally important residues. Information on more than 400 domain types in more than 54 000 different proteins is stored in SMART using a relational database management system. For each domain hit, boundaries, a score and an E-value are recorded. SMART is furthermore able to search for all proteins that have an identical domain architecture as the query (i.e. having all the domains of the query protein in the same colinear order), or an identical domain composition (Schultz *et al.*, 2000).

3.2.5 The identification of promoters

Several promoters could be identified visually, but to take a more systematic and objective approach to locate these regions, which can deviate somewhat from the published consensus for vaccinia, blast alignments were implemented. William Pearson's *lalign* program (<http://ch.embnet.org/cgi-cin/LALIGN>) allows one to find multiple matching sub-segments in two sequences. The program implements the algorithm of Huang and Miller (1991). To create a consensus sequence for an early, intermediate and late promoter, the vaccinia consensus and its characterized promoters were considered, along with obvious promoter sequences identified visually by inspection of the regions upstream of LSDV ORFs. Assembled LSDV *PstI* clone DNA sequences were searched with consensus sequences for early, intermediate and late promoters. To accommodate ORFs on the non-coding DNA strand, reading towards the left, the promoter consensus sequences were reverse-complemented. Positive ORFs found by *lalign* were further verified by visual inspection, and those that had substitutions at the most conserved residues were excluded.

3.3 RESULTS AND DISCUSSION

3.3.1 Nucleotide sequences of LSDV *PstI* fragments

The nucleotide sequences of the *PstI* fragments were submitted to GenBank as two annotated sequences: *PstI*-E (7024 bp), *PstI*-M (2225 bp) and *PstI*-K (3281 bp) were combined under the accession number **AF336128**, whereas *PstI*-F (8553 bp) and *PstI*-G (7803 bp) were combined under the accession number **AF336131**.

Table 5: Identified LSDV ORFs and blastp matches of known specific genes with known or unknown function. Please see table legend (pg. 85) for details of the abbreviations and column headings.

LSDV ORF	Size		Top Hit				Putative Structure/function	Promoter type	
	Position	(aa)	E value	% Identity	Positives	Length (aa)			ORF description
E1L	E, 1-718	238	2e-34	82/224 (36%)	122/124 (53%)	274	SPV hypothetical protein H6 P32226 VV interferon gamma receptor	Interferon-binding protein	I/L
E2L	E, 755-1445	230	4e-05	32/121 (26%)	64/121 (52%)	170	VV O93116 VAR N2 protein	Alpha-amanitin sensitive protein	E
E3L	E, 1498-1984	162	3e-26	49/150 (32%)	82/150 (54%)	155	SPV hypothetical protein C7 P32225 Murine herpesvirus BHV4-IE1 homolog		I
E4L	E, 2030-3173	380	e-170	306/380 (80%)	308/380 (80%)	381	CAP Q2/3L partial ORF Q86917 <i>Macaca mulatta</i> chemokine receptor	G-protein coupled chemokine receptor homolog	E
E5L	E, 3283-3919	212	e-111	192/196 (97%)	194/196 (98%)	202	CAP Q2/2L full ORF Q86916 Orf virus ankyrin-like repeat protein	Actin - binding	E
E6L	E, 3966-4893	309	0.0	304/309 (98%)	306/309 (98%)	317	CAP Q2/1L partial ORF Q86915 VV interleukin-1 binding protein precursor	Interleukin-1 receptor	E



E7L	E, 5053-5320	88	1e-21	42/85 (49%)	68/85 (79%)	86	SPV C8 hypothetical protein P32224 VV hypothetical 11.1 kD protein		L
E8L	E, 5309-5792	161	2e-27	56/129 (43%)	89/129 (68%)	134	SPV hypothetical protein C9 P32223 <i>Homo sapiens</i> interleukin-18 binding protein A precursor	Interleukin-18 binding protein	L
E9L	E, 5811-6045	78	0.004	21/53 (39%)	30/53 (55%)	80	SFV growth factor H2 P08441 <i>Xenopus laevis</i> neureglin-1	Growth factor	(?)
E10L	E, 6093-6621	176	0.004	37/139 (26%)	62/139 (43%)	167	SPV hypothetical protein C10 P32222 MsEPV ORF 71	Putative early transcription factor-small subunit	L
M1L	E, 6665-7024 M, 1-85	147	5e-46	(73%)	(83%)	142	SPV dUTPase P32208 VAR dUTPase	dUTPase, Nucleotide metabolism	I
M2L	M, 129-1611	494	5e-97	187/466 (40%)	187/466 (40%)	500	SPV hypothetical protein C13 P32206 VV 55 K kelch-like protein	Actin-binding	I
K1L	M, 1713-2225 K, 1-487	321	3e-69	242/321 (75%)	283/321 (88%)	319	SPV ribonucleoside-diphosphate reductase-small chain P20493 VV F4L	Ribonucleoside reductase-nucleotide metabolism	E
K2L	K, 529-787	86	8e-06	20/47 (43%)	33/47 (69%)	86	SPV hypothetical protein C15 P32220		L
K3L	K, 830-1166	112	9.4	15/39 (38%)	22/39 (55%)	435	<i>Nicotiniana glauca</i> A membrane-associated salt inducible protein Q40452		E
K4L	K, 1398-1614	72	0.011	18/40 (45%)	26/40 (65%)	65	VV protein F8 P29887 VAR protein F8		E
K5L	K, 1691-2429	218	5e-72	129/216 (59%)	163/216 (74%)	215	SPV hypothetical protein C9 P32207 VV protein F9		L
A1L partial	K, 2319-3281	318	e-137	232/314 (73%)	271/314 (85%)	440	SPV protein kinase C20 P32216 VV protein kinase 2	Protein kinase	?
AXR partial	F, 1-386	128	4e-48	91/128 (71%)	104/128 (81%)	338	MYX poly(a) polymerase regulatory subunit (VP39) P18628 VV poly(a) regulatory subunit	Poly(a) polymerase regulatory subunit	?
FIR	F, 303-858	185	7e-78	135/185 (72%)	163/185 (87%)	185	MYX DNA-directed RNA polymerase 21 kD polypeptide	DNA-directed RNA	E



							P18620 VAR DNA-directed RNA pol 22 kD polypeptide	polymerase subunit	
F2L	F, 855-1272	139	1e-39	72/118 (61%)	90/118 (76%)	133	VV J5L protein P33055 VAR protein J5		L
F3R	F, 1484-5113	1210	0.0	920/1215 (75%)	1052/1215 (85%)	1286	VV DNA-directed RNA polymerase 147 kD polypeptide P20504 VAR Rpol47	DNA-directed RNA polymerase subunit	L
F4L	F, 5097-5712	205	8e-76	131/171 (76%)	134/171 (78%)	172	MYX tyrosine phosphatase (11L) Q85297 RFV tyrosine phosphatase	Tyrosine phosphatase	L
F5R	E, 5728-6299	190	2e-74	123/188 (65%)	153/188 (80%)	189	VV late protein H2 VV putative 21.5 k protein		L
F6L	F, 6300-7269	323	1e-45	99/326 (30%)	167/326 (50%)	325	VV protein H3L Q85385 VAR immunodominant envelope protein	Envelope protein	I/E
G1L	F, 7300-8553 G, 1-1135	799	0.0	566/799 (70%)	656/799 (81%)	797	VV H4L protein MYX m72L	RNA polymerase-associated protein	L
G2R	G, 1277-1955	226	0.001	42/73 (43%)	29/43 (66%)	220	VAR (=VV protein H5R) Q85386 orf virus envelope antigen homolog	Envelope protein	I/L
G3R	G, 1998-2949	317	e-117	210/317 (66%)	247/317 (77%)	314	SFV DNA topoisomerase I P16472 VV late protein H6	DNA topoisomerase I	L
G4R	G, 2971-3337	122	9e-18	44/106 (41%)	71/106 (66%)	129	VAR ORF 85R Q89221 VAR late protein H7		L
G5R	G, 3388-5650	754	0.0	466/719 (64%)	587/719 (80%)	836	SFV mRNA capping enzyme, large subunit P25950 VV mRNA capping enzyme	mRNA capping enzyme	E
G6L	G, 5684-6149	155	5e-22	57/154 (37%)	94/154 (64%)	143	SFV protein D4 P25951 VAR protein D2		?
G7R	G, 6468-6774	102	2.1	20/58 (34%)	32/58 (58%)	569	<i>Plasmodium falciparum</i> trophozoite cysteine proteinase precursor P25805 SFV protein D5 (length = 241 aa)		L
G8R	G, 6852-7505	218	5e-99	160/218 (73%)	187/213 (85%)	218	SFV uracil-DNA glycosylase	uracil-DNA glycosylase	E

							VV uracil-DNA glycosylase		
G9R	G, 7551-7803 (partial)	83	1e-16	37/57 (64%)	45/57 (78%)	791	FPV 92.6 kD protein		E
							VV 90.4 kD protein		

Legend to Table 5: Summary of the blast output files for each of the LSDV ORFs identified. The lengths and positions of the respective ORFs in their respective *PstI* clones are indicated, with the ORF size in amino acids (aa). The Top Hit columns give information of the homologous ORFs in the GenBank database. Two references are given. The first reference, with a GenBank accession number, refers to the “top hit”- the protein with the highest homology at the top of the output file. The information in the other top hit columns relates specifically to the top hit, i.e. the E-value, % identity, positives, and length in amino acids. The second entry was the second hit in most, but not all cases, included to give extra information about the other types of proteins that demonstrated significant homology. Some ORFs are exclusive to poxviruses, particularly those of the terminal regions, while others, like the DNA topoisomerase I gene has counterparts with high homology in eukaryotic organisms like mice and humans. The “% identity” refers to the number of matches in the particular alignment that match precisely, at that point. Insertions or deletions of amino acids are therefore penalised in this value. “Positives” refers to the amounts of matching amino acids in the linear peptide sequence. The promoter column again refers to the LSDV ORF, where “I” represents Intermediate, “E” represents Early, and “L” represents a Late promoter. These results are discussed in 3.3.3, LSDV ORFS.

3.3.2 SMART analysis

Each peptide sequence, in FASTA format (Appendix III), was cut and pasted into the SMART program for the detection of protein motifs and domains. The results were as follows:

Identification of a RING finger motif. A RING finger motif was detected in ORF E3L beginning at aa 11 and ending at aa 54. An E-value of 1.81e+01 was assigned by SMART.

Table 6: E5L - Identification of Ankyrin repeats

MOTIF	BEGIN	END	E-value
ANK	21	50	2.79e+01
ANK	51	82	4.13e-02
ANK	87	120	9.92e+02
ANK	124	155	3.60e-02
ANK	159	189	1.70e+02

Five ANK repeats were detected in ORF E5L. The ANK domain in the ORF E5L query of 212 amino acids starts at 87, and ends at position 120. The ANK repeat sequence in ORF E5L was:

NNLSALAHYLSFNKNVEPEIVKILIIDSGSSVTE

Table 7: E6L- Identification of immunoglobulin-like domains

MOTIF	BEGIN	END	E-VALUE
IGc2	4	83	4.79e+00
IG	6	94	1.87e+00
IG-like	71	166	1.37e+01
IGc2	102	171	8.42e-02
IG	96	201	3.38e-01

Due to overlapping domains in ORF E6L, there were three representations of the proteins.

IGc2: Immunoglobulin C-2 type

IG: Immunoglobulin

IG-like: Ig domains that cannot be classified into one of IGv1, IGc1, IGc2 or IG.

Table 8: F4R- Identification of tyrosine phosphatase motifs

MOTIF	BEGIN	END	E-VALUE
PTPc	2	169	24e+01
DSPc	26	169	1.05e-47
PTPc	69	170	6.45e-07

Three tyrosine phosphatase motifs were identified in ORF F4R.

PTPc: Protein tyrosine phosphatase, catalytic domain

DSPc: Dual specificity phosphatase, catalytic domain

Identification of an Epidermal Growth Factor (EGF)-like domain. An EGF-like domain was identified in ORF E9L, beginning at aa 20 and ending at aa 65. An E-value of 1.30E+01 was assigned by SMART.

Table 9: Identification of TRANSMEMBRANE regions

ORF	BEGIN	END
E3I	79	99
	123	143
E4L	17	37
	89	109
	127	147
	165	185
	207	227
	256	276
	294	314
	334	354
E10L	48	68
	113	133
F2L	119	139
F5R	24	49
F6L	286	306
K1L (probable)	74	94
K2L	16	36
K3L	47	67
K5L	180	200

Table 10: Identification of SIGNAL PEPTIDE sequences (collective)

ORF	BEGIN	END
E1L	1	17
E2L	1	22
K2L	1	44

3.3.3 LSDV ORFs (Please refer to Table 5 and 3.3.2 SMART Analysis)

Proteins involved in transcription and mRNA biosynthesis. Five LSDV ORFs that could be involved in viral transcription and mRNA synthesis have been identified. All occur in the central regions as would be expected for genes essential for the viability of the virus. ORF G1L encodes the RNA-polymerase-associated transcription specificity factor (RAP94), spanning the *PstI* junction between *PstI* clones -F and -G. The RAP94 of variola virus has been shown to associate with the RNA polymerase, and is required for the transcription of the early genes, where it possibly mediates the binding of the core RNA polymerase to viral early transcription factors (VETF) (Massung et al., 1993). The poxvirus DNA-directed RNA polymerase is known to consist of at least eight subunits (Jackson and Bults, 1990). In this study, two of these have been identified for LSDV, namely the RNA polymerase subunits encoded by ORFs F1R and F3R, the homologs of the MYX 21 kD polypeptide and VV 147 kD polypeptide, respectively. Although ORF F3R shows high homology to its VV counterpart (85% positives), the LSDV ORF appears to be 76 amino acids shorter at the C-terminus. A regulatory subunit of the RNA polymerase, encoded by partial ORF AXR, is expected to extend for another estimated 210 amino acids (including the amino terminal) in the uncloned LSDV *PstI*-A fragment. ORF G5R encodes the large subunit of the mRNA-capping enzyme. The mRNA capping enzyme is a heterodimer of a large and a small subunit, and catalyses the first two reactions in the mRNA cap formation pathway (Upton *et al.*, 1991). The LSDV ORF is 82 aa shorter than its SFV homolog, with approximately 10% of the C-terminus truncated. ORF E10L encodes the small subunit of a putative early transcription factor. It has a relatively low percent identity (26%) to the SPV homolog, and appears to be some 24 amino acids shorter. Two transmembrane regions were predicted by SMART; the first from aa residues 48 to 68, the second occurring from residues 113 to 133.

Other poxvirus enzymes also involved in transcription and mRNA biogenesis, but not identified in these LSDV clones include additional RNA polymerase subunits, mRNA transcription, initiation elongation and termination factors, enzymes that direct posttranscriptional processing of viral mRNA, other transcription factors and additional poly(A)polymerase subunits. All of the transcription and mRNA biogenesis protein homologs identified so far in LSDV have been found in the central region represented by *PstI* clones -F and -G, and additional members of the group are therefore expected in the flanking *PstI* fragments of the central conserved region: -A, -D, -L, -I, -H and -C (Figure 5).

Proteins involved in nucleotide metabolism. Enzymes known to be involved in poxvirus nucleotide metabolism include the thymidine kinase, thymidylate kinase, dUTP pyrophosphatase (dUTPase) and ribonucleotide reductase. ORF MIL encodes a viral dUTPase with high (83% positives) homology to the SPV counterpart. This enzyme produces dUMP, the immediate precursor of thymidine nucleotides which decreases the intracellular concentration of dUTP, so that uracil cannot be incorporated into DNA (Massung *et al.*, 1993). The ribonucleoside reductase is a heterodimer of a large and a small chain. Poxvirus ORFs LSDV K1L, SPV and VV F4L all belong to the ribonucleoside diphosphate reductase small chain family (Goebel *et al.*, 1990). These enzymes catalyze the first reaction in the viral DNA replication pathway, providing precursors necessary for DNA synthesis. The catalytic activity involves the conversion of 2'deoxyribonucleoside diphosphate, oxidised thioredoxin and water to ribonucleoside diphosphate and reduced thioredoxin, with a cofactor containing two iron ions (Goebel *et al.*, 1990). ORF K1L contains a probable transmembrane region, predicted by SMART, from aa residues 74 to 94.

Proteins involved in DNA replication and repair. Uracil DNA glycosylase is an important enzyme for DNA replication and repair, because it excises uracil residues from the DNA arising as a result of misincorporation of dUMP residues or due to deamination of cytosine (Upton *et al.*, 1993). ORF G8R encodes such a putative enzyme of 212 amino acids, corresponding precisely in size to the SFV homolog with 75% identity. DNA topoisomerase is able to relax both positively and negatively supercoiled DNA in the

absence of an energy cofactor, and the poxvirus topoisomerase homologs, such as ORF G3R and its SFV and VV homologs, which it closely resembles, has the properties of a cellular type I enzyme, except that it is resistant to camptothecin (Bauer *et al.*, 1977; Fogelson and Bauer, 1984; Shaffer and Traktman, 1987; Shuman *et al.*, 1988). The failure of attempts to construct a mutant vaccinia virus with deletions within the topoisomerase gene suggests it plays an essential role in the life cycle of poxviruses (Shuman *et al.*, 1989). Other replication and repair enzymes of LSDV expected to be encoded in adjacent *PstI* clones include the DNA ligase, uracil DNA glycosylase, DNA polymerase, and replication-essential protein kinase.

Proteins involved in protein modification. Protein tyrosine phosphatases are recognized as important regulatory enzymes, which together with protein tyrosine kinases regulate protein phosphorylation within a cell. Although structurally diverse, both tyrosine phosphatases and kinases can be classified into two major groups: transmembrane or receptor-like and cytosolic or non-receptor-like. Both classes of tyrosine phosphatases contain one or two homologous catalytic domains where an active site cysteinyl residue is located within a conserved sequence motif (Guan and Dixon, 1991). Mossman *et al.* (1995) demonstrated the importance of poxviral phosphatases by showing that MYX IIL is essential to virus viability in tissue culture. Poxviral tyrosine phosphatases constitute proteins that are highly conserved, both within and between different genera (Mossman *et al.*, 1995). The open reading frames which encode for all the known poxviral phosphatases are located within the central portion of the virus genome, adjacent to another essential virus gene, RPO147. ORF F4L encodes a tyrosine phosphatase, flanked by an LSDV RPO147 (F3R), with 76% identity to the MYX tyrosine phosphatase (IIL). SMART analysis additionally identified three tyrosine phosphatase motifs: two PTPc (protein tyrosine phosphatase, catalytic domain) domains from aa residues 2 to 169 and 69 to 170, and a DSPc (dual specificity phosphatase, catalytic domain) motif from aa residues 26 to 169. At a length of 205 aa, the LSDV ORF is slightly longer at the C-terminus than the MYX homolog of 172 aa. Homologous phosphatase genes have also been reported in the central regions of eight other orthopoxviruses to date (Mossman *et al.*, 1995). Vaccinia H1L phosphatase has been

reported to be packaged into virions and required for early virus gene expression *in vivo* (Mossman *et al.*, 1995; unpublished data), further supporting the essential role of this enzyme. Partial ORF A1L encodes a protein kinase. A predicted 122 amino acids of the N-terminus is expected to complete the ORF in *PstI* fragment A. At 73% identity, the homology to the SPV ORF is relatively high. It is most likely that poxvirus-encoded phosphatases and kinases could influence a variety of cellular functions, ranging from the replication of the viral genome to the disruption of cellular signaling pathways critical for the host immune response.

Structural proteins. Poxviral structural proteins include core proteins, membrane-associated proteins and proteins of the envelope complex. SMART analysis identified several proteins containing transmembrane regions, suggesting membrane association (Table 9). These include ORFs E3L (two regions), E4L (eight regions), E10L (two regions), F2L, F5R, F6L, K2L, K3L, and K5L each with one transmembrane region, and K1L with a probable transmembrane region from amino acid residues 74 to 94. F6L is a putative LSDV envelope protein with 30% identity to VV ORF H3L and the VAR immunodominant envelope protein. No function is assigned to ORF E3L, a homolog of SPV ORF C7. ORF E4L is a G-protein-coupled chemokine receptor homolog and is discussed further on. ORF E10L is a putative early transcription factor subunit. F2L's VV J5L homolog has no assigned function, neither has a function been assigned to the F5R VV putative late protein H2 homolog. The LSDV ORF K1L is a small subunit of the ribonucleoside reductase. ORF K2L, the LSDV homolog of SPV protein C15 has no assigned function. Furthermore, SPV C15 was the only hit, suggesting that this protein is unique to SPV and LSDV. K3L is a salt-inducible protein with no homology to any other poxvirus proteins identified to date, and is also discussed later on. ORF K5L has no assigned function. ORF F6L is a homolog of a known envelope protein, VV H3L.

Excluding ORFs E4L, K1L and F6L, no definite functions for the ORFs containing transmembrane regions are known. These proteins presumably associate with the cell membrane, and might be components of the complex poxvirus capsid structure. Some of them could possibly encode antigenic determinants on the virion surface, which could be

involved in host cell receptor recognition and binding. The reasons why an early transcription factor subunit, which theoretically binds to a DNA molecule, would have a transmembrane region are unknown; it is possible that the transmembrane signal plays some role in the packaging of the early transcription factor during viral assembly. ORF G2R is an envelope protein, a homolog of VV H5R, additionally showing similarity to the orf virus envelope antigen. No transmembrane regions were detected in the 226 aa peptide sequence, suggesting that ORF G2R is one of the outer capsid proteins. Outer capsid proteins assemble onto another structural proteins and can be presented on the surface of the virus, possibly playing a role as antigenic determinants.

Host-related functions:

Proteins with immune evasion functions. Growth factors, soluble chemokines, chemokine receptors, interleukins, serpins and epidermal growth factor (EGF) are all implicated in the interference of host immune mechanisms. All of the identified LSDV protein homologs suspected of playing a role in host-related functions and the evasion of the immune response occur in the left-hand terminal regions represented by the the *PstI* clones -E, -M and -K, although the possible role of the tyrosine phosphatase and protein kinase, which occur in *PstI* clones -F and -G respectively, have previously been mentioned. ORF E9L encodes homolog of a SFV growth factor H2. It furthermore has an EGF-like domain from aa residues 20 to 65, identified by SMART. The EGF receptor has been implicated as the portal of entry for vaccinia viruses (Eppstein *et al.*, 1965; Marsh and Eppstein, 1987). ORF E1L encodes an interferon gamma receptor homolog. The first 17 amino acids were identified as a signal peptide sequence, which will determine its destination in the host cell. Two proteins with probable interleukin-binding functions were identified: ORF E8L is an IL-18 binding homolog, and ORF E6L shows homology to the VV interleukin-I binding protein precursor. SMART furthermore identified five immunoglobulin-like domains, from three representations of the proteins due to overlapping domains (refer to Table 7). Two immunoglobulin C-2 type domains were detected, from aa residues 4-83 and 102-171. "C-2" refers to a particular type of domain, found specifically in the constant region of an immunoglobulin heavy chain (Roitt, 1997). Two immunoglobulin domains were identified, from residues 6 to 94 and 96-201, and

one immunoglobulin-like domain, which cannot be classified into one of IGvI, ICcI, IGc2 or IG is found in residues 71-166. The poxviral interferon- γ -binding proteins contain relatively low (~20%) homology to the ligand binding domain of the human and murine IFN- γ receptors, although similar lengths are observed within the chordopoxvirus homologs (Mossman *et al.*, 1995). ORF E1L contains nine cysteinyl residues (Appendix IV), eight of which are known to be important for the ligand binding domain. The MYX homolog contains all eight, whereas VV and VAC counterparts have only six, with the first two cysteinyl residues replaced by tyrosine in each case (Mossman *et al.*, 1995).

ORF E4L shows 80% identity to ORF Q2/3L, identified as a G-protein coupled chemokine receptor homolog in sheeppox isolate KS-1 *HindIII* fragment (Cao *et al.*, 1995). The authors were able to demonstrate, through Southern blot analysis, that all three species of the capripox genus (SP, GP and LSDV) contain copies of this ORF. ORF Q2/3L showed 38% sequence identity to SPV ORF K2R (Massung *et al.*, 1993), and 27% identity with HCMV ORF US28 (Human cytomegalovirus chemokine receptor homolog) (Chee *et al.*, 1990). The authors report that a highly conserved motif, DRYLAIVHA, at the end of the third transmembrane domain is present in ORFs Q2/3L and SPV-K2R. Other hits of the same protein family ORFs CKR-1, NY-3R, IL-8ra, and 8rb contain the motif, but it is absent from ORF C5a, fmlp binding proteins (which are also chemokine receptor homologs) and ORF HCMV-US28. SMART identified eight transmembrane regions in ORF E4L (Table 9). A similar motif, DRYLAVVHP, was found from aa residues 186-194, which corresponds to the end of the fourth transmembrane region in LSDV. Certain features of ORF Q2/3L (and LSDV ORF E4L) and the related proteins make them distinct from classical seven transmembrane-spanning receptors: the carboxyl terminus is relatively short and lacks the cysteinyl residue involved in membrane anchorage (O'Dowd *et al.*, 1989) and the segments between the transmembrane domains are quite short (Cao *et al.*, 1995). By comparison of the ORF E4L aa sequence (Appendix III) to ORF Q2/3L aa sequence (Cao *et al.*, 1995), the conservation of several potential N-linked glycosylation sites located mainly in the N-terminus is evident. An additional site in the transmembrane domain is unlikely to be glycosylated, owing to its predicted position within the membrane (Cao *et al.*, 1995).

Proteins with other host range functions. ORF E5L shows very high (97% identity) homology to capripox (SP) ORF Q2/2L, but also shows homology to an orf virus ankyrin-like repeat protein. SMART identified five repeats of the motif NNLSALAHYLSFNKNVEPEIVKILIIDSGSSVTE in the 212 aa LSDV protein, namely from residues 21 to 50, 51 to 82, 87 to 120, 124 to 155 and 159 to 189. The presence of these five ankyrin repeat motifs suggests that ORF E5L binds actin elements of the cytoskeleton, thereby playing a role in tissue tropism. ORF M2L shows 40% identity to a SPV C13 ORF, and also has homology with other known kelch-like proteins, such as the VV 55K protein. Kelch repeats are also implicated in actin-binding.

The RING finger is an evolutionarily conserved structure identified in more than 200 proteins to date (Schultz *et al.*, 2000), in which two loops of amino acids are pulled together at their base by eight cysteinyl or histidinyl residues that bind two zinc ions. In order to keep a cell healthy, some proteins have to be destroyed, and these are tagged for elimination by the attachment a small peptide, ubiquitin. The tagging occurs in steps, with one enzyme binding to the protein marked for destruction and another ferrying the ubiquitin label to the target. Recently, RING fingers have been identified as having ubiquitin-protein ligase activity, identifying them as the molecular mediators that couple ubiquitin and E2 ubiquitin-conjugating enzymes so that the tagging can take place (Barinaga, 1999). SMART identified a RING finger motif in residues 11 to 54 of ORF E3L. The ability of a virus-encoded protein to mediate the targeting of host proteins, particularly antiviral or immune-signalling proteins for elimination would have obvious benefits for evasion of the host immune response.

Proteins with cellular functions. A fowlpox virus ORF, FPV114, has been shown to share a 180 aa conserved domain with proteins found in plants, yeast, roundworms and bacteria. ORF FPV114 is most closely related to the yeast Hal3 and SIS2 genes and a putative Hal3 homolog from the plant *Arabidopsis thaliana* (Afonso *et al.*, 2000). These proteins function as inhibitory subunits of cellular protein phosphatases, and they promote salt tolerance and affect growth (De Nadal *et al.*, 1998). LSDV ORF K3L, a 112 aa putative protein, has no homologs in poxviruses but includes a region with low (38%)

identity to a 39 amino acid domain of a *Nicotiniana tabacum*, (common tobacco) membrane-associated salt inducible protein. A possible role for ORF K3L in the host could therefore be in the regulation of the host cellular functions. SMART identified a transmembrane region from residues 47 to 67, suggesting that ORF K3L too is membrane-associated.

Other proteins of unknown function. In the left terminal region, ORF E2L encodes a 212 aa protein with low percentage identity (26%) to a VV alpha-amanitin sensitive protein and ORF E7L encodes a homolog of hypothetical protein C8 of SPV and a VV 11.1kD protein. In the central region, ORF G6L encodes a homolog of similar length to SFV protein D4, whereas ORF G7R encodes a potential protein of unknown function with highest homology to a 58 aa region of *Plasmodium falciparum* throphozoite proteinase precursor, but also shares homology with SFV protein D5. Partial ORF G9R's 92.6kD protein homolog in FPV has no assigned function.

3.3.4 Nucleotide composition (GCG)

>**Composition** was used to calculate the nucleotide contents of the assembled *PstI* clone DNA sequences

Table 11: Nucleotide Composition

Fragment (bp)	#A (%)	#C(%)	#G(%)	#T(%)
E (7, 024)	2,465 (35.1)	1,033 (14.7)	714 (10.2)	2,812 (40.0)
M (2, 225)	774 (34.8)	373 (16.8)	233 (10.5)	845 (40.0)
K (3, 281)	1,126 (34.3)	467 (14.2)	353 (10.8)	1,335 (40.7)
F (8, 553)	3,278 (38.3)	1,133 (13.2)	1,219 (14.3)	2,932 (34.3)
G (7, 803)	3,187 (40.8)	902 (11.6)	1,066 (13.7)	2,648 (33.9)
TOTAL (28, 886)	36.7	14.1	11.9	37.8

74.5% A+T

A total of 28 886 bp of LSDV genomic DNA sequence has been determined. This is the largest amount of sequence data available for the SA vaccine strain (Neethling), or a capripoxvirus, to date. The 74.5 % A+T calculated (GCG) corresponds closely to the value of 72.4 % determined by restriction endonuclease analysis of Gershon and Black (1989).

3.3.5 Comparison of poxvirus genome organizations




Figure 14: Linear comparison between the left-hand terminal regions of SPV, LSDV and VV genomes. Homologs are indicated by a line; additional poxvirus homologs are indicated in text below the VV genome. The shaded boxes indicate novel genes. Boxes that are neither shaded nor linked by a line have homologs in poxviruses other than SPV, LSDV and VV.

3.3.6 Relationship of LSDV to other poxviruses. Figure 14 illustrates the linear order of the genes in the left near-terminal regions of SPV (top), LSDV (middle) and VV, the prototypal poxvirus (below). The vaccinia virus (Copenhagen strain) genome was determined to be 192 kb in length (Goebel *et al.*, 1990), whereas the swinepox virus genome is ~175 kb in length (Massung *et al.*, 1993) and LSDV is estimated to be 152 kb in length (unpublished data). SPV was chosen for comparison because its ORFs came up as the top hit most frequently in the blast searches of the LSDV ORFs against the SwissProt protein database, and show the highest homology to the LSDV ORFS identified, suggesting that the capripoxviruses are more closely related to the suipoxvirus




Figure 14: Linear comparison between the left-hand terminal regions of SPV, LSDV and VV genomes. Homologs are indicated by a line; additional poxvirus homologs are indicated in text below the VV genome. The shaded boxes indicate novel genes. Boxes that are neither shaded nor linked by a line have homologs in poxviruses other than SPV, LSDV and VV.

SPV than to any of the other ChPV genera, despite differences in genome sizes, although Shope fibroma virus (a leporipoxvirus), at 159.8 kb (Willer *et al.*, 1999) is closer to LSDV in size.

Central region genome organisation of LSDV and the other poxviruses is indeed similar when the linear order of genes (refer to Table 5) is compared to similar tables in publications. This colinearity was also noticed by Gershon *et al.* (1989) who showed that a 100-115 kb piece of the genome is co-linear in organisation according to cross-hybridisation studies of capripoxviruses and vaccinia virus. No cross-hybridisation was detected between VV DNA and the respective left- and right-hand terminal 8 and 25 kb of capripoxvirus DNA, or between capripoxvirus DNA and the respective left- and right-hand terminal 38 and 35 kb of VV, but Figure 14 illustrates that the two regions do indeed have several ORFs in common.

As indicated in Fig. 14, homologous ORFs have been linked by a line. Starting from the left, SPV ORF C6L has a homolog in LSDV ORF E1L, although this protein is not found in VV. LSDV has a homolog of VV ORF N2 (ORF E2L) which is not found in SPV, but also occurs in VAR and CPX. ORF E3L again has a homolog in SPV but not VV. ORFs E4L, E5L and E6L are not the equivalent of VV K1L and K2L, although these ORFs have homologs in poxviruses other than VV and SPV (data not shown). This region of ~2000 bp seems to be absent from SPV, and the three missing ORFs, a G-protein chemokine receptor homolog, an actin-binding protein and an interleukin-I receptor homolog respectively, are all implicated in host-range functions in LSDV. These are presumably not required for the infection of leporid host cells, unless the genes have translocated and are present elsewhere in the SFV genome. The block of ORFs from LSDV ORFs E7L to K2L corresponds closely to SPV ORFs C8L to C15L, although LSDV ORF E9L is absent from SPV but present in other poxviruses (data not shown). ORF E9L is a growth factor implicated in the LSD virus/host interaction. LSDV ORFs M1L, M2L and K1L, a dUTPase, actin-binding protein and ribonucleoside reductase enzyme are conserved in most poxviruses. ORFs M1L and K1L are involved in nucleotide metabolism and therefore essential to poxviruses. SPV ORF C12L is similarly

absent from LSDV, but is homologous to VV ORF K7R (no line indicated in Fig. 14). It is interesting to note that VV ORF K4L which seems to be widely conserved among genera, encodes a 37k major EEV antigen IMCBH sensitive protein (palmityl protein) (data not shown) which is absent from the suipoxviruses and capripoxviruses. Furthermore, three genes of SPV: C16L, C17L and C18L, are not present in this region of LSDV, and do not correspond to a similar location in VV (containing VV ORFs F5L, F6L and F7L). These last three genes seem to be unique to orthopoxviruses (VV, VAC, CPX) as no homologs for members of other genera have been identified as yet. LSDV ORF K3L has no homology to any other poxvirus protein, and has therefore been highlighted. As a potential gene unique to LSDV, it possibly contributes to the bovine-specific nature of LSDV infection. The ORF resembles salt-inducible proteins, with roles in cellular functions. LSDV ORFs K4L, K5L and A1L again have homologs in VV ORFs F8L, F9L and F10L. ORFs K5L (unknown function) and A1L (encoding an essential protein kinase) are seemingly conserved among poxvirus genera.

3.3.7 Discussion of the regulatory elements

	critical region	spacer region	initiation region		
	-28	-13 -12	-2 -1	+6	
E2L	ATAAAAAATGAAAAAAAA	TATTACACTTT	TTAAAAA	...19	ATG
E5L	ACAAAAATGAAATATAA	CTTTTATTAA	TAATAAG	...26	ATG
K1L	AAAAATAATGAAATATAA	TTTTTATGGTA	TAAAAATA	...7	ATG
K4L	TTAAAAATGAAACATAA	ATCATAGCTAA	TAACATA	...23	ATG
G9R	GCTTTAGTGAAATTTTA	ACTAACTTGTG	TATTAAA	...1	ATG +L
F1R	TAAAAATATGAAAAAAAAAG	ATGTTTTATTT	TAATAAA	...193	ATG
G8Ra	GGTGTAAATGAAATTATT	CAAAAAATGA	TAATATC	...50	ATG
G8Rb	TAGAAAAATGAAAAAGGTA	AAAAAAAAATA	CAATGAT	...4	ATG
F6L	GGATAGATGAAAAACATA	ACTAAAATTAG	AGAGCTA	...51	ATG
E4L	AAAAAAATAAAAATAAAA	GTGTATGATTA	AGTAAAG	...16	ATG
K2L	TAAAAAAATAAAAAAAAG	TATAAATTTTA	CAATAGT	...8	ATG
K3L	AAAAAAATAAACTAAGT	TATACGTTATT	AGATAGT	...9	ATG
G5R	AACAAAAATAAAAAATA	ATTAACGCAAG	TAAAAAA	...32	ATG
E6L	GATAAGATGAAAAAAGT	AACGACATTTA	TTTCTA	...68	ATG
VV early promoter consensus	AAAAAAATGAAAAAAAA				
VV strong promoter	AAAAAAATGAAAAACTA				
LSDV promoter consensus	AAAAAAATGAAAAAAAA	AATAAAATTTA	TAATAAA		

Figure 15: Alignment of LSDV early promoters with the VV consensus (Davison and Moss, 1989). The deduced LSDV consensus is indicated at the bottom.

Early promoters. Nine examples of early promoters which closely resemble the VV consensus have been identified and aligned (Fig.15). These are situated upstream of ORFs E2L, E5L, K1L, K4L, G9R, F1R, G8Ra, G8Rb and F6L. The ORF E2L promoter region is the best example of this, with the closest homology to the VV consensus sequence, having only one nucleotide difference at -27 in the critical region. With the exception of upstream regions of ORFs G8Rb and F6L, all of these contain a T at -1 and

an A at +4. There is no evidence to suggest that these specific nucleotides are critical for early promoter function, but they do provide a useful guideline in the blast identification of LSDV early promoters. The initiation region for ORF F1R's promoter is unusually large, and it is possible that the true site for initiation occurs further to the initiation site in other A/T- rich tracts closer to the ATG start site. However, none of these A/T-rich tracts were found to resemble the early promoter consensus as closely as the presented sequence. The promoter type for the corresponding homolog in SFV happens to be unknown (Willer *et al.*, 1999). The region immediately upstream of the ORF G9R initiation codon, presented in the early promoter alignment as an early promoter also has the characteristics of a late promoter (Fig. 16). This would suggest that ORF G9R can be expressed both at early and late times, and that the product, of unknown function, may be required in large amounts by the virus.

Cao *et al.* (1995) reported that although the sheeppox Q2/3L ORF has an upstream A+T -rich region. The Q2/3L ORF shares an 80% nucleotide sequence homology with LSDV ORF E4L. There is no obvious sequence upstream of ORF E4L matching the conserved motifs found in early or late poxvirus promoters. Although the proposed promoter for ORF E4L has a CAAAAT motif adjacent to the RNA start (Fig. 16), the upstream region is relatively G+C-rich, whereas this region is characteristically A+T-rich in late and intermediate promoters. The early promoter sequence in the alignment was therefore considered to be the best candidate for a regulatory element. Although the critical region contains a TAAAA motif instead of a TGAAA motif for promoter regions of ORFs E4L, K2L and K3L and G5R, the VV 42 kD protein (Venkatesan *et al.*, 1982) promoter, which has been characterized as a definite early promoter (sequence not shown), shows a similar motif.

The region immediately upstream of ORF E6L lacks any motif to suggest a late or intermediate promoter. However, the regions further upstream are A+T-rich, resembling the early promoter motif. A TGGAA sequence here, is reminiscent of the TGAAA early promoter motif. Although the region upstream of ORF G5R has a TGTAA motif instead

of a TGAAA motif, the VV RNA polymerase gene (Broyles and Moss, 1986) shares the same pattern and has been characterized as a definite early promoter.




Figure 16: Alignment of LSDV late promoters with the VV consensus sequence (Davison and Moss, 1989). The deduced LSDV consensus is indicated for comparison.

Late promoters. By visual examination and blast searches of the regions immediately upstream of the RNA start sites for all the LSDV ORFs identified, upstream regions of ORFs F3R, F4R, K5L, G4R and G1L were found to closely match the VV late promoter consensus. All four contain the typical TAAATG site within which transcription initiates. The four nucleotides at +5 to +9 of F4L, the putative tyrosine phosphatase gene, are an exact match with the VV consensus.

ORFs F5R and K2L promoter sequences initiate with CAAATG instead of TAAATG, although this specific mutation have been shown in vaccinia virus to have a minimal detrimental effect on transcription (Davison and Moss, 1989).

The region upstream of ORF F6L (Fig. 17) closely resembles the late/intermediate motif. Position -19 is however occupied by a C, a mutation which has been shown to be detrimental to late promoter function. Although it lacks the upstream AAANAA motif characteristic of intermediate promoters, the region upstream of ORF F6L has been aligned with the intermediate promoters. An early promoter further upstream was identified for ORF F6L and is presented in Figure 15. The VV P35 immuno-dominant envelope protein, to which this LSDV ORF F6L shows 30% identity, has however been described as a late protein (Goebel *et al.*, 1990).

The regulatory region upstream of ORF E7L lacks motifs resembling the early promoter consensus, but initiates with CAAAATG. There are no motifs to suggest intermediate promoter status, and the region upstream of the SPV homolog, ORF C8L, has additionally been described as a late promoter (Massung *et al.*, 1993). Similarly, the region upstream of SPV ORF C9L, the homolog of LSDV E8L, initiates with an AAAATG motif and was also classified as a late promoter.

ORF G7R has no obvious upstream early promoter motif, and the A+T-rich initiation region ATAATG has previously been cited as a poxvirus late motif for SPV ORFs C1L, C8L, C12L, C16L and K4R (Massung *et al.*, 1993). ORF E10L too contains this upstream ATAATG motif, and an upstream region is additionally presented in the intermediate promoter alignment (Fig. 17). The AAANAA motif characteristic, of intermediate promoters, lies upstream at the unusually high position of -20.


```

F6L      ATTTTAATAACTAAATAGTGCTTTAGATAACTAATTATC AAAAT GGCAG
MIL      AAAAAACAAAAAAAAAATATCCTAATTTTAAAAAATAAC AAAAT GGATC (I/L)
E1L      TTTTTTGACGAAATAAGTCATTTTAGAGAAAAAGAATTTG AAAAT GGGCG (I/L)
E3L      AAATAAAAAAAAAATAATAACAACAAATAATGATATTTTATA AAAAT GGAAG (I)
M2L      ATAAAGAATATGTAGAAGAACTAAAGTACATGGTATTAA AAAAT GATTA (I/L)
E10L     AGAATAGAATCATTAAATAATAATGAGTTGGCAATTTTA ATAAT GATAC (I/L)
G2R      ATTATAAAAAATAGCTTCATATAAATACAAACAATTATTA AAAAT GTCGT (I/L)

VV I3      GGTAAACAAAAACATTTTTTATTCT CAAAT GAG
VV I8      GGTAAGTCAAAAAACATCATATAT AGAAT GGTAA

ATAATAAAAAAAAAAAAAATAAACTAAAGATAATAATTTTTA AAAAT GGTAG
           A   A   A           A
           C           C

```

Figure 17: Alignment of LSDV intermediate promoters with two *characterized* VV intermediate promoters, I8 and I3 (Hirschman *et al.*, 1990) and the LSDV consensus sequence.

Intermediate promoters. (Fig. 17) The region upstream of ORF MIL resembles that of a late promoter, but it could also have characteristics of an intermediate promoter as position -19 is occupied by a C. The AAANAA motif starts at +3. ORF E1L is preceded by an upstream AAAGAA motif, and is therefore also considered to be transcribed in the intermediate time interval. The ORF M2L upstream region lacks the AAANAA motif, but position -19 is a C, whereas the ORF E3L upstream region contains both the intermediate upstream motif, and the C at -19. ORF G2R again only has the intermediate promoter motif. The VV I3 and I8 promoter sequences (Hirschman *et al.*, 1990) which have been characterized as intermediate promoters in VV, are presented for comparison. In both cases, a C-residue is present at 18 instead of -19. A consensus for an LSDV intermediate promoter is also presented.

3.4. Conclusions

In this chapter, the edited fragment sequences described in Chapter II were assembled into two continuous nucleotide sequences, one from the LHT of the LSDV genome, and the other from the central region, which were translated to amino acids, from which the ORFs were identified. To be able to recreate the full-length sequence, the individual fragments were first translated to amino acid sequences, and blasted against public protein databases. Consequently, it was possible to assemble the fragments into the correct orders and orientations, based on full-length poxvirus homologs from the databases. Gaps revealed in the LSDV nucleotide sequences were filled by primer walking sequencing, also described in Chapter II.

At present, these 12530 bp from the LHT and 16356 bp from the central region represent the largest amount of continuous sequence data available for the LSDV genome (Neethling str.). The 3600 bp *PstI* J-fragment, of the same isolate has also been sequenced, by an Australian group (personal communication). Further analysis of the LSDV ORFs included the identification of specific protein motifs (SMART) which can aid in the assignment of possible protein function in the host cell, and the identification of upstream promoter sequences for the regulation of transcription.

In total, 35 conserved gene homologs were identified in the sequenced regions, including proteins involved in transcription and mRNA biosynthesis, nucleotide metabolism, DNA replication and repair, protein processing and virion structure. Comparison of the LSDV genome with those of other ChPVs (Table 5 and Fig. 14) furthermore revealed extensive genome colinearity in the central regions, and lesser colinearity in the terminal region. Predicted proteins with putative functions involving immune evasion included a G-protein-coupled chemokine receptor, an interleukin-18-binding protein, an interleukin-1 receptor homolog, a growth factor and a putative interferon-binding protein. Other potential LSDV host range proteins included homologs of those involved in tissue tropism (e.g. an ankyrin repeat-containing protein, a kelch repeat-containing protein and a

ring finger repeat- containing protein). In addition to a novel LSDV protein, several proteins with homologs but unknown function, such as those containing immunoglobulin domains were identified. This diverse complement of genes with likely host range functions in LSDV suggests that it is highly adapted for replication in the bovine host.



CHAPTER IV

Concluding Remarks

There can be no doubt that poxviruses have played an important role in the history of humankind. A.D. The smallpox scourge of previous centuries devastated entire civilisations, and caused massive loss of life in others. The directed efforts at control and the eventual eradication of the disease in 1977, was a social and scientific triumph. The means thereof, viz. the deliberate inoculation of healthy individuals with the related but non-pathogenic vaccinia virus, coined the term and founded the principles that are currently universally adopted to prevent diseases of many other pathogens from spreading. Despite the eradication of the human pathogen (smallpox), other poxvirus species continue to be a veterinary threat, with serious impact on animal health and national economies. As a first step to combating serious diseases however, a thorough knowledge of the pathogen is crucial. Furthermore, it is necessary to be able to understand how and why it replicates in specific host cells, and how transmission from these cells occurs.

In this regard, genome projects are becoming increasingly important, and poxvirus genomes are no exception. Computer-assisted genome analysis of the sequence data is providing a basic knowledge of what types of roles the putative pox proteins identified might be playing in the host cell. Furthermore, as increasingly more completed poxvirus genome sequences become available, comparisons can reveal which proteins are specifically responsible for certain abilities of the particular virus. Despite the great variations in genome sizes between and within poxvirus genera, a central core of between 100 and 115 kb is conserved in gene composition and length (Gershon *et al.*, 1989), encoding the genes known to be essential for poxviral growth and survival, and deletions in these regions have often been shown to be fatal to the viruses. Deletions in the terminal regions however, whose varying lengths are responsible for general variations in genome sizes in different poxvirus species, still permit virus growth in tissue culture (Wittek *et al.*, 1980). The genes of these regions are implicated in the ability of different poxviruses to infect different types of cells and cause a particular severity of infection. Furthermore, each poxvirus genome so far sequenced has been shown to encode genes unique to that particular virus. A knowledge of the locations of these host range specificity and virulence genes is particularly important, as poxviruses are considered to have enormous

potential as viral veterinary expression vectors: poxviruses have a large capacity to accommodate foreign genes (antigens), and the limited replication of a poxvirus in a non-host species still seems to lead to a protective immune response in the host (Taylor and Paoletti, 1988). Capripoxviruses, possessing some of the smaller poxviral genomes due to their somewhat shorter termini and have received much attention in recent years, as the sequencing of their genomes is expected to shed some light on the specific factors that influence host-range specificity and virulence of poxviruses.

In this study, the two largest continuous stretches of nucleotide sequence for a capripox virus genome to date (one region from the LHT of the genome and the other from the central region) are presented, along with the identification and computational analysis of the genes encoded in those regions. Specifically, the subject of this study was the Neethling strain of LSDV, an avirulent bovine-specific capripoxvirus used as a vaccine for the past 50 years in South Africa. The general poxvirus genome organisation, initially implied by the results of hybridisation studies undertaken by Gershon and Black in 1989, was verified again. The central region represented by *PstI* clones -F and -G, closely resembles corresponding regions in many other Chordopoxviruses, in gene content, homology and linear organisation. The near-left terminal region however has revealed some unique features. Firstly, the *PstI*-E fragment is expected to be within 6000 bp of the left hairpin loop, yet no inverted repeat sequences have been identified. If LSDV inverted terminal repeats could be short and few in number, and are expected to occur within the yet un-cloned and -sequenced regions. Secondly, one gene unique to LSDV has been identified, so far: ORF K3L has no homolog in any other poxvirus, and only low homology to a salt-inducible protein of the tobacco plant *Nicotiniana tabacum*. The poxvirus to which LSDV seems to share the closest homology with in terms of gene content, organisation and percent identity, is the *suipoxvirus* swinepoxvirus (SPV). This virus is host-restricted to pigs. One would have assumed closer homology to poxviruses such as variola virus and cowpox virus (both orthopoxviruses) which are known to infect the same hosts as capripoxviruses. Two host-restricted viruses (infecting totally different species) therefore appear to be more closely related to each other, than either is to a larger genus with a broader host range. This may suggest a common ancestor in the evolution of

LSDV, sheeppox, goatpox and SPV. If the gene composition is compared, LSDV proteins differ slightly in length and amino acid sequence, with truncations (where applicable) occurring mostly at the C-terminus. Seemingly slight variations such as these might introduce subtle changes in the protein folding, enabling the recognition of specific bovine receptors and not those of sheep and goats, or indeed other animal species, in the recognition and infection of cells. In this way, slight changes over a broad array of virus proteins may have a greater effect on the infectivity of the virus for cattle, than the presence of one or more absolutely unique LSDV proteins that recognise a bovine cell-surface receptor. The presence of such genes cannot be ruled out, however, as only a relatively small percentage of the total LSDV genome has been sequenced and analysed in this study.

In the event of the discovery of such a gene, whose absence or disruption would cause a drastic change in the infectivity of LSDV for cattle or an enhancement of its infectivity for another species or range of species, an excellent target for the engineering of novel vaccine viruses and expression vectors with enhanced efficacy and greater versatility would have been located. Additionally, the identification and characterization of specific LSDV virulence and host range genes would contribute to our overall understanding of pathogen-host interactions- information that is likely to have a broad impact on future studies for controlling bovine infectious diseases in general. These objectives will be attainable once the entire LSDV genome is completely sequenced, a grand-scale collaborated project which is likely to be completed within the next two years.

CHAPTER V

Appendices and References

5.1 APPENDIX I: EPGs:

Example 1: G6800/800 REV (sequencing of a cloned fragment with vector sequence primers)

Example 2: F66A (primer walking sequencing)



Model 377
Version 3.3
ABI100
Version 3.2


10-G68800F
G68800REV
Lane 10



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

331 T:1627 C:1030
DT {DD Set Any Primer} copy
dRhod 09/1999
Points 813 to 8264 Pk 1 Loc: 813

Page 1 of 2
Thu, Jun 22, 2000 7:26
Wed, Jun 21, 2000 15:28
Spacing: 9.93{9.93}





Model 377
Version 3.3
ABI100
Version 3.2

10-G68800F
G68800REV
Lane 10




UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA 31 T:1627 C:1030


DT {BD Set Any-Primer} copy
dRhod 09/1999
Points 813 to 8264 Pk 1 Loc: 813

Page 2 of 2
Thu, Jun 22, 2000 7:26
Wed, Jun 21, 2000 15:28
Spacing: 9.93(9.93)


T G A A A T C A A C C A C T A T A T T T T T A C T T T A G T T T G T A C T A A A T T A A C T A A T T C T A G T T T T A T A G A T G A A G T A T A T C T T T T G T
410 420 430 440 450 460 470 480




A A T C T A A A A A T A C A T G T C T T T C T T C A G A A G A G T A T C T T A T A T G C A A T G T T T A T C A A T T T T T T T T C T T T T A T T A A G T T T T
490 500 510 520 530 540 550 560 570




T C T T T T C C A A T T A T A T C A T C G A T T A A A T C A A C T A A T T G G A A A T T T T T T A A A T C T A A C C C A T G T T T T T G A C A T G G G T C T
570 580 590 600 610 620 630 640 650



T T A A T C T A A T T T A T A C T T C T T C N T T A T T A N T A C A G T A A A A A G T T T N T N T G A T C T G T A C C G A T G A A A T A T T A T T
650 660 670 680 690 700 710 720



T A N T T A C N T A T G N A
730





Model 377
Version 3.3
ABI100
Version 3.2


06-C-6F66A
C-6F66A
Lane 6



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

T:113 C:65
DT {BD Set Any-Primer}
48cmfilterE7/3/00
Points 1374 to 11804 Pk 1 Loc: 1374 Spacing: 10.97{10.97}

Page 1 of 3
Thu, Sep 28, 2000 8:05
Wed, Sep 27, 2000 15:17





Model 377
Version 3.3
ABI100
Version 3.2






06-C-6F66A
C-6F66A
Lane 6



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA ; T:113 C:65

DT {BD Set Any-Primer}
48cmfilterE7/3/00
Points 1374 to 11804 Pk 1 Loc: 1374 Spacing: 10.97{10.97}

Page 2 of 3
Thu, Sep 28, 2000 8:05
Wed, Sep 27, 2000 15:17





Model 377
Version 3.3
ABI100
Version 3.2

06-C-6F66A
C-6F66A
Lane 6



UNIVERSITEIT VAN PRETORIA
UNIVERSITY OF PRETORIA
YUNIBESITHI YA PRETORIA

DT {BD Set Any-Primer}

48cmfilterE7/3/00

Points 1374 to 11804 Pk 1 Loc: 1374 Spacing: 10.97{10.97}

Page 3 of 3


Thu, Sep 28, 2000 8:05

Wed, Sep 27, 2000 15:17

AAA CATCTTTTTT TT CATA TTTTATTAGAAA CCATCCC TT GGGGAAGGCATC TAAAGCTTTTTTNGGATTACCCGTTT
0 800 810 820 830 840 850 860 870

AAAATAC TTTTAAACCCCT CTTTTTTTGCNNGGC TTGCCAANCTTGGANG TTTTNTNTANNNGCC CCTAAANA NCTTTG
880 890 900 910 920 930 940 950

GNCGGTAA C CNAAGGN CAT ANGCTTG TTTCCCTGGGGGGAANTGGTTATCCCCNNCCCCCCC
960 970 980 990 1000 1010



5.2 APPENDIX II: DNA sequences from primer walking sequencing

Primer G550P

G6800/550 ATTAATAAAAATAAATGAGTTTATAGACAATAATATTATTAAT G6800/800

Primer F66A - No gap identified at *AseI* junction

Primer K12/K5P - No gap identified at *AseI* junction

Primer E2150A - No gap identified at *AseI* junction

Primer F66B

F6600/800 ATTAATAAAAAACCTAGTAATAAAATGCAGTAATATCTAAGTAACATATAGTTTATATAAT
CAGGAAGAAATTAATGCTACTGATATATTTATTAAT F6600/y

Primer F29A - No gap identified at *AseI* junction

Primer F29B

F6600/1000 ATTAATTGAAAAATCCGACGAGTTTTAACTTTTTATCCATTAAT F6600/x

Primer F29C

F2900/y ATTAATTGCATCATCATTAAAT F2900/x

Primer G6800/501 (Fragment G6800/603)

G6800/602

ATTAATATTTTTCTCATATGAAGTAAGTCTGCATGATGTGTGTAGAATTAATAAATGTAAGTCTCTCACAT
TATTAAGATAGATATGTCACAGAGAATTTATTGTGAGGATGCCAAAGAATGGTGTAAATGAAATTATTCAA
AAAATGATAATATCACTAATTCGATCTAATAATAATCAAGATATTCTTATTTTGAAAAAAAAATATGGAAG
AGGTTATTATTTGCAACTGTCAACTGCCAGAAATGAAAAATAGTTCATATGAAATCTTTTTAATAAATCCA
TTTGTAATAAAAAACAACACAGATATATTTAAAAATTTGATTTTAAGGTCATCGATTAACTATTTTCATATT
TGATAATTATGCACCACAGAAAAAATTTTAACGCATATATACCCATCCTTTAATATAGAAAAACGTATA
TATATATAAACTTTAACGAAATAAATAATATTTAAAAATAATAAAAAAATGTTATCATAGAAATAAAATTAGA
GCTTTATGCGTGGTTTAATTTTCAAATATGTGAAAAATAATGAAATAGAAAATGAAAAGGTAAAAAATAA
ACAATGATTTGTATAGCTTAATATGAAAACCATAAAAAACAAAATCTTTTCCTTATTGTATAGAATATCATG
ACGATTGGGAAGCCGTTATTAAT G6800/502

Manual DNA sequence of the region between the *AseI* junctions of clone K650 and K500

K650

ATTAATGTATATCTATTACTCATTGATTTCAATTATTGTATTCATAACACAATTTGCTTCAGAAG
TTCCAGAATTAAT K500

DNA Sequence of clone BC6 (with T7 primer) determined by automated DNA sequencing

The following DNA sequence of a fragment between G6800/601 and G6800/550 was determined from an overlapping *NdeI* fragment cloned into pMOS.

G6800/601

```
ATTAATTGTAGATTATATAGTAAATAGAGACACTATATAAAAAAACCTTAAACGATAAATGGATGAAAGA  
TTAAAGACGATTTCTATGACTTTTTTTGGTGAATTAACAACACTACAGATATAATGGTTTTAAAGGCACACCT  
GTTAAACATTTTTCCAAATGATACTATTTTTCTATAAATGAGGATAATAAATTTATAATTGACTTTAAAT  
ATAACGATGTTTAGCTTCAGGTTATATTAACCAAAAAATAATACCTATAACTCCAGAAAAATACAATGAAT  
ATTCATCGATGATAGCTAAAGAGTTGACAAAATTATAATATTATCATTGATGATATTAAGGGCATATACTAC  
ATCTAAAAAACTTAAAAGATTTATTAATTTTATAAAAACAAATAAATAATAAACAAAATAAAAAATAATT  
AACGCAAGTAAAAAATTAATATTGGCGTTAAATAAAAAGGAATTGATTATGATTATATTAGACATTAAT
```

G6800/550

5.3 APPENDIX III: Peptide amino acid sequences

>E1L TRANSLATE of: e29sept.seq /rev check: 3757 from: 4 to: 718
MGAVVFFAFLFLFKLCYSFPKDIKLTNSDFNSKIEWTNDVSDSNYRVMIMTYSSGEWKQAC
NYTIQKYCNVSPFIDDNTDDFWIKFITVDNTESNVFTFKPICESVVITTPSVFIKRQDVN
TVLTIHPLAKDNNKNSPIYNNDKYCNIVFKYILSITFGDSNTIKYEVDQFCDKKGCAL
EFGSQEKVCVTVFGNYETDYYQIRTNETSACIDELTPRKVDVTLVKQKTDLSLLKRR

>E2L TRANSLATE of: e29sept.seq /rev check: 3757 from: 755 to: 1445
MYTKNFKIFTKYITFLFSINEKKVKYFLNKVYFLSNYDYTKDDITKIVLKNSNKFTFTM
IKVISEYVLNENDYKVKIKELKIDGEYYADFYPFIKSKSPKHINSMKKVNFNMMENYFM
VRKMKNTKKIGKIYAEFLTYDAMAVNHYGVEYINKIISKLRLSKTRYCFSLYEKNENNV
DITTMKYIIGLISIISSHDTCKYPSFYIPFDEISHPKRKEFEKYICDRFP

>E3L TRANSLATE of: e29sept.seq /rev check: 3757 from: 1498 to: 1984
MEGSDNTNTHCWICKDEYNVSTNFCNCKNEFKIVHKNCLEEWINFSHNTKCKICNGKYNI
KKNKKSCLRWKCSFMYCNVPAICVSLICLILLPLTILLVKFNLKSMLNENRDLIALIS
AMAYSLPCVVGFITVWHILIALYDYYLAAKSDNTTYQVYEYI

>E4L TRANSLATE of: e29sept.seq /rev check: 3757 from: 2030 to: 3173
MNYTLSTVSSATMYNSSSNITTIATTIISTILSTISTNQNNVTPSTYENTTTISNYTTA
YNTTYYSDDYDDYEVNIVDIPHCDGVDTTSFGLITLYSTIFFLGLFGNIIVLTVLRKYK
IKTIQDIFLLNLTLSDLIFVLVFPFNLYDSIAKQWSLGDCLCKFKAMFYFVGFYNSMSFI
TLMSIDRYLAVVHPVKSPMIRTKRYGIVLSMVVWIVSTIESFPIMLFYETKKVYGITYCH
VFYNDNAKIWKLFINFEINIFGMIIPLIILLYCYKILNLTAKTSQTKNKAIAKMFVFLIVI
CSVLFLLPFSVTVFVSSLYLLNVFSGCTALRFVNLAHVVAEIVSLCHCFINPLIDAFCSR
EFTKLLRLRSTSSAGSISI

>E5L TRANSLATE of: e29sept.seq /rev check: 3757 from: 3283 to: 3919
MEKEKLCSDYDNDFTDYLFRYCNPLFYVEQDDINGVKKWIKFVNDNCLYETPLFSCV
EKDKVNVVEILKFLIENGSDINPKTRDNNLSALAHYLSFNKNVEPEIVKILIIDSGSSVTE
EDENGKNLLHMYMCFNVRINVIKLLIDSGVNFLQKDFDNNNIIYSYILFHSDDKIFDYL
TSLGIDIDETNTSGYNCKDLIKFRNLTFDFKQ

>E6L TRANSLATE of: e29sept.seq /rev check: 3757 from: 3966 to: 4893
MKTFFENNSEIVKCPYVDTLNNTTVKWFVNYNEYVKTGDVKKSFHEFKNTDRVYVSVGHS
LWINNITKNDSGIYACNVHNSTYYFTSSVMLDIYKKTINSVIGTNYELLCINTKNFINT
FNCSYEVNWWKDREKINNNFKYKKSKEKLLIRNISKSDYVYLCISITTATRCNPKNLALK
RYYHNNVIKKRFKDDINLTVNFLNSTIALGKNFLMECIGESKNIQRVYRSSFIFWLINGVN
VLDYDRSKNIYLGREMYVGNYSYKIALIIEVKRKYLSANFTCNLHNLEYNLYLTKKIYVN
LKTLYKNEI

>E7L TRANSLATE of: e29sept.seq /rev check: 3757 from: 5053 to: 5320
MSSNSDLAFCYVLPNINEVTDGIVFIKDNIVYVKLINYGLEALVIDYVNINMDQMNNIKK
TLVNKLINVQIIRMNKIKGYIDVKVYNN

>E8L TRANSLATE of: e29sept.seq /rev check: 3757 from: 5309 to: 5792
MISFKKVVICLTLFTTFYVYVYSKCAKKRDLVIYFPHKEGENVLLQCKGYSHHSNYAYVYV
LIGNNNSFVEFMNGDIYKERMYFNKKPLKCGKEPRSDLIKKNVTEBIKNTNLTCLVMDLE
EPIKKTILINDIWNCLNNTCEHKNGISSEKVVSESESKNVIE

>E9L TRANSLATE of: e29sept.seq /rev check: 3757 from: 5811 to: 6045
MLSKENKNDYITILNKDIMMCDKSNFCLNGGTCYKTTFILSYNKKPLMFCRCKLGYEGR
LMSFKKFVSLFLKKKYKI

>E10L TRANSLATE of: e29sept.seq /rev check: 3757 from: 6093 to: 6621
MDTSNYNIEKVLNVYLRDLRIESLNNNELAILIMIRECCEVIKKDYKTEFNEICNFILHNNVKSCYDINDV
KNIIIIETINSDFRPSVILASISLLSIIKKKKSENNEVVNDLALNELINTFSSYQKDIISFVEKNKKIDE
QNDFIFSIIINFFVMIGSIIITYYLLKIIGRIRWK

>M1L TRANSLATE of: mcorrect.seq /rev check: 1649 from: 4 to: 85
: e29sept.seq /rev check: 3757 from: 6665 to: 7022
MDHSSSVVNCIRLSAFAKLPTTSTDFSAGYDLYSAYDYIVKSKERILVKTDISLSIPKKCYGRIAPRSGLS
LYYCIDIGGGVIDEDYRGNIGVIFINNGKNTFNKIKRGDRVAQIIFEKVEYPKIKEVKCLDGTNRDNNNGFGS
SGIL

>M2L TRANSLATE of: mcorrect.seq /rev check: 1649 from: 129 to: 1611
MINTGYITLNSKNVVDIFSISNVIEIKFIMDACTDFMINYIDDSNCVDILEDSYMYGICYD
VYDVADKYIKKRFMYISNDLTKLRVNELRPILKSSDLVVAEDFVLNFIKKGTVKKTNR
LNTMKLVNDAVRFTFLTEKGGKRLQAWSSRFKKKPYDFNKNSDKHIPRCNYKNREFINSD
KFTKSFKFKVYNDNLTKILFTNNIMDINI IDESVYDNELLYENNCNEIDENKTLNESIQQ
PSNLSKLSNIIDENFKFCTSAIGNNIYFLGGVDKYLRSVNSVFAINVKTFERENLPSLI
YPRKCPGATYFNNRIYVIGGIYNNCIVNKVESWSFGESVWREEPNLLYPRYNPCVVNVND
TIYVIGGISEYDKSVEVYNLKYKWSLGECKYSHYGGCAIYHHGLIYVVGGISYINNIIK
VFNMVESFNPMSCKWRIESCLNQPRFNSSICIFDDCIMIIVGGFHYERYIREIEIFDDKTK
GWDVIGALDIDSVF

>K1L TRANSLATE of: mcorrect.seq /rev check: 1649 from: 1743 to: 2223
: k29sept.seq /rev check: 4453 from: 4 to: 487
MEPILKETSSRFVVPILYKEIWMYKKAVASFWTVDEVLDLADWKKLNNEEQYFIK
NILAFFAASDGI VNNLAERFYSEVQWSEARCFYGFQIAMENIHSEMYSLIDITYISSTK
EKEHLFNAIETMDFIKKKSEWARKWISNKKASFGERLIAFAAVEGIFFGSFAAIFWLKK
RGLMPGLTFSNELISRDEGLHCDFACLI FKHLYPPSNDIITIIINEAVSIEKEFLTNI
PVKLI GMNCVLM SQYIEFIADRLLELGLCDKVMSTNPFDFMENISLEGKTNFFEKR VSE
YQKMGVISNKDDNVFSLDVDF

>K2L TRANSLATE of: k29sept.seq /rev check: 4453 from: 529 to: 787
MHQMNLTTAMPNNNAF SIGTVLILMVLIIVIVISLYLLFQLVNC FYLFDL FNKIKVRMMK
LTTTRSFDELENNVYIDDKCVGVNVD

>K3L TRANSLATE of: k29sept.seq /rev check: 4453 from: 830 to: 1166
MDKKIYCGIVFGYRLLKKS I KEKAIKCVS FIRKSNMKPAISI ERVTLLDGDGDGNGANDS
NSNSDSDTVSSKYNNYKYKFTKRKTPHKVMYYINYDDSVSNDDVFL

>K4L TRANSLATE of: k29sept.seq /rev check: 4453 from: 1398 to: 1614
MSEKLLKVNKV VVNGKPYNSNSNSTPSKDEIKKYGYCLNIKKPSSHNDKKETYLHNDYP
MVIITNTS FYDT

>K5L TRANSLATE of: k29sept.seq /rev check: 4453 from: 1692 to: 2340
MENHFQVDTLYNLFIERYLQNL SLYSVPVNTTCGIHISEIKGTLKGCKLKI INLCIDDKE
LSFYLLIKTFKEFANTLSQNEKYELANEVGDLDNODKNYIPEIIRKCTSSAAVTNVIDI
QTFDIGECIAPNGKNILLQIINFGTSEANCMNTIMKSMNRYTINNYIDNRIPFINDVH
WFIFVLIIFII FLLGLCSIKRKRINIKYKYG SFLYV

>A1L TRANSLATE of: k29sept.seq /rev check: 4453 from: 2320 to: 3274
CRISIPKFLFNNLKGDEKKLIVCAWAMGVNFKLTFLYNLYKRVLYMILLLIQTMDDQKLS
ISNF SHKYFLKSFNEKKGDVKFVKLLSYFYPIVIQSNVNVINYFTHMFHFFEHEKRSNYL
YDRGNIIFPLAKFSSDKVSEKMAIELGFKSLVEYIKFIFLQMALLYVKIYELPCCNNFL
HVDLKP DNILIFDSDESIKISLNENTYIFNEPIKA CLMILDFSQVANI INKKIKNNIKVE
HNWYDFHF IHTLLKTY PDKETDKEFYNTLEKFI ICCNKNTCDKFR LKISILHPISFLEK
IISKKNIFSTWINGKPLSS

>AXR TRANSLATE of: f3oct.seq check: 615 from: 3 to: 386
AEMRLISIIYSGNPIKLRICITGDDSIKYEKMFYFNKIIRNRIIIINFDYSNQEYDFYHMYN
MLKTVVSNKDFSSIKSKVLFHHSIFKFLKIPFNTEKINYEPTQRKILSKNIMFKNRNI
KKSIRYNK

>F1R TRANSLATE of: f3oct.seq check: 615 from: 303 to: 858
MNPHNVKYLAKILCLKTEILKNPYAIIISKDVVLRYNNTTIKYGDLVTYITVNIKLDATKTL
FQVFNESVVTYSPLENDYGFPPIIITSFLQGTGHNKFPINFLYIDIVASDLFPKFVRLTDEE
IVTVQSVLQIGDSKESLKLPKMLETEIAAKILFHKDIPLKIIIRFFRNIIITGIEISDRAV
ITVLD

>F2L TRANSLATE of: f3oct.seq /rev check: 615 from: 855 to: 1272
MLDEDIYSFCDKNENDIRCGCLNPDSSIIKMGEEITRLPYWCWYEPCKRSDALIVKSLKKN
ISLCNISDCRVTLGNIKIKNGYIDVKNVCGTNSSTNEYIRTKYLNQEIEEPIIHPIWLP
ISLFIITSLILITYIILLI

>F3R TRANSLATE of: f4oct.seq check: 2316 from: 1355 to: 5114
MAVISKVTYSLYNQEEINATDIFINHVKNDDDDVGTVDGRLGAMDGALCKTCGKTELQCF
GHWGKVRLYETHIKPEYIGEIVIRILNHICIRCGFLRSREPYIEDVTMSSHALRKLKDK
ILSKKKSCWNSKCMQQYQKITFSKKKVCFVNSDDITIPNALIYQKITSIYKRFWPLLEI
HQKPENLFYKNFFPVPPFIIRPAISFWIDSIPKETNELTYLLGMIVKYCNMNADEQVIQK
AIIYDDIKIISNNTTSINLSYITSGKNMIRSYIVARRKDHNARSVIGPDITLTINEVG
VPFYIRNTLTKEIFVNPFITDEVQRLFTNNEIKFYFNKRLNQLTRIKQGFINKIHMPLP
GDWVEVPLKENTSIFGRQPSLHRYNVIASVYKIEGDTIKIPPGIANSQNADFDGDEEW
MILEQNPKAVIEQSILMYPTLLKHDVNGSPVYGSIQDEIVAAYSFRMENLTLDEVMNL
LGKYGINFSSNGKTVFSGKDILEFLINDKVNYPGILSNGRIVANDIISDFIVAMRMSLA
GFISDYKSNVEGIEFIIKSSYVFKRYLSIYGFVTFKELRPNSDFTNKLEAINSEKIELI
KNSYKKYLTVDKDGKILPLSKSMESDAVESMLSNLTNLNIKEIEEYMKTTLINNPDNNLL
KMAKAGYKVNPTELMYILGTYGQQRIDGEPTETRVMGRVLPYYLPDSKDPPEGRGYILNSL
TQGLTGSQYFMSLVARSQSTDIVCETSRTGTLARKIIKKMEDMVVDGYGQVIYGNILIK
YAANYTKISASVCKPIDLIFPRESMVWYFEISSIWEKIKDGFISYQKQKISKKTLSPFNF
LVFLEPSDEKHAISSKDLYDMIQNVIDDVSEKYFFTISIDFIKYVFLTHLNPSIIRITK
ETATTIFKKFYEKLNYSLGGGTPIGIIAAQVLSEKFTQOALSSFHTTEKSGAIKHKLGFN
EFNNLTNLSKNKTELISED IENLQSVKINFEFVCLGELNPDIVLNNNDNEKYIIDITINRI
YIKRADITELVVEHMIERFVSFVSVLVKEWGLETHIEDNMIKFTILLVIFIEPEELSLNK
MMVLPGAANKGKISKFKIPIISNYNYDDHNKSRKMNKLTVELMNLKELGTFNLECNISW
YMEYTDYIWRYSRYSYLCEALIKYIREGFRLFDHPCDLLASLICMSYEPESVKNKFKFGVT
SSLKATFGDNKALLNAALHKKTEPVNDNSSCHFFSKVPKIGTGYYRYFVNLE

>F4L TRANSLATE of: f3oct.seq /rev check: 615 from: 5097 to: 5712
MDKKSLEYENVLLKSTGSLPKAKAPTMMRVTDVYVYLGNYDDAINAISSNVNFKYILNLT
EKYCFNDSRINIIMPLIDDEKTNLNDHFDYVTNFLSKCDEEHYPVLVHCVAGVNRSGAM
IMAYLMSKRKSDIPAFIYFLYIYHSMREKRGAFIENPSFRKQLIDKYIINELKVKTRRIF
QLILLSDIVTESFFSNLVSYSLTK

>F5R TRANSLATE of: f3oct.seq check: 615 from: 5728 to: 6299
MDKTTLVNNGVELEYAREKENKTIQSAKTSTLCFFMLILGISILLWFQVSDNSIFSELM
KYIRIKKSIRGWRPLVETKTNLESDRGKMLSMGRDEYFSPNCVDFGSYFVPIRLDRKTF
PQAIRRGKGDGWMVQKADKIDVSAQQFCQYLIKHXSENIITCGTHMINEIGYSGYFTNSH
WCSDFHNLN

>F6L TRANSLATE of: f3oct.seq /rev check: 615 from: 6300 to: 7269
MADIPLYVIPIVGREISDVVPELKSNDNIFYKKVDTVKDFKNSDVNFFFKDKDISLSYK
FLIWEKVEKSGGVENFTEYFSGLCNALCTKEAKSSIVKHFSWLSYADADIKNSENKFIV
VIEDNTLKDILTIHNIIEMQEKNIDIFQLRETFHNSNSRILFNQENNNFMYSLTRGGY
DFTLSAYVIRLSSAIKIINEIKKNGFSTSLSFEMYKLEKELKLNQVLDSSKYILHNT

KYLSKCRANEMKNGIWNRVGKWMHRFPDFSYIISHPLVSFFGIFDISIIGALIILFIIII
MIIFDLNSKLLWFLAGMLFTYII

>G1L TRANSLATE of: g16nov.seq /rev check: 2095 from: 3 to: 1135
METKESVLEIEIIPKIKIKEYILNPNINPKSYSDFISNNKNIFIINLYNVSTITEEDIRLLYM
TIEQNLEVDDQTLISIFSYIGYKFEQNVKKEITSSLFINEYNTTTDEMFTNLYNLFFDNL
DVYLRQRRINVLVNDLNGDIMINYKTSDLTSNFKNDIDPEVREIPFNMKDMISYVSKNI
DQFRFSKKYLDFAYLCHRIGIPISKKKLNMRYYIYLYKVDGVSIPIVIKDFLDVKYVYLEE
TNKTYKNSFSEDNNSLIDWGNIIIPKIKNKHLYSYIFLSNFYLRDLFPKLEEKKEITFKD
LKNIKKIEVIEPKSLRGEVKIEFAPCEHQVKLIEALKVDTEYFTKVNNFATEYIYYENGL
AFCNICGMNVPHFNLDAADVKNVIVSTFNKSIPLSEPYSYFVHSQRFIIPNIIMSFDNIM
KSQTVWMKYNNRIILNFLIEINSRRQKYEKKFSNEIKKGIFFLRLSANLFDIHVSSTELF
YSSKILNLYIVVLVILNSSADFIVSYMNSKKKKVDESSLKYAISVIIYDFLLKTKICEK
RFLDTIILFTRCLYIIMPEELDLLFQRIIIELRKLVSTIEKIFIAPIMPLSKHWIPTCALKFF
EKYTLIVNNMPVSKQHLKARNIMAPPILILTNEGNGVQFKKITSDEDFKVLIRTPHTATK
LVIFPRIKIEIEREKMIIALKNLFINNVLYYYISIPSLYVFRFGDPFPFDELVDKYHVQS
KVNCYNLLRYHLLPESDVVYFSDSLNRDKLEYTFYRFLSRYVNDVSIWIDENITKIRELY
FFNFNN

>G2R TRANSLATE of: g16nov.seq check: 2095 from: 1277 to: 1955
MSWSINLGNNGDNFKTLEEIRAHVVRSTTENMDKVADEIFPSDVKIPTTSSSSKQKPKVVR
KKAATTPKSKKIKKEKTPIEDHDDENDNDNDDENNDNDNNDNDDINNIEADDKNNDTNN
SDTEENENDKKEDNKSKKSPNDNNQHDDGVIDNSDLKIATESIIKGLKILNNKVSSVS
TVLEDVQAASINRQYSSLIKNIDLLKSLAECGKSQVIRKKVKNTKK

>G3R TRANSLATE of: g16nov.seq check: 2095 from: 1998 to: 2949
MRGLFYNDGKLFDTKDLTTLVSDNPTYEIIRIRIPPHLTDVIVYEQTYEQSLTRLIFV
GSDSKGRRQYFYGKLHVKNRNSNRNKIFIKVFNKINEFIDNNINEKDKNDVLFQSG
VFMLMETSFFIRMGKCYLKENETVGLLTLKKNKHISISNGKIVIKFIGKDKVPHTFIVHK
SNKLYKPLLLKLFDFKFPDNFLFSLKSEQKIYKLMKKFKIRLKLDRTYGVNYTFLYNFWSN
VKSLNPIPSTKLISTSIKQTAEIVGHSPSISKSAYIATTVIDFLIQDSNILETIKEKSF
EEFIELIVDYIVNRDTI

>G4R TRANSLATE of: g16nov.seq check: 5068 from: 2971 to: 3337
MDERLKTISMTFFYGELTTTDMVLKAHLLNIFPNDTIFSINEDNKFIIDFKYNDCLASG
YINQKIIPITPEKYNEYSSMIAKELTNYNIIIDDIKGIYYHLKKNKDLLNFIKQIIINKI
KK

>G5R TRANSLATE of: g16nov.seq check: 7938 from: 3388 to: 5650
MIILDILIKVKKNKTKNKIVDERDLENSLSDYINKIVEIYDEIPNPTLSNDVNHEVELVF
IQPPIITLSNVYNISSVTESYILFTVTNKGECIKIRTKVPMSKIHGLDLKNLQLVLDLIDD
IIWKKKTLIKEKKIDKHCIIRYSSEERHVFLDYKRYTSSIKLELVNLVQTKVKNIVVDFK
IKYFLGSGAQAKSSLLHVLNHPKSKPTPTLEFEIITREKNSRDLLDELHILFKNIFMA
DPKNVFLPTVIFTSPVKTIMLKKQEIHNIELDKLYITTKTDGVTGLIKINKNGILCYFTH
LNYIIKYNLLRKFNDTVILYGEAIKQNKWFIYLIKLLKPELSNRFKERDFLIEKLTSDI
SDRIVFKTKKYEGPYETHSEVIDLLSTYLPLQPEGVILFYSEGNSKIDYKIKHDNTTDH
MINAVYRYMSSEPVIFGDKYTFIEFKKFSDERGFPEKHGTSKIILGDNIKYLNNIYCIIEF
KNIYNDVGLKNIVLPKIFISEFSFNGDFLPRLDKTMKYFYKEYYGNQYQVLEHIRDQE
LRINDIFDENKLSDLGKKYVDDEFRLNPEVSYFTNKRTRGPLGILSNYIKTLLISLYCSK
TFLDNPNKRKVLAVDFNGADLEKYFYGEIALLVATDPDKDAISRCIERYNKLNLSGKSK
YYKLDYIRETIRSSVYVSKIREVFFGKFDIVDWNFAIHYSFHPKHYSTIMRNLSELTPA
GGNVLIEVKNSSIMFLKWKVNVNQKTFNLNIGKR

>G6L TRANSLATE of: g16nov.seq /rev check: 7938 from: 5684 to: 6149
MESEIKRLTNIKERNIICPIDIEKMYNEKFLLEKGLDETLYAIHIYDSMARFDNGTFF
KIAKFLYRNDIDVLKKIFIDEKKEIESTNALLPIYSVNIIERKNALIPLTEIPNGSEGILL
ILLHLFNSFKFNKLTNISTIPYYLPFGKYINNI



>G7R TRANSLATE of: g16nov.seq check: 7938 from: 6468 to: 6774
MEEVIICNCQLPEMKNSSYEIFLINPFVIKNNTDIFKNLILRSSINYFIFDNYAPQKKIL
THIYPSFNIEKTYIYINFNEINNIKI I K K C Y H R N K I R A L C V V

>G8R TRANSLATE of: g16nov.seq check: 1719 from: 6852 to: 7505
MKTIKTKSFPYCI EYHDDWEAVINQLVDLYDEIAEWILKDETSPIPENFFKQLQNPLNDK
LVCICGIDPYPRDATGVPPFESP NFSKKT I K S I A E T I S N I T G I S N Y K G Y N L N N V K G V F P W N
YYLSCKIGETKSHSLHWKKISKLLLQHITKYVNI FDCLGKTDFSNIKSIIEVPVTTIIGY
HPAARDRQFSKDKSFEAINILLEINGKEI IHWEEGFCY

>G9R TRANSLATE of: g16nov.seq check: 1719 from: 7550 to: 7799
MAGHLVNN EY I F V L K K I G V H T S H R E S E D P R F V D I F T C E E L E N Y I L K N P T C T L F E T L R D E E
A Y S V V R V F F D V D L D I V L D E I D Y T

5.4 REFERENCES

- 1 ABI PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit. August 1995. Protocol Revision A. (Perkin Elmer)
- 2 Adelaar, T. F. and Neitz, W. O. 1948. Knopvelsiekte. Onderstepoort. (In the Press) cited by Henning, M. W. 1949. In *Knopvelsiekte, Lumpy-skin disease. Animal Diseases in Africa*, 2nd Ed. Central News Agency, Ltd. South Africa.
- 3 Ahn, B. Y., Jones, E. V., and Moss, B. 1990. Identification of the vaccinia virus gene encoding an 18-kilodalton subunit of RNA polymerase and demonstration of a 5' poly(A) leader on its early transcript. *J. Virol.* **64**, 3019-3024.
- 4 Ahuja, S. K., Gao, J. L., and Murphy, P. M. 1991. Chemokine receptors and molecular mimicry. *Immunol. Today* **15**(6), 281-287.
- 5 Ahuja, S. K., and Murphy, P. M. 1993. Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. *J. Biol. Chem.* **268**, 20691-20694.
- 6 Alcami, A., and Smith, G. L. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response. *Cell* **71**, 253-176.
- 7 Alexander, R. A., Plowright, W., and Haig, D. A. 1957. Cytopathic agents associated with lumpy skin disease in cattle. *Bull. Epizoot. Dis. Afr.* **5**, 489-492.
- 8 Alexander, R. A. and Weiss, K. E. 1959. Unpublished observations, cited in *Lumpy Skin Disease. Virus Monographs*. Vol 3. New York: Springer Verlag.
- 9 Afonso, C. L., Tulman, E. R., Lu, Z. *et al.* 1999. The Genome of *Melanoplus sanguinipes* Entomopoxvirus. *Virology*. **Jan**, 533-552.
- 10 Afonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Kutish, G. F., and Rock, D. L. 2000. The Genome of Fowlpox Virus. *Journal of Virology*. **Apr**. 3815-3831.
- 11 Anonymous: 1988, Lumpy Skin Disease, vol I, no 1. O.I.E., Disease Information, Paris, France.

- 12 Antoine, G., Scheiflinger, F., Dörner, F., and Falkner, F. G. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses. *Virology* **244**, 365-396.
- 13 Archard, L. C. 1979. De novo synthesis of two classes of DNA induced by vaccinia virus infection of HeLa cells. *J. Gen. Virol.* **42**, 223-229.
- 14 Archard, L. C. 1983. Synthesis of full-length, virus genomic DNA by nuclei of vaccinia-infected HeLa cells. *J. Gen. Virol.* **64**, 2561-2575.
- 15 Arita, I. and Fenner, F. 1985. In: Vaccinia viruses as vectors for vaccine antigens (Ed. G. V. Quinnan) Elsevier, New York: 49-60.
- 16 Axton, J. M., Shamanski, F. L., Young, L. M., Henderson, D. S., Boyd, J. B. and Orr-Weaver, T. L. 1994. The inhibitor of DNA replication encoded by the *Drosophila* gene plutonium is a small, ankyrin repeat protein. *EMBO J.* **13**, 462-470.
- 17 Baldick, C. J., Keck, J. G., and Moss, B. 1992. Mutation analysis of the core, spacer, and initiation regions of vaccinia virus intermediate-class promoters. *J. virol.* **67**, 3515-3527.
- 18 Bankier, A. T., Beck, S., Bohni, R., Brown, C. M., Cerny, R., Chee, M. S., Hutchison, C. A. D., Kouzarides, T., Martignetti, J. A., Preddie, E. *et al.* 1991. The DNA sequence of the human cytomegalovirus genome. *DNA seq.* **2**, 1-12.
- 19 Bardwell, V. J. and Treisman, R. 1994. The POZ domain: a conserved protein-protein interaction motif. *Genes Dev.* **8**, 1664-1677.
- 20 Barinaga, M. 1999. A new finger on the protein destruction button. *Science* **286**, 223-225.
- 21 Baroudy, B. M. and Moss, B. 1980. Purification and characterization of a DNA-dependent RNA polymerase from vaccinia virus. *J. Biol. Chem.* **255**, 4372-4380.
- 22 Baroudy, B. M., Venkatesan, S., and Moss, B. 1982. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. *Cell* **28**, 315-324.
- 23 Baroudy, B. M., Venkatesan, S., and Moss, B. 1983. Structure and replication of vaccinia virus telomeres. *Cold Spring Harbour Symp. Quant. Biol.* **47**, 723.

- 24 Bateman, A. J. 1975. Simplification of palindromic telomere theory. *Nature* **253**, 379-380.
- 25 Bauer, W. R., Ressler, E. C., Kates, J., and Patzke, J. 1977. A DNA nicking-closing enzyme encapsidated in vaccinia virus: partial purification and properties. *Proc. Natl. Acad. Sci. USA.* **74**, 1841-1845.
- 26 Baxby, D. in *Textbook of Human Virology Second Edition* (Ed. Belshe, R. B) Mosby Year Book, 1991.
- 27 Beattie, E., Tartaglia, J. and Paoletti, EC. 1991. Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. *Virology* **183**, 419-422.
- 28 Ben-Baruch, A., Michiel, D. F., and Oppenheim, J. J. 1995. Signals and receptors involved in recruitment of inflammatory cells. *J. Biol. Chem.* **270**, 11703-11706.
- 29 Benson, D. A., Karsch-Mizrahi, I., Lipman, D. J., Ostell, J., Rapp, B. A., and Wheeler, D. L. 2000. Genbank. *Nucleic Acids Res.* **28(1)**, 15-18.
- 30 Berns, K. I. and Silverman, C. 1970. natural occurrence of cross-linked vaccinia virus deoxyribonucleic acid. *J. Virol.* **5**, 299-304.
- 31 Bertholet, C., Stocco, P., Van Meir, E., and Wittek, R. 1986. Functional analysis of a vaccinia virus late gene. *EMBO J.* **5**, 1951.
- 32 Bertholet, C., Van Meir, E., ten Heggeler-Bordier, B., and Wittek, R. 1987. Vaccinia virus produces late mRNAs by discontinuous synthesis. *Cell* **50**, 153-162.
- 33 Beuken, E., Vink, C., and Bruggeman, C. A. 1998. One-step procedure for screening recombinant plasmids by size. *BioTechniques* **24**, 748-750.
- 34 Black, D. N., Hammond, J. M., and Kitching, R. P. 1986. Genomic relationship between capripoxviruses. *Virus Research* **5**, 277-292.
- 35 Blake, N. W., Porter, C. D., and Archard, L. C. 1991. Characterization of a molluscum contagiosum virus homolog of the vaccinia virus p37K major envelope antigen. *J. virol.* **65**. 3583-3589.

- 36 Bloom, D. C., Edwards, K. M., Hager, C. and Moyer, R. W. 1991. Identification and Characterization of the Rabbitpox Virus Genome involved in Virulence. *Journal of Virology* **Mar.**, 1530-1542.
- 37 Boone, R. F. and Moss, B. 1977. Methylated 5'- terminal sequences of vaccinia virus mRNA species made in vivo at early and late times after infection. *Virology* **79**, 67-80.
- 38 Boone, R. F., Ensinger, M. J., and Moss, B. 1977. Synthesis of mRNA guanylyltransferase and mRNA methyltransferases in cells infected with vaccinia virus. *J. Virol.* **21**, 475-483.
- 39 Boone, R. F. and Moss, B. 1978. Sequence complexity and relative abundance of vaccinia virus mRNA's synthesized *in vivo* and *in vitro*. *J. Virol.* **26**, 554-569.
- 40 Bork, P. 1993. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? *Proteins.* **17**, 363-374.
- 41 Boyle, D. B. 1992. Quantitive assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. *Virus Genes* **6**, 281-290.
- 42 Breathnach, R. and Chambon, P. 1981. Organization and expression of eukaryotic split genes. *Annu. Rev. Biochem.* **50**, 349-383.
- 43 Breeden, L. and Nasmyth, K. 1987. Similarity between cell-cycle genes of budding yeast and fission yeast and the Notch gene of *Drosophila*. *Nature* **329**, 651-654.
- 44 Broyles, S. S. and Moss, B. 1987. Sedimentation of an RNA polymerase complex from vaccinia virus that specifically initiates and terminated transcription. *Mol. Cell. Biol.* **7**, 7-14.
- 45 Broyles, S. S. and Moss, B. 1986. Homology between RNA polymerases of poxviruses, prokaryotes and eukaryotes: nucleotide sequence and transcriptional analysis of vaccinia virus genes encoding 147-kDa and 22-kDa subunits. *Proc. Natl. Acad. Sci. USA.* **83**, 3141-3145.
- 46 Broyles, S. S., Yuen, L., Shuman, S., and Moss, B. Purification of a factor required for transcription of vaccinia virus early genes. *J. Biol. Chem.* **263**, 10754-10760.
- 47 Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L., and Moss, B. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. *Nature* **317**, 813-815.

- 48 Buller, R. M. L and Palumbo, G. J. 1991. Poxvirus pathogenesis. *J. Microbiol Rev.* **55**, 80-122.
- 49 Chang-Yeh, A., Jabs, E. W., Li, X., Dracopoli, N., and Huang, R. C. C. 1993. The IPP gene is assigned to human chromosome 1p32-1p22. *Genomics* **15**, 239-241.
- 50 Cairns, J. 1960. *Virology* **11**, 603.
- 51 Cameron, C., Hota-Mitchell, S., Chen, L. *et al.* 1999. The Complete DNA Sequence of Myxoma Virus. *Virology*. **264**, 298-318.
- 52 Cao, J. X., Gershon, P. D. and Black, D. N. 1995. Sequence Analysis of HindIII Q2 Fragment of Capripoxvirus Reveals a Putative Gene Encoding a G-Protein-Coupled Chemokine Receptor Homologue. *Virology* **209**, 207-212.
- 53 Caplan, H. S. and Holowczak, J. A. 1983. Some enzymatic activities associated with purified parapoxviruses. *J. Virol.* **46**, 384-393.
- 54 Capstick, P. B. 1959. Lumpy Skin Disease- experimental infection. *Bulletin of Epizootic Diseases of Africa.* **7**, 27-36.
- 55 Capstick, P. B. and Coakley, W. 1961. Protection of cattle against lumpy skin disease. Trials with a vaccine against Neethling type infection. *Res. Vet. Sci.* **2**, 362-368.
- 56 Carn, V. M. 1993. Control of capripoxvirus infections. *Vaccine* **11**, 1275-1279.
- 57 Chakrabarti, S., Brechling, K., and Moss, B. 1985. Vaccinia virus expression vector: Co-expression of β -galactosidase provides visual screening of recombinant virus plaques. *Mol. Cell Biol.* **5**, 3403-3409.
- 58 Chalberg, M. D. and Englund, P. T. 1979. Purification and properties of the deoxyribonucleic acid polymerase induced by vaccinia virus. *J. Biol. Chem.* **254**, 7812-7819.
- 59 Chang, A. and Metz, D. H. 1976. Further investigations on the mode of entry of vaccinia virus into cells. *J. Gen. Virol.* **32**, 275-282.

- 60 Chang, H., Watson, J. C., and Jacobs, B. L. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. *Proc. Natl. Acad. Sci. USA*. **89**, 4825-4829.
- 61 Chee, M. S., Satchwell, S. C., Preddie, E., Weston, K. M., and Barrell, B. G. 1990. Human cytomegalovirus encodes three G protein-coupled receptor homologues. *Nature* **344**, 774-777
- 62 Claverie, J. M. 1994. Some useful statistical properties of position-weight matrices. *Comp. Chem.* **18**, 287-294.
- 63 Coakley, W. and Capstick, P. B. 1961. Protection of cattle against lumpy skin disease. Factors affecting small scale production of tissue culture propagated virus vaccine. *Res. Vet. Sci.* **2**, 369-371.
- 64 Cochran, M. A., Puckett, C., and Moss, B. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. *J. virol.* **54**, 30-37.
- 65 Cohen, S. N., A. C. Y., Chang, and Hsu, L. 1972. Nonchromosomal antibiotic resistance in bacteria: Genetic transformation of *Escherichia coli* by R-factor DNA. *Proc. Natl. Acad. Sci. USA.* **69**, 2110.
- 66 Cooper, J. A., Wittek, R., and Moss, B. 1981. Extension of the transcriptional and translational map of the left end of the vaccinia genome to 21 kilobase pairs. *J. Virol.* **39**, 733-745.
- 67 Coupar, B. E., Boyle, D. B., and Both, G. W. 1987. Effect of *in vitro* mutations in a vaccinia virus early promoter region monitored by herpes simplex virus thymidine kinase expression in recombinant vaccinia virus. *J. Gen Virol.* **68**, 2299-2309.
- 68 Cox, W. I., Tartaglia, J., and Paoletti, E. 1992. Poxvirus recombinants as live vaccines. In: *Recombinant poxviruses*. CRC Press, 405-418.
- 69 Cremer, M. A., Mackett, M., Wohlenberg, C., Notkins, A. L., and Moss, B. 1985. Vaccinia virus recombinant expressing herpes simplex type I glycoprotein D prevents latent herpes in mice. *Science* **228**, 737-739.
- 70 Dales, S. 1965. Penetration of animal viruses into cells. *Prog. Med. Virol.* **7**, 1-43.
- 71 Dales, S. and Kajioka, R. 1964. The cycle of multiplication of vaccinia virus in Earle's strain L cells. *Virology* **24**, 278-294.

- 72 Davies, F. G. 1980. The possible role of wildlife as maintenance hosts for some African insect-borne virus diseases. Proceedings of the workshop, *Wildlife Disease Research and Economic Development* (Eds. Karstad, L., Nestel, B., and Graham, N.)
- 73 Davies, M., Elroy-Stein, O., Jagus, R., Moss, B., and Kaufman, R. J. 1992. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. *J. Virol.* **66**, 749-769.
- 74 Dales, S. and Siminovitch, L. 1961. The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy. *J. Biophys. Biochem. Cytol.* **10**, 475-503.
- 75 Davies, F. G. 1982. Observations on the epidemiology of lumpy skin disease in Kenya. *J. Hyg. Camb.* **88**, 95-102.
- 76 Davies, F. G., and Otema, C. 1981. Relationships of capripox viruses found in Kenya with two Middle Eastern strains and some orthopoxviruses. *Res. Vet. Sci.* **12**, 123-127.
- 77 Davis, R. E., and Mathews, C. K. 1993. Acidic C terminus of vaccinia virus DNA-binding protein interacts with ribonucleotide reductase. *Proc. Natl. Acad. Sci. USA* **90**, 745-749.
- 78 Davison, A. J., and Moss, B. 1989a. The structure of vaccinia virus early promoters. *J. Mol. Biol.* **210**, 749-769.
- 79 Davison, A. J., and Moss, B. 1989b. The structure of vaccinia virus late promoters. *J. Mol. Biol.* **210**, 771-784.
- 80 Davison, A. J., and Moss, B. 1990. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. *Nucleic Acids Res.* **18**, 4285-4286.
- 81 Dawson, M. J., and Trapani, J. A. 1995. The interferon-inducible autoantigen, IFI 16: Localization to the nucleolus and identification of a DNA-binding domain. *Biochem. Biophys. Res. Commun.* **214**, 152-162.
- 82 Dawson, M. J., and Trapani, J. A. 1996. HIN-200: A novel family of IFN-inducible nuclear proteins expressed in leukocytes. *J. Leukocyte Biol.* **60**, 310-316.

- 83 De Lange, A. M. 1989. Identification of temperature-sensitive mutants of vaccinia virus that are defective in conversion of concatameric replicative intermediates to the mature linear DNA genome. *J. Virol.* **63**, 2437-2444.
- 84 deMagistris, L. and Stunnenberg, H. G. 1988. Cis-acting sequences affecting the length of the poly (A) head of vaccinia virus late transcripts. *Nucleic Acids Res.* **16**, 3141-3156.
- 85 De Nadal, E., Clotet, J., Posas, F., Serrano, R., Gomez, N., and Arino, J. 1998. The yeast halotolerance determinant Hal3p is an inhibitory subunit of the Ppz1p Ser/Thr protein phosphatase. *Proc. Natl. Acad. Sci. USA.* **95**, 7357-7362.
- 86 Diesel, A. M. 1949. *Proc. XIVth Int. Vet. Cong.*
- 87 Easterbrook, K. B. 1966. Controlled degradation of vaccinia virions *in vitro*: an electron microscopic study. *J. Ultrastruc. Res.* **14**, 484-496.
- 88 Epstein, L. B. 1984. The special significance of interferon-gamma. In "Interferon" (J. Vilcek and E. deMaeyer, Eds) pp. 185-220, Elsevier, Amsterdam.
- 89 Eppstein, D. A., Marsh, Y. V., Scriber, A. B., Newman, S. R., Todaro, G. J., and Nestor, J. J. 1985. Epidermal growth factor receptor occupancy inhibits vaccinia virus infection. *Nature* **266**, 550-552.
- 90 Esposito, J. J. and Knight, J. C. 1985. Orthopox DNA: a comparison of restriction profiles and maps. *Virology* **143**, 230-251.
- 91 Esposito, J. J. in *Classification and Nomenclature of Viruses Arch. Virol. Suppl.* 2 (eds Francki, R. I. B. *et al.*) 91-102 (Springer, New York, 1991)
- 92 Esteban, M., Flores, L., and Holowczak, J. A. 1977. Model for vaccinia virus DNA replication. *Virology* **83**, 467-473.
- 93 Esteban, M. and Holowczak, J. A. 1977. Replication of vaccinia DNA in mouse L cells. In vivo DNA synthesis. *Virology* **78**, 57-75.
- 94 FAO. 1985. FAO-WHO-OIE Animal Health Yearbook 1985. (Ed. V. Kouba)

- 95 Farrar, M. A. and Schreiber, R. D. 1993. The molecular cell biology of interferon- γ and its receptor. *Annu. Rev. Immunol.* **11**, 571-611.
- 96 Federspiel, B., Melhado, I., Duncan, A. M., Delaney, A. D., Schappert, K. T., Clark Lewis, I., and Jirik, F. 1993. Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen. *Genomics* **16**, 707- 712.
- 97 Fenner, F. and Ratcliffe, F. N. 1965. "Myxomatosis". Cambridge University Press, Cambridge, UK.
- 98 Fenner, F. 1979. Portraits of viruses: The poxviruses. *Intervirology* **11**, 137-157.
- 99 Fenner, F. 1983. Biological control, as exemplified by smallpox eradication and myxomatosis. *Proc. R. Soc. Lond.* **218**, 259-285.
- 100 Fenner, F. *et al.* *Smallpox and its Eradication* (World Health Organization, Geneva, 1988)
- 101 Fenner, F., Wittek, R. and Dumbell, K. *The Orthopoxviruses* (Academic, San Diego, 1989).
- 102 Fick, W C., and Viljoen, G. J. 1994. Early and late transcriptional phases in the replication of lumpy skin virus. *Onderstepoort J. Vet. Res.* **61**, 255-261.
- 103 Fick, W. C., and Viljoen, G. J. 1999. Identification and characterisation of an early/late bi-directional promoter of the capripoxvirus, lumpy skin disease virus; Brief Report. *Arch. Virol.* **144**, 1229-1239.
- 104 Fogelson, P. D. and Bauer, W. R. 1984. Effects of ATP and inhibitory factors on the activity of vaccinia virus type I topoisomerase. *J. Virol.* **49**, 1-8.
- 105 Francki, R. I. B., Fauquet, C. M., Knudson, D. L., and Brown, F. 1991. *Arch Virol.* Suppl. 2.
- 106 Gafford, L. G. and Randall, C. C. 1976. Virus-specific RNA and DNA in nuclei of cells infected with fowlpox virus. *Virology* **69**, 1.
- 107 Garon, C. F., Barbosa, E., and Moss, B. 1978. Visualization of an inverted terminal repetition in vaccinia virus DNA. *Proc. Natl. Acad. Sci. USA* **75**, 4863-4867.
- 108 Gershon, P. D, Ansell, D. M. and Black, D. N. 1989. A Comparison of the Genome Organization of Capripoxvirus with That of the Orthopoxviruses. *Journal of Virology.* **Nov**, 4703-4708.

- 109 Gershon, P. D. and Black, D. N. 1988. A comparison of the genomes of capripoxvirus isolates of sheep, goats and cattle. *Virology* **164**, 341-349.
- 110 Gershon, P. D. and Black, D. N. 1989. The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene shared specifically with leporipoxvirus. *J. gen. Virol.* **70**, 525-533.
- 111 Gershon, P. D. and Black, D. N. 1989. A Capripoxvirus Pseudogene Whose Only Intact Homologs Are In Other Poxvirus Genomes. *Virology* **172**, 350-354.
- 112 Gershon, P. D. and Black, D. N. 1987. Physical Characterization of the Genome of a Cattle Isolate of Capripoxvirus. *Virology* **160**, 473-476.
- 113 Gershon, P. D., and Moss, B. 1990. Early transcription factor subunits are encoded by vaccinia virus late genes. *Proc. Natl. Acad. Sci. USA.* **87**, 4401-4405.
- 114 Gillard, S., Spehner, D., Drillien, R., and Kirm, A. 1986. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. *Proc. Natl. Acad. Sci. USA.* **83**, 5573-5577.
- 115 Goebel, S. J., Johnson, G. P., Perkus, M. E., *et al.* 1990. The Complete Sequence of Vaccinia Virus. *Virology* **179**, 247-266.
- 116 Golini, F. and Kates, J. R. 1985. A soluble transcription system derived from purified vaccinia virions. *J. Virol.* **53**, 205-213.
- 117 Gooding, L. R. 1992. Virus proteins that counteract host immune defences. *Cell* **71**, 5-7.
- 118 Gorina, S. and Pavletich, N. P. 1996. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. *Science* **274**, 1001-1005.
- 119 Graham, K. A., Opgenorth, A., Upton, C., and McFadden, G. 1992. Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical for manifestation of viral virulence. *Virology* **191**, 112-124.
- 120 Graham, K. A., Lalani, A. S., Macen, J., Ness, T. L., Barry, M., Liu, L., Lucas, A., Clarke-Lewis, I., Moyer, R. W., and McFadden, G. 1997. The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. *Virology* **229**, 12-24.

- 121 Guan, K., and Dixon, J. E. 1991. Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. *J. Biol. Chem.* **266**, 17026-17030.
- 122 Haig, D. A. 1957. Lumpy Skin Disease. *Bull. Epizoot. Dis. Afr.* **5**, 421-430.
- 123 Hänggi, M., Bannwarth, W., and Stunnenberg, H. G. 1986. Conserved TAAAT motif in vaccinia virus late promoters: overlapping TATA box and site of transcription initiation. *EMBO J* **5**, 1071-1076.
- 124 Harper, D. R. in *Molecular Virology, Second Edition*. BIOS Scientific Publishers Limited, 1998.
- 125 Hedger, R. S., and Hamblin, C. 1983. Neutralising antibodies to lumpy skin disease virus in African wildlife. *Comp. Immun. Microbiol. Infect. Dis.* Vol 6 No. 3, 209-213.
- 126 Heine, H. G., Stevens, M. P., Foord, A. J., and Boyle, D. B. 1999. A capripox detection PCR and antibody ELISA based on the major antigen P32, the homolog of the vaccinia virus H3L gene. *J. Immunol. Methods* **227**, 187-196.
- 127 Hendricks, S. P., and Matthews, C. K. 1998. Allosteric regulation of vaccinia virus ribonucleotide reductase, analysed by simultaneous monitoring of its four activities. *J. Biol. Chem.* **273**, 29512-29518.
- 128 Henning, M. W. 1949. In *Knopvelsiekte, Lumpy-skin disease. Animal Diseases in Africa*, 2nd Ed. Central News Agency, Ltd. South Africa.
- 129 Hernandez, M. C., Andres-Barquin, P. J., Martinez, S., Bulfone, A., Rubenstein, J. L. R., and Israel, M. A. 1997. ENC-1: a novel mammalian Kelch-related gene specifically expressed in the nervous system encodes an actin-binding protein. *J. Neurosci.* **17**, 3038-3051.
- 130 Hiller, G., Jungwith, C., and Weber, K. 1981. Fluorescence microscopical analysis of the life cycle of vaccinia virus in chick embryo fibroblasts. *Exp. Cell Res.* **132**, 81-87.
- 131 Hiller, G. and Weber, K. 1985. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. *J. Virol.* **55**, 651-659.
- 132 Hirschmann, P., Vos, J. C., and Stunnenberg, H. G. 1990. Mutational analysis of a vaccinia virus intermediate promoter in vivo and in vitro. *J. Virol.* **Dec**, 6063-6069.

- 133 Holmes, W. E., Lee, J., Kuang, W. J., Rice, G. C., and Wood, W. I. 1991. Structure and functional expression of a human interleukin-8 receptor. *Science* **253**, 1278-1280.
- 134 Holowczak, J. A. 1983. In *Replication of Viral and Cellular Genomes* (Ed. Y Becker) p202. The Hague, Nijhoff.
- 135 Hopkins, D. R. 1983. *Princes and Peasants: Smallpox in History*. Chicago, University of Chicago Press.
- 136 House, J. A., Terrance, M., Wilson, S. E. N., Ikram, A., Karim, I. I., Danaf, N. E., Moussa, A. M., and Ayoub, N. N. 1990. The isolation of lumpy skin disease virus and bovine herpesvirus-4 from cattle in Egypt. *J. Vet. Invest* **2**, 111-115.
- 137 Hruby, D. E. and Ball, L. A. 1982. Mapping and identification of the vaccinia virus thymidine kinase gene. *J. Virol.* **40**, 456-464.
- 138 Hruby, D. E., Lynn, D. L., and Kates, J. R. 1979. Vaccinia virus replication requires active participation of the host cell transcriptional apparatus. *Proc. Natl. Acad. Sci. USA* **76**, 1887.
- 139 Huang and Miller. 1991. *Adv. Appl. Math.* **12**, 337-357.
- 140 Jackson, R. J. and Bults, G. H. 1990. A myxoma virus nucleotide sequence with homology to the vaccinia virus RNA polymerase 22-kDa subunit gene. *Nucleic Acids Res.* **18**, 5290-5290.
- 141 Jackson, R. J., Hull, D. F., and Kerr, P. J. 1999. Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence. *J. virol.* **73**, 2367-2384.
- 142 Jenner, E. 1798. *An inquiry into the causes of the variolae vaccinae, a disease known by the name of cow pox*. Sampson Low No 7, Soho, London.
- 143 Johnson, G. P., Goebel, S. J., and Paoletti, E. 1993. An update on the vaccinia virus genome. *Virology* **196**, 381-401.
- 144 Johnstone, R. W., Kerry, J. A., and Trapani, J. A. 1998. The human interferon-inducible protein, IFI 16, is a repressor of transcription. *J. Biol. Chem.* **273**, 17172-17177.
- 145 Joklik, W. K. 1964. *J. Molec. Biol.* **8**, 263.

- 146 Jones, D. T., Taylor, W. R., and Thornton, J. M. 1994. A model recognition approach to the prediction of all-helical membrane protein structure. *Biochemistry* **33**, 3038-3049.
- 147 Jordan, A., and Reichard, P. 1998. Ribonucleotide reductases. *Annu. Rev. Biochem.* **67**, 71-98.
- 148 Jungwith, C. and Dawid, I. B. 1967. Vaccinia DNA: separation of viral from host cell DNA. *Arch. Virol.* **20**, 464-468.
- 149 Karupiah, G., Fredrickson, T. N., Holmes, K. L., Khairallah, L. H., and Buller, R. M. L. 1993. Importance of interferons in recovery from mousepox. *J. Virol.* **67**, 4214-4226.
- 150 Kates, J. and Beeson, J. 1970. Ribonucleic acid synthesis in vaccinia virus. II. Synthesis of polyribonucleic acid. *J. Molec. Biol.* **50**, 19-33.
- 151 Kates, J. R and McAuslan, B. R. 1967. Poxvirus DNA-dependent RNA polymerase. *Proc. Natl. Acad. Sci. USA.* **57**, 314.
- 152 Kaverin, N. V., Varich, N. L., Surgay, V. V., and Chernos, V. I. 1975. A quantitative estimation of poxvirus genome fraction transcribed as early and late mRNA. *Virology* **65**, 112-119.
- 153 Keck, J. G., Baldick, C. J., and Moss, B. 1990. Role of DNA replication in vaccinia virus gene expression: A naked template is required for transcription of three late transactivator genes. *Cell*, **61**, 801-809.
- 154 Kelvin, D. J., Michiel, D. F., Johnston, J. A., Lloyd, A. R., Sprenger, H., Oppenheim, J. J., and Wang, J. M. 1993. Chemokines and Serpentine- The molecular biology of chemokine receptors. *J. Leucocyte Biol.* **54**, 604-612.
- 155 Kerr, P. J. and Best, S. M. 1998. Myxoma virus in rabbits. *Rev. Sci. Tech.* **17**, 256-268.
- 156 Kim, T. A., Lim, J., Ota, S., Raja, S., Rogers, R., Rivnay, B., Avraham, H., and Avraham, S. 1998. NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. *J. Cell. Biol.* **141**, 553-566.

- 157 King, C. S., Cooper, J. A., Moss, B., and Twardzik, D. R. 1986. Vaccinia virus growth factor stimulates tyrosine protein kinase activity of A431 cell epidermal growth factor receptors. *Mol. Cell. Biol.* **6**, 332-336.
- 158 Kim, I. F., Mohammadi, E., and Huang, R. C. C. 1999. Isolation and characterization of IPP, a novel human gene encoding an actin-binding, kelch-like protein. *Gene* **228**, 73-83.
- 159 Kitching, R. P. 1983. Progress towards sheep and goat pox vaccines. *Vaccine* **1**, 4-9.
- 160 Kitching, R. P., McGrane, J. J., and Taylor, W. P. 1986. Capripox in the Yemen Arab Republic and the Sultanate of Oman. *Trop. Anim. Hlth. Prod.* **18**, 115-122.
- 161 Kitching, R. P., Hammond, J. M., and Taylor, W. P. 1987. A single vaccine for the control of capripox infection in sheep and goats. *Res. Vet. Sci.* **42**, 53-60.
- 162 Kitching, R. P and Smale, C. 1986. Comparison of the external dimensions of capripoxvirus isolates. *Res. Vet. Sci.* **41**, 424-427.
- 163 Kitching, R. P. 1986. Passive protection of sheep against capripoxvirus. *Res. Vet. Sci.* **41**, 247-250.
- 164 Kitching, R. P., Bhat, P. P., and Black, D.N. 1989. The characterization of African strains of capripoxvirus. *Epidem. Inf.* **102**, 335-343.
- 165 Kleiman, J. H. and Moss, B. 1975. Purification of a protein kinase and two phosphate acceptor proteins from vaccinia virions. *J. Biol. Chem.* **250**, 2420-2429.
- 166 Kleiman, J. H. and Moss, B. 1975. Purification of a protein kinase and two phosphate acceptor proteins from vaccinia virions. *J. Biol. Chem.* **250**, 2430-2437.
- 167 Kohonen-Corish, M. R. J., King, N. J. C., Wookhams, C. E. and Ramshaw, I. 1990. Immunodeficient mice recover from infection with vaccinia virus expressing interferon- γ . *Eur. J. Immunol.* **20**, 157-161.
- 168 Koonin, E. V., Senkevich, T. G., and Chernos, V. I. 1992. A family of DNA virus genes that consist of fused portions of unrelated cellular genes. *Trends Biochem. Sci.* **17**, 213-214.

- 169 Kotwal, G., Isaacs, S. N., McKensie, R., Frank, M. M., and Moss, B. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. *Science* **250**, 827-830.
- 170 Kotwal, G., and Moss, B. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. *Nature* **335**, 176-181.
- 171 Kumar, S., and Boyle, D. B. 1990a. A poxvirus bi-directional promoter element with early/late and late functions. *Virology* **179**, 151-158.
- 172 Kumar, S., and Boyle, D. B. 1990b. Activity of a fowlpox late gene promoter in vaccinia and fowlpox virus recombinants. *Arch Virol.* **112**, 139-148.
- 173 laColla, P. and Weissbach, A. 1975. Vaccinia virus infection of HeLa cells. I. Synthesis of vaccinia DNA in host cell nuclei. *J. Virol.* **15**, 305-315.
- 174 Lane, J. M. and Millar, J. D. 1971. Risk of small pox vaccination complications in the United States. *American J. Epidem.* **93**, 238-243.
- 175 Lakritz, N., Foglesong, P. D., Reddy, M. *et al.* 1985. A vaccinia virus DNase preparation which cross-links superhelical DNA. *J. Virol.* **53**, 935.
- 176 Law, S. K. A. and Reid, K. B. M. 1988. In Male, D. K. (Ed.) *Complement*. (In Focus Series,) IRL, Oxford.
- 177 Lloyd, A., Notredame, C., Hide, W., Joubert, F., and Kelso, J. *Sequence Analysis for South African Scientists*, SANBI course notes, University of Pretoria, Nov. 1999.
- 178 Lee-Chen, G. J., Bourgeois, N., Davison, K., Condit, R. C., and Niles, E. G. 1988. Structure of the transcription initiation and termination sequences of seven early genes in the vaccinia virus *HindIII* D fragment. *Virology* **163**, 64-79.
- 179 Luftig, R. B. 1982. Does the cytoskeleton play a significant role in virus replication? *J. Theor. Biol.* **99**, 173-191.
- 180 Luo, Y., and Shuman, S. 1991. Antitermination of vaccinia virus early transcription: Possible role of RNA secondary structure. *Virology* **185**, 432-436.

- 181 Lux, S. E., John, K. M., and Bennett, V. 1990. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins. *Nature* **344**, 36-42.
- 182 MacDonald, R. A. S. 1931. Pseudo-urticaria of cattle. *Dept. Animal Health, Gov. N. Rhodesia. Newsletter, March 21, 1945*, 1-4.
- 183 Mackett, M., Smith, G. L., and Moss, B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc. Natl. Acad. Sci. USA* **79**, 7415-7419.
- 184 Mackett, M., Yilma, T. Y., Rose, J. A. and Moss, B. 1985. Vaccinia virus recombinants express vesicular stomatitis virus genes and protectively immunize mice and cattle. *Science* **227**, 433-435.
- 185 MacDonald, R. A. S. 1931. Pseudo-urticaria of cattle. *Northern Rhodesia Department of Animal Health, Annual Report 1930*. pp 20-21.
- 186 MacOwan, K. D. S., 1959. Observations on the Epizootiology of Lumpy Skin Disease during the first year of its occurrence in Kenya. *Bull. Epiz. Diz. Afr.* **7**, 2-20.
- 187 Mahr, A. and Roberts, B. E. 1984. Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. *J. Virol.* **49**, 510-520.
- 188 Mars, M. and Beaud, G. 1987. Characterization of vaccinia virus early promoters and evaluation of their information content. *J. Mol. Biol.* **198**, 619-631.
- 189 Marsh, Y. V. and Eppstein, D. A. 1987. Vaccinia virus and the EGF receptor: a portal of entry for infectivity? *J. Cell. Biochem.* **34**, 239-245.
- 190 Massung, R. F., Esposito, J. J., Liu, L., Qi, J., Utterback, T. R., Knight, J. C., Aubin, L., Yuran, T. E., Parsons, J. M., Loparev, V. N., Selivanov, N. A., Cavallaro, K. F., Kerlavage, A. R., Mahy, B.W.J. and Venter, J. C. 1993a. Potential virulence determinants in terminal regions of variola smallpox virus genome. *Nature* **366**, 748-751.
- 191 Massung, R. F., Jayarama, V., and Moyer, R. W. 1993b. DNA sequence analysis of conserved and unique regions of swinepox virus: identification of genetic elements supporting phenotypic observations including a novel G-protein coupled receptor homolog. *Virology* **197**, 511-528.

- 192 Massung, R. F., Liu, L. I., Qi, J., Knight, J. C., Yuran, T. E., Kerlavage, A. R., Parsons, J. M., Venter, J. C., and Esposito, J. J. 1994. Analysis of the complete strain of smallpox variola major virus strain Bangladesh-1975. *Virology* **201**, 215-240.
- 193 Massung, R. F. and Moyer, R. W. 1991b. The molecular biology of swinepox virus II. The infectious cycle. *Virology* **180**, 355-364
- 194 Matthews, R. E. F. 1982. Classification and nomenclature of viruses. *Intervirology*. **17**, 42-46.
- 195 Mattaj, I. W., and Englmeier, L. 1998. Nucleocytoplasmic transport: The soluble phase. *Annu. Rev. Biochem.* **67**, 265-306.
- 196 Maxam, A. M., and Gilbert, W. 1980. Sequencing end-labeled DNA with base-specific chemical cleavages. In "Methods in Enzymology" (Eds. L. Grossman and K. Moldave), Vol. 65, 499-560.
- 197 Medzon, E. L. and Bauer, H. 1970. Structural features of vaccinia virus revealed by negative staining. *Virology* **40**, 860-867.
- 198 Mercer, A.A., Lyttle, D. J, Whelan, E. M., *et al.* 1995. The Establishment of a Genetic Map of ORF Virus Reveals a Pattern of Genomic Organization That Is Highly Conserved among Divergent Poxviruses. *Virology* **212**, 698-704,
- 199 Merchlinsky, M., Garon, C., and Moss, B. 1988. Molecular cloning and sequence of the concatamer junction from vaccinia virus replicative DNA: viral nuclease cleavage sites in cruciform structures. *J. Mol. Biol.* **199**, 399-413.
- 200 Merck Veterinary Manual. 1986. Sheeppox and goatpox. *A handbook of Diagnosis, Therapy and Disease Prevention and Control for the Veterinarian*. Merck, Rahway, New Jersey. 799-800.
- 201 Michaely, P. and Bennett, V. 1992. *Trends Cell Biol.* **2**, 127-129.
- 202 Miller, G. 1957. *The Adoption of Inoculation of Smallpox in England and France*. Philadelphia, University of Pennsylvania Press.
- 203 Minnigan, H. and Moyer, R. W. 1985. Intracellular location of rabbit poxvirus nucleic acid with infected cells as determined by in situ hybridization. *J. Virol* **55**, 634.

- 204 Morgan, C. 1976. The insertion of DNA into vaccinia virus. *Science* **193**, 591-592.
- 205 Morgan, C. 1976. Vaccinia virus reexamined: development and release. *Virology* **73**, 43-58.
- 206 Morris, J. P. A. 1931. Pseudo-urticaria. *Northern Rhodesia Department of Animal Health, Annual Report 1930*. p 12.
- 207 Moss, B., Rosenblum, E. N., and Gershowitz, A. 1975. Characterization of a polyriboadenylate polymerase from vaccinia virions. *J. Biol. Chem.* **250**, 4722-4729.
- 208 Moss, B., Smith, G. L., Gerin, J. L., and Purcell, R. 1984. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. *Nature* **311**, 67-69.
- 209 Moss, B. in *Concepts in Viral Pathogenesis II* (Eds. Notkins, A. L., and Oldstone, M. B. A.) Springer-Verlag, New York, 1986.
- 210 Moss, B. 1990. Regulation of vaccinia virus transcription. *Annual Reviews of Biochemistry* **9**, 661-688.
- 211 Moss, B. 1990. Regulation of the orthopoxvirus gene expression. *Curr. Top. Microbiol. Immun.* **163**, 41-71.
- 212 Moss, B. 1992. Molecular Biology of Poxviruses, in *Recombinant Poxviruses* (Eds. M. M. Binns and G. L. Smith). Boca Raton: CRC Press: 45-80.
- 213 Moss, B. 1985. In *Virology* (Ed. B. N. Fields). Raven Press, New York. 685-703.
- 214 Moss, B. 1990. In *Virology* (Eds. Fields, B. B., Knipe, D. M. *et al.*) Raven Press, Ltd., New York. 2079-2111.
- 215 Mossman, K., Upton, C., Buller, R. M. L., and McFadden, G. 1995. Species specificity of ectromelia virus and vaccinia virus interferon- γ binding proteins. *Virology* **208**, 762-769.
- 216 Mossman, K., Ostergaard, H., Upton, C., and McFadden, G. 1995. Myxoma Virus and Shope Fibroma Virus Encode Dual-Specificity Tyrosine/Serine Phosphatases Which Are Essential for Virus Viability. *Virology* **206**, 572-582.

- 217 Moyer, R. W. and Graves, R. L. 1981. The mechanism of cytoplasmic orthopoxvirus DNA replication *Cell* **27**, 391-401.
- 218 Müller, G., and Peters, D. 1963: Cited by Munz, E. K., and Owen, N. C. (1966).
- 219 Munyon, W. E., Paoletti, E., and Grace, J. T. Jnr. 1967. RNA polymerase activity in purified infectious vaccinia virus. *Proc. Natl. Acad. Sci. USA*. **58**, 2280-2288.
- 220 Munz, E. K., and Owen, N. C. 1966. Electron microscopic studies on lumpy skin disease virus type "Neethling". *Onderstepoort J. vet. Res.* **33** (1), 3-8.
- 221 Murphy, P. M., and Tiffany, H. L. 1991. Cloning of complementary DNA encoding a functional human interleukin-8 region. *Science* **253**, 1280-1283.
- 222 Murphy, P. M. 1996. Chemokine receptors: Structure, function and role in microbial pathogenesis. *Cytokine Growth Fact. Rev.* **7**, 47-64.
- 223 Nagington, J. and Horne, R. W. 1962. Morphological studies of orf and vaccinia viruses. *Virology* **16**, 248-260.
- 224 Nakano, E., Panicali, D., and Paoletti, E. 1982. Molecular genetics of vaccinia virus: Demonstration of marker rescue. *Proc. Natl. Acad. Sci. USA* **79**, 1593-1596.
- 225 Nakano, J. H. in *Clinical Virology Manual* (Eds. Specter, S. and Lancz, G. J.) Elsevier, 1986).
- 226 Nathanson, N. and McFadden, G. 1997. Viral virulence. In "Viral Pathogenesis" (N. Nathanson, Ed.) pp. 85-108, Lippincott-Raven, Philadelphia.
- 227 Neote, K., Digregorio, D., Mak, J. Y., Horuk, R., and Schall, T. J. 1993. Molecular cloning, functional expression, and signalling characteristics of a C-C chemokine receptor. *Cell* **72**, 415-425.
- 228 Oda, K. and Joklik, W. K. 1967. Hybridization and sedimentation studies of "early" and "late" vaccinia messenger RNA. *J. Molec. Biol.* **27**, 395-419.
- 229 Odend'hal, S. 1983. The geographical distribution of animal virus diseases. *Exp. Virol. Series*. Academic Press, New York, 219 and 313.

- 230 O'Dowd, B. F., Hnatowich, M., Caron, M. G., Lefkowitz, R. J., and Bouvier, M. J. 1989. Palmitoylation of the human beta 2-adrenergic receptor. Mutation of cys 341 in the carboxyl tail leads to an uncoupled nonpalmitoyl form of receptor. *J. Biol. Chem.* **264**, 7564-7569.
- 231 Office International des Epizooties (OIE), Vol. I. 1989. Sheep pox and goat pox. In: *Recommended diagnostic techniques and requirements for biological products*. (Paris)
- 232 Office International des Epizooties (OIE) Manual. 1996. *Lumpy Skin Disease* pp 93-100.
- 233 O'Hare, P. and Goding, C. R. 1988. Herpes simplex virus regulatory elements and the immunoglobulin octamer domain bind a common factor and are both targets for viral transcription *Cell* **52**, 435-445.
- 234 Panicali, D. and Paoletti, E. 1982. Construction of poxviruses as cloning vectors; Insertion of the thymidine kinase gene of herpes simplex virus into the DNA of infectious vaccinia virus. *Proc. Natl. Acad. Sci. USA* **79**, 4927-4931.
- 235 Panicali, D., Davies, S. W., Weinberg, R. L., and Paoletti, E. 1983. Construction of live vaccines using genetically engineered poxviruses: Biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. *Proc. Natl. Acad. Sci. USA* **80**, 5364-5368.
- 236 Paoletti, E., Lipinskas, B. R., Samsonoff, C., Mercer, S., and Panicali, D. 1984. Construction of live vaccines using genetically engineered poxviruses: Biological activity of vaccinia virus recombinants expressing the hepatitis B surface antigen and the herpes simplex virus glycoprotein D. *Proc. Natl. Acad. Sci. USA* **81**, 193-197.
- 237 Palumbo, G. J., Glasgow, W. C., and Buller, R. M. L. 1993. Poxvirus-induced alteration of arachidonate metabolism. *Proc. Natl. Acad. Sci. USA* **90**, 2020-2024.
- 238 Patel, D. D. and Pickup, D. J. 1987. Messenger RNAs of a strongly-expressed late gene of cowpox virus contain 5' - terminal poly (A) sequences. *EMBO J.* **6**, 3787-3794.
- 239 Patty, R. E. 1970. Inhibition of foot-and-mouth disease virus by normal bovine serum. *Am. J. vet. Res.* **31**, 165-171.
- 240 Payne, L. G. and Kristensson, K. 1979. Mechanism of vaccinia virus release and its specific inhibition by N₁-isonicotinoyl-N₂-3-methyl-4-chlorobenzoylhydrazine. *J. Virol.* **32**, 614-622.

- 241 Pedley, C. B. and Cooper, R. J. 1987. The assay, purification and properties of vaccinia virus-induced uncoating protein. *J. Gen. Virol.* **68**, 1021-1028.
- 242 Perkus, M. E., Goebel, S. J., Davis, S. W., Johnson, G. P., Limbach, K., Norton, E. K., and Paoletti, E. 1990. Vaccinia virus host range genes. *Virology* **179**, 276-286.
- 243 Perkus, M. E., Goebel, S. J., Davis, S. W., Johnson, G. P., Norton, E. K., and Paoletti, E. 1991. Deletion of ss open reading frames from the termini of vaccinia virus. *Virology* **180**, 381-401.
- 244 Peters, D. 1956. The fine structure of the DNA containing core of vaccinia virus. *Virology* **21**, 266-269.
- 245 Peters, D. 1956. Morphology of resting vaccinia virus. *Nature* **287**, 1453-1455.
- 246 Pogo, B. G. T. 1977. Elimination of naturally occurring crosslinks in vaccinia virus DNA after viral penetration into cells. *Proc. Natl. Acad. Sci. USA* **74**, 1739-1742.
- 247 Pogo, B. G. T. and O'Shea, M. T. 1977. Further characterization of deoxyribonucleases from vaccinia virus. *Virology* **77**, 55-66.
- 248 Pogo, B. G. T. and O'Shea, M. 1978. The mode of replication of vaccinia virus DNA *Virology* **84**, 1.
- 249 Pogo, B. G. T. and O'Shea, M., and Freimuth, P. 1981. Initiation and termination of vaccinia virus DNA replication. *Virology* **108**, 241-248.
- 250 Preston, C. M., Frame, M. C., and Campbell, M. E. M. 1988. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulating DNA sequence. *Cell* **52**, 425-434.
- 251 Prydie, J., and Coakley, W. 1959. Lumpy skin disease: tissue culture studies. *Bull. Epizoot. Dis. Afr.* **7**, 37-49.
- 252 Rajagopal, I., Ahn, B. Y., Moss, B., and Mathews, C. K. 1995. Roles of vaccinia virus ribonucleoside reductase and glutaredoxin in DNA precursor biosynthesis. *J. Biol. Chem.* **270**, 27415-27418.

- 253 Ramshaw, I., Ruby, J., Ramsay, A., Ada, G., and Karupiah, G. 1992. Expression of cytokines by recombinant vaccinia viruses: A model for studying cytokines in virus infections *in vivo*. *Immunol. Rev.* **127**, 157-182.
- 254 Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath, P. R., Salvesen, G. S., and Pickup, D. J. 1992. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the IL-1 β converting enzyme. *Cell* **69**, 597-604.
- 255 Reddy, M. K. and Bauer, W. R. 1989. Activation of the vaccinia virus nicking-joining enzyme by trypsin. *J. Biol. Chem.* **264**, 443-449.
- 256 Reid, K. B. M. 1995. The complement system- a major effector mechanism in humoral immunity. *The Immunologist* **3**, 206.
- 257 Robinson, A. J., and Lyttle, D. J., in *Recombinant Poxviruses* (Eds. Binns and Smith) CRC Press, Boca Raton, FL, 1992.
- 258 Robinson, D. N. and Cooley, L. 1997. *Drosophila* kelch is an oligomeric ring canal actin organizer. *J. cell. Biol.* **138**, 799-810.
- 259 Rohrmann, G. and Moss, B. 1985. Transcription of vaccinia virus early genes by a template-dependent soluble extract of purified virions. *J. Virol.* **56**, 349-355.
- 260 Rohrmann, G., Yuen, L., and Moss, B. 1986. Transcription of vaccinia virus early genes by enzymes isolated from vaccinia virions terminates downstream of a regulatory sequence. *Cell* **46** 1029-1035.
- 261 Roitt's Essential Immunology. Ivan Roitt. 9th Edition, Blackwell Science
- 262 Romero, C. H., Barrett, T., Evans, S. R., Kitching, R. P., Gershon, P. D., Bostock, C., and Black, D. N. 1993. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease viruses. *Vaccine* **11**, 737-742.
- 263 Romero, C. H., Barrett, T., Chamberlain, R. W., Kitching, R. P., Fleming, M., and Black, D. N. 1994. Recombinant capripox expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses. *Virology* **204**, 425-429.

- 264 Romero, C. H., Barrett, T., Kitching, R. P., Bostock, C., and Black, D. N. 1995. Protection of goats against peste des pestis ruminants with recombinant capripoxvirus expressing the fusion and hemagglutinin protein genes of rinderpest virus. *Vaccine* **13**, 36-40.
- 265 Rosell, J. L., Earl, P. L., Weir, J. P., and Moss, B. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. *J. virol.* **60**, 436-439.
- 266 Rouslahti, E. and Perschbacher, M. D. 1986. Arg-Gly-Asp: A versatile cell recognition signal. *Cell* **44**, 517-518.
- 267 Ruby, J. and Ramshaw, I. 1991. The antiviral activity of CD8⁺ T cells is dependent on interferon- γ . *Lymphokine Cytokine Res.* **10**, 353-358.
- 268 Sambrook, J., Fritesh, E. F., and Maniatis, T. (Eds.) 1989. *Molecular Cloning- A laboratory manual*. Second Edition. Cold Spring Harbor Laboratory Press.
- 269 Sanders, M. C., Way, M., Sakai, J., and Matsudaira, P. 1996. Characterization of the actin cross-linking properties of the scruin-calmodulin complex from the acrosomal process of *Limulus* sperm. *J. Biol. Chem.* **271**, 2651-2657.
- 270 Schall, T. J. 1991. Biology of the RANTES/SIS cytokine family. *Cytokine* **3**, 165-183.
- 271 Schmitt, J. F. C. and Stunnenberg, G. 1988. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment. *J. Virol.* **62**, 1889-1897.
- 272 Schultz, J., Milpetz, F., Bork, P., and Ponting, C. P. 1998. SMART, a simple modular architecture research tool: Identification of signalling domains. *Proc. Natl. Acad. Sci. USA.* **95**, 5857-5864.
- 273 Schultz, J., Copley, R. R., Doerks, T., Ponting, C. P., and Bork, P. 2000. SMART: A web-based tool for the study of genetically mobile domains. *Nucleic Acids Res.* **28**, 231-234.
- 274 Schwer, B. and Stunnenberg, H. G. 1988. Vaccinia virus late transcripts generated in vitro have a poly (A) head. *EMBO J.* **7**, 1183-1190.
- 275 Schwer, B., Visca, P., Vos, J. C., and Stunnenberg, H. G. 1987. Discontinuous transcription or RNA processing of vaccinia virus late messengers results in a 5' poly (A) head. *Cell* **50**, 163-169.

- 276 Sedgwick, S. G. and Smerdon, S. J. 1999. The ankyrin repeat: a diversity of interactions on a common structural framework. *TIBS* **24**, 311-316 (Review).
- 277 Senkevich, T. G., Joachim, J. B., Sisler, J. R., Koonin, E. V., Gholamreza, D., and Moss, B. 1996. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. *Science* **273**, 813-816.
- 278 Senkevich, T. G., Koonin, E. V., Bugert, J. J., *et al.* 1997. The Genome of Molluscum Contagiosum Virus: Analysis and Comparison with Other Poxviruses. *Virology* **233**, 19-42.
- 279 Shaffer, R. and Traktman, P. 1987. Vaccinia virus encapsidates a novel topoisomerase with the properties of a eukaryotic type I enzyme. *J. Biol. Chem.* **262**, 9309-9315.
- 280 Sharma, A., Hanai, R. and Mondragon, A. 1994. Crystal Structure of the amino-terminal fragment of vaccinia virus DNA topoisomerase I at 1.6-Å resolution. *Structure* **2**: 767-777.
- 281 Shchelkunov, S. N., Marennikova, S. S., Totmenin, A. V., Blinov, V. M., Chizhikov, V. Ye., Gutorov, V. V., Gashnikov, P. V., Andzhaparidze, O. G., and Sandakhchiev, L. S. 1991. *Dokl. Akad. Nauk. SSSR* (in Russian) **321**, 402-406.
- 282 Shchelkunov, S. N., Totmenin, A. V., Loparev, V.N *et al.* 2000. Alastrim Smallpox Variola Minor Genome DNA Sequences. *Virology* **226**, 361-386.
- 283 Shchelkunov, S. N., Blinov, V. M., and Sandakhchiev, L. S. 1993. Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms. *FEBS Lett.* **319**, 80-83.
- 284 Shchelkunov, S. N., Blinov, V. M., and Sandakhchiev, L. S. 1993. Ankyrin-like proteins of variola and vaccinia viruses. *FEBS Lett.* **319**, 163-165.
- 285 Shchelkunov, S. N., Massung, R. F., Esposito, J. J. 1995. Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. *Virus Res.* **36**, 107-118.
- 286 Schmitt, J. F. and Stunnenberg, H. G. 1988. Sequence and transcription analysis of the vaccinia virus *HindIII* I fragment. *J. Virol.* **62**, 1889-1897.

- 287 Shuman, S., Golder, M., and Moss, B. 1988. Characterization of vaccinia virus DNA topoisomerase I expressed in *Escherichia coli*. *J. Biol. Chem.* **263**, 16401-16407.
- 288 Shuman, S., Golder, M., and Moss, B. 1989. Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth. *Virology* **170**, 302-306.
- 289 Silver, M., McFadden, G., Wilton, S., and Dales, S. 1979. Biogenesis of poxviruses: role for the DNA-dependent RNA polymerase II of the host during expression of late functions. *Proc. Natl. Acad. Sci. USA* **76**, 4122-4125.
- 290 Slabaugh, M. B., Johnson, T. L., and Matthews, C. K. 1984. Vaccinia virus induces ribonucleotide reductase in primate cells. *J. Virol.* **52**, 507-514.
- 291 Smith, G. L., and Moss, B. 1983. Infectious poxvirus vectors have a capacity for at least 25,000 base pairs of foreign DNA. *Gene* **25**, 21-28.
- 292 Smith, G. L., Mackett, M., and Moss, B. 1983. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. *Nature* **302**, 490-495.
- 293 Smith, G. L., Murphy, B. R., and Moss, B. 1983. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. *Proc. Natl. Acad. Sci. USA* **80**, 7155-7159.
- 294 Smith, G. L. 1993. Vaccinia virus glycoproteins and immune evasion. The sixteenth Fleming lecture. *J. Gen. Virol.* **74**, 1725-1740.
- 295 Soloski, M. J. and Holowczak, J. A. 1981. Characterization of supercoiled nucleoprotein complexes released from detergent-treated vaccinia virions. *J. Virol.* **37**, 770-783.
- 296 Spehner, D., Gillard, S., Drillien, R., and Kim, A. 1988. A cowpox virus gene required for multiplication in chinese hamster ovary cells. *J. Virol.* **62**, 1297-1304.
- 297 Spencer, E., Shuman, S., and Hurwitz, J. 1980. Purification and properties of vaccinia virus DNA-dependent RNA polymerase. *J. Biol. Chem.* **255**, 5388-5395.

- 298 Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R. M.L., and VanSlyke, J. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. *Cell* **71**, 145-157.
- 299 Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. *Cell* **76**, 301-314.
- 300 Steinert, P. M. and Roop, D. R. 1988. Molecular and cellular biology of intermediate filaments. *Annu. Rev. Biochem.* **57**, 593-625.
- 301 Staden, R., Beal, K. F., and Bonfield, J. K. 1998. The Staden Package, Computer Methods in Molecular Biology (Eds. Steven Misener and Steve Krawetz). The Human Press, Inc., Totowa, NJ 07512.
- 302 Stroobant, P., Rice, A. P., Gullick, W. J., Cheng, D. J., Kerr, I. M., and Waterfield, M. D. 1985. Purification and characterization of vaccinia virus growth factor. *Cell* **42**, 383-393.
- 303 Stokes, G. V. 1976. High-voltage electron microscope study of the release of vaccinia virus from whole cells. *J. Virol.* **18**, 636-642.
- 304 Szybalski, W. R., Erikson, R. L., Gentry, L. G., Gafford, L. G., and Randall, C. C. 1963. Unusual properties of fowlpox virus DNA. *Virology* **19**, 586-589.
- 305 Tattersall, P. and Ward, D. C. 1976. Rolling hairpin model for replication of parvovirus and linear chromosomal DNA. *Nature* **263**, 106-109.
- 306 Taylor, L., Weinberg, R., Rawaoka, Y., Desmetre, R., and Paoletti, E. 1988. Efficacy studies on a canarypox-rabies recombinant virus. *Vaccine* **9**, 190-193.
- 307 Taylor, J. and Paoletti, E. 1988. Fowlpoxvirus as a vector for non-avian species. *Vaccine* **6**: 466-472.
- 308 Thomas, A. D., and Maré. 1945. Knopvelsiekte. *J. S. Afr. Vet. Med. Ass.* **16**, 36-43.
- 309 Thomas, A. D., Robinson, E. M. and Alexander, R. A. (1945) Lumpy Skin Disease- Knopvelsiekte. *Veterinary Newsletter No. 10, Div. Vet. Services, Onderstepoort, May 5th, 1945*, 1-3.

- 310 Tooze, J. (ed.) 1981. DNA Tumor viruses, 2nd Ed. Cold Spring Harbor Laboratory. Cold Spring Harbor, N. Y.
- 311 Twardzik, D. R., Brown, J. P., Ranchalis, J. E., Todaro, G. J., and Moss, B. 1985. Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. *Proc. Natl. Acad. Sci. USA*. **82**, 5300-5304.
- 312 Ueda, Y., Morikawa, S. and Watanabe, T. 1995. Unclassified Poxvirus: Characterization and Physical Mapping of Cotia Virus DNA and Location of a Sequence Capable of Encoding a Thymidine Kinase. *Virology*. **210**, 67-72.
- 313 Ulaeto, D., Grosenbach, D., and Hruby, D. E. 1996. The vaccinia virus 4c and A-type inclusion proteins are specific markers for the intracellular mature virus particle. *J. virol.* **70**, 3372-3377.
- 314 Upton, C., Mossman, K., and McFadden, G. 1992. Encoding of a homolog of the IFN- γ receptor by myxoma virus. *Science* **258**, 1369-1372.
- 315 Upton, C., Stuart, D. T. and McFadden, G. 1991. Identification and DNA sequence of the large subunit of the capping enzyme from Shope fibroma virus. *Virology* **183**, 773-777.
- 316 Upton, C., Stuart, D. T. and McFadden, G. 1993. Identification of a poxvirus gene encoding a uracil-DNA glycosylase. *Proc. Natl. Acad. Sci. U.S.A.* **90**: 4518-4522.
- 317 Upton, C., Macen, J. L., Schreiber, M., and McFadden, G. 1991. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. *Virology* **184**, 370-382.
- 318 Van Rooyen, P. J., Kümm, N. A. L., Weiss, K. E., and Alexander, R. A. 1959. A preliminary note on the adaptation of a strain of lumpy skin disease virus to propagation in embryonated eggs. *Bull. Epiz. Dis. Afr.* **7**, 79-85.
- 319 Varkey, J. P., Muhlrud, P. J., Minniti, A. N., Do, B., and Ward, S. 1995. The *Caenorhabditis elegans* spe-26 gene is necessary to form spermatids and encodes a protein similar to the actin-associated proteins kelch and scruin. *Genes Dev.* **9**, 1074-1086.
- 320 Vassef, A. 1987. Conserved sequences near the early transcription sites of vaccinia virus. *Nucleic Acids Res.* **15**, 1427-1443.

- 321 Vassef, A., Mars, M., Dru, A., Plucienniczak, A., Streek, R. E., and Beaud, G. 1985. Isolation of *cis*-acting vaccinia virus DNA fragments promoting expression of herpes simplex virus thymidine kinase by recombinant vaccinia viruses. *J. Virol.* **55**, 1643-1672.
- 322 Venkatesan, S., Baroudy, B. M., and Moss, B. 1981. Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. *Cell* **25**, 805-813.
- 323 Venkatesan, S., Gershowitz, A., and Moss, B. 1982. Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition. *J. Virol.* **44**, 637-646.
- 324 Vilcek, J., Gray, P. W., Rinderknecht, E., and Sevastopoulos, C. G. 1985. Interferon gamma: A lymphokine for all seasons. *Lymphokines* **11**, 1-32.
- 325 Villarreal, E. C. and Hruby, D. E. 1986. Mapping the genome location of the gene encoding alpha-amanitin resistance in vaccinia virus mutants. *J. Virol.* **57**, 65-70.
- 326 Villarreal, E. C., Roseman, N. A., and Hruby, D. E. 1984. Isolation of vaccinia virus mutants capable of replicating independently of the host cell nucleus. *J. Virol* **51**, 539-566.
- 327 Von Backstrom, U. 1945. *Ngamiland cattle disease. Preliminary report on a new disease, the etiological agent being probably of an infectious nature.* *J. S. A. V. M. A.*, **16** (2), 29-35.
- 328 Von Bulow, M., Heid, H., Hess, H., and Franke, W. W. 1995. Molecular nature of calicin, a major basic protein of the mammalian sperm head cytoskeleton. *Exp. Cell. Res.* **219**, 407-413.
- 329 Vos, J. C. and Stunnenberg, H. G. 1988. Derepression of a novel class of vaccinia virus genes upon DNA replication. *EMBO J.* **7**, 3487-3492.
- 330 Wade-Evans, A. M., Romero, C. H., Mellor, P., Takamatsu, H., Anderson, J., Thevasagayam, J., Fleming, M. J., Mertens, P. P. C., and Black, D. N. 1996. Expression of the core major structural protein (VP7) of bluetongue virus by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. *Virology* **220**, 227-231.
- 331 Way, M., Sanders, M., Chafel, M., Tu, Y-H., Knight, A., and Matsudaira, P. 1995. β -Scruin, a homologue of the actin-crosslinking protein scruin, is localized to the acrosomal vesicle of *Limulus* sperm. *J. Cell. Sci.* **108**, 3155-3162.

- 332 Wei, C. M. and Moss, B. 1974. Methylation of newly synthesized viral messenger RNA by an enzyme in vaccinia virus. *Proc. Natl. Acad. Sci. USA*. **71**, 3014-3018.
- 333 Wei, C. M. and Moss, B. 1975. Methylated nucleotides block 5'-terminus of vaccinia virus mRNA. *Proc. Natl. Acad. Sci. USA*. **72**, 318-322.
- 334 Weir, J. P., Bajszar, G., and Moss, B. 1982. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. *Proc. Natl. Acad. Sci. USA* **79**, 1210-1214.
- 335 Weir, J. P., and Moss, B. 1987. Determination of the transcriptional regulatory region of a vaccinia virus late gene *J. Virol.* **61**, 75-80.
- 336 Weiss, K. E. 1960. Unpublished observations, cited in *Lumpy Skin Disease. Virus Monographs*. Vol 3. New York: Springer Verlag.
- 337 Weiss, K. E. 1963. *Lumpy skin disease. Emerging diseases of Animals, FAO Agricultural Studies*, **61**, 179-201.
- 338 Weiss, K. E. 1968. Lumpy skin disease virus, *Virology Monographs*. **3**, 111-131.
- 339 Westwood, J. C. N., Harris, W. J., Zwartou, H. T., Titmus, D. H. J., and Appleyard, G. 1964. Studies on the structure of vaccinia virus. *J. gen. Microbiol.* **34**, 67.
- 340 Whitaker-Dowling, P. and Youngner, J. S. 1983. Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity. *Virology* **131**, 128-136.
- 341 Willer, D. O., McFadden, G. and Evans, D. H. 1999. The Complete Genome Sequence of Shope (Rabbit) Fibroma Virus. *Virology*. **264**, 319-343.
- 342 Wiktor, T. J., McFarlan, R. I., Reagan, K. J., Dietzschold, B., Curtis, P. J., Wunner, N. H., Kieny, M. P., Lathe, R., Lecocq, J-P, Mackett, M., Moss, B., and Koprowski, H. 1984. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. *Proc. Natl. Acad. Sci. USA* **81**, 7194-7198.

- 343 Wittek, R., Menna, A., Muller, K., Schumperli, D., Bosley, P. G., and Wyler, R. 1978. Inverted terminal repeats in rabbit poxvirus and vaccinia virus DNA. *J. Virol.* **28**, 171-181.
- 344 Wittek, R., Kuenzle, C. C., and Wyler, R. 1979. High G+C content in parapoxvirus DNA. *J. gen. Virol.* **43**, 231-234.
- 345 Wittek, R., Richner, B., and Hiller, G. 1984. Mapping of the genes coding for the two major vaccinia virus core polypeptides. *Nucleic Acids Res.* **12**, 4835-4848.
- 346 Winslow, O. E. 1974. *A Destroying Agent: the Conquest of Smallpox in Colonial Boston*. Boston, Houghton Mifflin.
- 347 Wittek, R., Cooper, J., Barbosa, E., and Mos, B. 1980. Expression of the vaccinia virus genome-analysis and mapping of mRNAs encoded within the inverted terminal repetition. *Cell* **21**, 487-493.
- 348 Wolff, T., O'Neill, R. E. and Palese, P. 1998. NS1-Binding protein (NS1-BP): a novel human protein that interacts with the influenza A virus nonstructural NS1 protein is relocalized in the nuclei of infected cells. *J. Virol.* **72**, 7170-7180.
- 349 Woods, J. A. 1988. Lumpy Skin Disease- a review. *Trop. Anim. Hlth. Prod.* **20**, 11-17.
- 350 Wright, C. F. and Moss, B. 1987. In vitro synthesis of vaccinia virus late mRNA containing a 5' poly (A) leader sequence. *Proc. Natl. Acad. Sci. USA.* **84**, 8883-8887.
- 351 Xue, F. and Cooley, L. 1993. Kelch encodes a component of intracellular bridges in *Drosophila* egg chambers. *Cell* **72**, 681-693.
- 352 Yasui, A., Eker, A. P., Yasuhira, S., Yajima, H., Kobayashi, T., Takao, M., and Oikawa, A. 1994. A new class of DNA photolyases present in various organisms including placental mammals. *EMBO J.* **13**, 6143-6151.
- 353 Young, E., Basson, P. A., and Weiss, K. E. 1970. Experimental infection of game animals with lumpy skin disease virus (Prototype strain Neethling). *Onderstepoort J. vet Res.* **37**, 79-88.
- 354 Yuen, L., Davison, J. A., and Moss, B. 1987. Early promoter-binding factor from vaccinia virions. *Proc. Natl. Acad. Sci. USA.* **84**, 6069-6073.

- 355 Yuen, L., and Moss, B. 1987. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. *Proc. Natl. Acad. Sci. USA* **84**, 6417-6421.
- 356 Zantinge, J. L., Krell, P. J., Derbyshire, B. J., and Nagy, E. 1996. Partial transcriptional mapping of the fowlpox virus genome and analysis of the EcoRI L fragment. *J. Gen Virol.* **77**, 603-614.
- 357 Zinkernagel, R. M. 1996. Immunology taught by viruses. *Science* **271**, 173-178.

5.5 PAPERS AND CONGRESS CONTRIBUTIONS

Paper (in preparation):

C. Stipinovich, F. T. Vreede, D. B. Wallace, L. H. Nel and G. J. Viljoen

Molecular Characterization of PstI clones E, M, K, F and G of the Lumpy Skin Disease Virus Genome, representative of the Left-Hand Terminal and Central Regions

Congress Contributions:

Poster:

Stipinovich, C., Vreede, F. T., Wallace, D. B., Viljoen, G. J., and Nel, L. H.

Sequencing and Characterization of Lumpy Skin Disease Virus

BIOY2K Combined Millenium Meeting, Grahamstown, South Africa,

January 2000

Poster:

Vreede, F. T., Stipinovich, C., Wallace, D. B., Taljaard, L. C. F., and Viljoen, G. J.

Sequence Analysis of Terminal and Central Regions of the LSDV Genome.

XIIIth International Poxvirus and Iridovirus Symposium, Mont Pellier, France,

September 2000

Poster:

Vreede, F. T., Stipinovich, C., Wallace, D. B., Taljaard, L. C. F., and Viljoen, G. J.

Sequence Analysis of Terminal and Central Regions of the LSDV Genome.

International Conference of Bacterial and Viral Virulence Factors, Smolenice, Slovakia,

September 2000